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The source of the SARS epidemic was traced to wildlife market civets and ultimately to bats. 58 
Subsequent hunting for novel coronaviruses (CoVs) led to the discovery of two additional human 59 
and over 40 animal CoVs, including the prototype lineage C betacoronaviruses, Tylonycteris bat 60 
CoV HKU4 and Pipistrellus bat CoV HKU5, which are phylogenetically closely related to the 61 
Middle East respiratory syndrome coronavirus that has affected >900 patients with >35% fatality 62 
since its emergence in 2012. All primary cases of MERS are epidemiologically linked to the 63 
Middle East. Some had contacted camels which shed virus and/or had positive serology. Most 64 
secondary cases are related to healthcare-associated clusters. The disease is especially severe in 65 
elderly men with comorbidities. Clinical severity may be related to MERS-CoV’s ability to infect 66 
a broad range of cells with DPP4 expression, evade host innate immune response, and induce 67 
cytokine dysregulation. Reverse transcription-PCR on respiratory and/or extrapulmonary 68 
specimens rapidly establishes diagnosis. Supportive treatment with extracorporeal membrane 69 
oxygenation and dialysis is often required in patients with organ failure. Antivirals with potent 70 
in-vitro activities include neutralizing monoclonal antibodies, antiviral peptides, interferons, 71 
mycophenolic acid, and lopinavir. They should be evaluated in better animal models before 72 
clinical trials. Developing camel MERS-CoV vaccine and implementing appropriate infection 73 
control measures may control the expanding epidemic.  74 
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INTRODUCTION: FROM SARS TO MERS 75 
Frequent mixing of different animal species in markets in densely populated areas and human 76 
intrusions into the natural habitats of animals have facilitated the emergence of novel viruses. 77 
Examples with specific geographical origins include severe acute respiratory syndrome 78 
coronavirus (SARS-CoV) and avian influenza A/H7N9 and H5N1 in China, Nipah virus in 79 
Malaysia and Bangladesh, and Ebola and Marburg viruses in Africa (1-8). The Middle East is a 80 
region encompassing the majority of Western Asia and Egypt that contains 18 countries with 81 
various ethnic groups. It is one of the busiest politicoeconomic centers in the world with many 82 
unique religious and cultural practices such as the annual Hajj along with a reliance on camels 83 
for food, business, and travel in both rural and urban areas. These distinct regional characteristics 84 
have provided favorable conditions for new and rapidly mutating viruses to emerge. Similar to 85 
the first decade of the new millennium during which the world witnessed the devastating 86 
outbreak of SARS caused by SARS-CoV, the beginning of the second decade was plagued by the 87 
emergence of another novel CoV, Middle East respiratory syndrome coronavirus, that has caused 88 
an outbreak of severe respiratory disease in the Middle East with secondary spread to Europe, 89 
Africa, Asia, and North America since 2012 (3, 9). MERS-CoV is similar to SARS-CoV in being 90 
a CoV that is likely to have originated from animal reservoirs and crossed interspecies barriers to 91 
infect humans (1). The disease, Middle East respiratory syndrome (MERS), was initially called a 92 
“SARS-like” illness at the beginning of the epidemic as both are human CoV infections that 93 
manifest as severe lower respiratory tract infection with extrapulmonary involvement and high 94 
case-fatality rates (10, 11), whereas the other four CoVs that cause human infections, namely 95 
human coronavirus (HCoV)-OC43, HCoV-229E, HCoV-HKU1, and HCoV-NL63, mainly cause 96 
mild, self-limiting upper respiratory tract infections such as the common cold (10). MERS-CoV, 97 
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like SARS-CoV, is considered by the global health community as a potential pandemic agent 98 
since person-to-person transmission occurs and effective therapeutic options are limited. 99 
However, unlike the SARS epidemic, which rapidly died off after the intermediate amplifying 100 
hosts were identified and segregated from humans by closure of wild animal markets in Southern 101 
China, the MERS epidemic has persisted for more than two years with no signs of abatement (3, 102 
12). Detailed analysis of the epidemiological, virological, and clinical aspects of MERS and 103 
SARS reveals important differences between the two diseases, and identifies unique aspects of 104 
MERS-CoV that may help to explain the evolution of the MERS epidemic. A summary of the 105 
key differences between the MERS and SARS epidemics is provided in Table 1. In this article, 106 
we review the biology of MERS-CoV in relation to its epidemiology, clinical manifestations, 107 
pathogenesis, laboratory diagnosis, therapeutic options, immunization, and infection control, and 108 
identify key research priorities that are important for the control of this evolving epidemic. 109 
  110 
TAXONOMY, NOMENCLATURE, AND GENERAL VIROLOGY 111 
MERS-CoV belongs to lineage C of the genus Betacoronavirus (βCoV) in the family 112 
Coronaviridae under the order Nidovirales (Fig. 1A). Prior to the discovery of MERS-CoV, the 113 
only known lineage C βCoVs were two bat coronaviruses that are phylogenetically closely 114 
related to MERS-CoV, namely Tylonycteris bat CoV HKU4 (Ty-BatCoV-HKU4) and Pipistrellus 115 
bat CoV HKU5 (Pi-BatCoV-HKU5) discovered in Tylonycteris pachypus and Pipistrellus 116 
abramus respectively in Hong Kong in 2006 (Fig. 1B) (13-15). MERS-CoV is the first lineage C 117 
βCoV and the sixth CoV known to cause human infection. It was designated as a novel lineage C 118 
βCoV based on the International Committee on Taxonomy of Viruses (ICTV) criteria for CoV 119 
species identification using rooted phylogeny. Calculation of pairwise evolutionary distances for 120 
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seven replicase domains showed that MERS-CoV had an amino acid sequence identity of <90% 121 
when compared to all other known CoVs at the time when MERS-CoV was discovered (16). 122 
Before the virus was formally named MERS-CoV by the Coronavirus Study Group of ICTV, it 123 
was also known by other names including “novel coronavirus”, “human coronavirus EMC”, 124 
“human betacoronavirus 2c EMC”, “human betacoronavirus 2c England-Qatar”, “human 125 
betacoronavirus 2C Jordan-N3”, and “betacoronavirus England 1”, which represented the places 126 
where the first complete viral genome was sequenced (Erasmus Medical Center, Rotterdam, the 127 
Netherlands) or where the first laboratory-confirmed cases were identified or managed (Jordan, 128 
Qatar, England) (9, 17-20). Similar to other CoVs, MERS-CoV is an enveloped positive-sense 129 
single-stranded RNA virus (16). Its single-stranded RNA genome has a size of approximately 30 130 
kb, G+C content of 41%, and contains 5’-capped, polyadenylated, polycistronic RNA (16, 20, 131 
21). The genome arrangement of 5’-replicase-structural proteins (spike-envelope-membrane-132 
nucleocapsid)-poly(A)-3’ [ie: 5’-ORF1a/b-S-E-M-N-poly(A)-3’] is similar to that of other 133 
βCoVs, and unambiguously distinguishes MERS-CoV from lineage A βCoVs, which universally 134 
contain the characteristic hemagglutinin-esterase (HE) gene (16, 20-22). Many of these genes 135 
and their encoded proteins are useful diagnostic, therapeutic, or vaccination targets (Fig. 2). 136 
There are 10 complete, functional open reading frames (ORFs) expressed from a nested set of 137 
seven subgenomic mRNAs carrying a 67-nt common leader sequence in the genome, eight 138 
transcription-regulatory sequences, and two terminal untranslated regions (16, 20, 21). The 139 
putative roles and functions of the ORFs and their encoded proteins are derived by analogy to 140 
other CoVs (Table 2). Proteolytic cleavage of the large replicase polyprotein pp1a/b encoded by 141 
the partially overlapping 5’-terminal ORF1a/b within the 5’ two-thirds of the genome produces 142 
16 putative non-structural proteins (nsp), including two viral cysteine proteases, namely nsp3 143 
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(papain-like protease) and nsp5 (chymotrypsin-like, 3C-like, or main protease), nsp12 (RNA-144 
dependent RNA polyemerase; RdRp), nsp13 (helicase), and other nsps which are likely involved 145 
in the transcription and replication of the virus (16, 20, 21). The membrane anchored trimeric S 146 
protein is a major immunogenic antigen involved in virus attachment and entry into host cell, and 147 
has an essential role in determining virus virulence, protective immunity, tissue tropism, and host 148 
range (23). The other canonical structural proteins, namely E, M, and N proteins, are encoded by 149 
ORF6, -7, and -8 respectively, and are involved in the assembly of the virion. The M protein, as 150 
well as the papain-like protease and accessory proteins 4a, 4b, and 5, exhibit in vitro interferon 151 
antagonist activities that may modulate in vivo replication efficiency and pathogenesis (24-28). 152 
 153 
VIRAL REPLICATION CYCLE  154 
The replication cycle of MERS-CoV consists of numerous essential steps that can be efficiently 155 
inhibited by antiviral agents in vitro (Fig. 3). CoVs are so named because of their characteristic 156 
solar corona (corona soli) or “crown-like” appearance observed under electron microscopy, 157 
which represents the peplomers formed by trimers of S protein radiating from the virus lipid 158 
envelope. The MERS-CoV S protein is a class I fusion protein composed of the amino N-159 
terminal receptor-binding S1 and carboxyl C-terminal membrane fusion S2 subunits (Fig. 2). The 160 
S1/S2 junction is the location of a protease cleavage site which is required to activate membrane 161 
fusion, virus entry, and syncytia formation. The S1 subunit consists of the C-domain, which 162 
contains the receptor binding domain (RBD), and an N-domain (29). The RBD of MERS-CoV 163 
has been mapped by different groups to a 200 to 300-residue region spanning residues 358 to 164 
588, 367 to 588, 367 to 606, 377 to 588, or 377 to 662 (29-36). Among these RBD-containing 165 
fragments, the one that encompasses residues 377 to 588 appears to be the most stable and 166 
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neutralizing fragment in structural analysis and virus neutralization assays (36). Neutralizing 167 
monoclonal antibodies against the RBD potently inhibit virus entry into host cells and receptor-168 
dependent syncytia formation in cell culture, and vaccines containing the RBD induce high 169 
levels of neutralizing antibodies in mice and rabbits (31, 34, 36-43). The S2 subunit contains the 170 
heptad repeat 1 and 2 (HR1 and HR2) domains, a transmembrane domain, and an intracellular 171 
domain that form the stalk region of S protein which facilitates fusion of the viral and cell 172 
membranes necessary for virus entry (44, 45). The binding of the S1 subunit to the cellular 173 
receptor triggers conformational changes in the S2 subunit which inserts its fusion peptide into 174 
the target cell membrane to form a six-helix bundle fusion core between the HR1 and HR2 175 
domains that approximates the viral and cell membranes for fusion. This fusion process can be 176 
inhibited by HR2-based antiviral peptide fusion inhibitors which prevent the interaction between 177 
the HR1 and HR2 domains (44, 45). 178 
The key functional receptor of the host cell attached to by the MERS-CoV S protein is 179 
dipeptidyl peptidase-4 (DPP4), which is also known as adenosine deaminase complexing protein 180 
2 or CD26 (46). MERS-CoV is the first coronavirus that has been identified to use DPP4 as a 181 
functional receptor for entry into host cells (1, 46). DPP4 is a multifunctional 766-amino-acid-182 
long type II transmembrane glycoprotein presented as a homo-dimer on the cell surface which is 183 
involved in the cleavage of dipeptides (46, 47). It has important roles in glucose metabolism and 184 
various immunological functions including T cell activation, chemotaxis modulation, cell 185 
adhesion, and apoptosis (46, 47). In humans, it is abundantly expressed on the epithelial and 186 
endothelial cells of most organs including lung, kidney, small intestine, liver, and prostate, as 187 
well as immune cells, and exists as a soluble form in the circulation (46-48). This broad tissue 188 
expression of DPP4 may partially explain the extrapulmonary manifestations seen in MERS. 189 
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Adenosine deaminase, which is a natural competitive antagonist, and some anti-DPP4 190 
monoclonal antibodies exhibit inhibitory effects on in vitro MERS-CoV infection (49, 50). 191 
The energetically unfavorable membrane fusion reaction in endosomal cell entry is 192 
overcome by low pH and the pH-dependent endosomal cysteine protease cathepsins, and can be 193 
blocked by lysosomotropic agents such as ammonium chloride, bafilomycin A, and cathepsin 194 
inhibitors in a cell type-dependent manner (23, 51). Additionally, various host proteases, such as 195 
transmembrane protease serine protease-2 (TMPRSS2), trypsin, chymotrypsin, elastase, 196 
thermolysin, endoproteinase Lys-C, and human airway trypsin-like protease, cleave the S protein 197 
into the S1 and S2 subunits to activate the MERS-CoV S protein for endosomal-independent host 198 
cell entry at the plasma membrane (23, 51-53). Inhibitors of TMPRSS2 can abrogate this 199 
proteolytic cleavage and partially block cell entry (23, 51, 52). In some cell lines, MERS-CoV 200 
demonstrates the ability to utilize both the cathepsin-mediated endosomal and the TMPRSS2-201 
mediated plasma membrane pathways to enter host cells (51, 52). 202 
In addition to these cellular proteases, furin has recently been identified as another 203 
protease that has essential roles in the MERS-CoV S protein cleavage activation (54). Furin and 204 
furin-like proprotein convertases are broadly expressed serine endoproteases that cleave the 205 
multibasic motifs RX(R/K/X)R and processes proproteins into their biologically active forms 206 
(55). Proprotein convertases including furin have been implicated in the processing of fusion 207 
proteins and therefore cell entry of various viruses including human immunodeficiency virus, 208 
avian influenza A/H5N1 virus, Marburg virus, Ebola virus, and flaviviruses (55-57). The MERS-209 
CoV S protein contains two cleavage sites for furin at S1/S2 (748RSVR751) and S2’ (884RSAR887) 210 
and exhibits an unusual two-step furin-mediated activation process (Fig. 2) (54). Furin cleaves 211 
the S1/S2 site during S protein biosynthesis and the S2’ site during virus entry into host cell (54). 212 
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Furin inhibitors such as dec-RVKR-CMK block MERS-CoV entry and cell-cell fusion (54). 213 
Treatment of MERS-CoV infection with a combination of inhibitors of the different cellular 214 
proteases utilized by MERS-CoV for S activation should be further evaluated in in  vivo settings. 215 
After cell entry, MERS-CoV disassembles to release the inner parts of the virion 216 
including the nucleocapsid and viral RNA into the cytoplasm for translation of the viral 1a and 217 
1b polyproteins and replication of genomic RNA (Fig. 3). The characteristic replication 218 
structures of CoVs including double-membrane vesicles and convoluted membranes are formed 219 
by the attachment of the hydrophobic domains of the MERS-CoV replication machinery to the 220 
limiting membrane of autophagosomes (58). These structures can be observed at the perinuclear 221 
region of the infected cells under electron microscopy (58). The viral papain-like protease and 222 
3C-like protease co-translationally cleave the large replicase polyproteins pp1a and pp1b 223 
encoded by ORF1a/b into nsp1 to nsp16 (16, 59, 60). These nsps form the replication-224 
transcription complex where transcription of the full length positive genomic RNA yields a full 225 
length negative strand template for synthesis of new genomic RNAs as well as a series of 226 
overlapping subgenomic negative strand templates for synthesis of subgenomic 3’ co-terminal 227 
mRNAs that will be translated to make viral structural and accessory proteins (58). The relative 228 
abundance of the subgenomic mRNAs of MERS-CoV is similar to those of other CoVs, with the 229 
smallest mRNA, which encodes the N protein, being the most abundant (58). After adequate 230 
viral genomic RNA and structural proteins have been cumulated, the N protein assembles with 231 
the genomic RNA in the cytoplasm to form the helical nucleocapsid. The nucleocapsid then 232 
acquires its envelope by budding through intracellular membranes between the endoplasmic 233 
reticulum and Golgi apparatus. The S, E, and M proteins are transported to the budding 234 
compartment where the nucleocapsid probably interacts with M protein to generate the basic 235 
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structure and complexes with the S and E proteins to induce viral budding and release from the 236 
Golgi apparatus (61). The viral replication cycle is completed when the assembled virion is 237 
released through exocytosis to the extracellular compartment. 238 
 239 
SEQUENCE OF EVENTS IN THE MERS EPIDEMIC  240 
On 23 September 2012, the World Health Organization (WHO) reported two cases of acute 241 
respiratory syndrome with renal failure associated with a novel CoV in two patients from the 242 
Middle East (Table 3). The viral strains obtained from the respiratory tract specimens of these 243 
two epidemiologically-unlinked patients shared 99.5% nucleotide identity with each other, with 244 
only one nucleotide mismatch in partial replicase gene sequencing (18). In the following week, 245 
the WHO and other collaborative healthcare authorities rapidly responded to the outbreak by 246 
providing a unified interim case definition, making the complete genome sequence publicly 247 
available in GenBank, and establishing a laboratory diagnostic protocol for real-time reverse 248 
transcription (RT)-PCR using the upE (upstream of E gene) and ORF1b assays (16, 62). With 249 
these important tools, sporadic cases were increasingly detected in the Middle East over the 250 
subsequent six months, including two retrospectively diagnosed cases that occurred in a 251 
healthcare-associated cluster of severe respiratory disease in Zarqa, Jordan, in April 2012 (19, 252 
63-66). Additional cases were also reported in Europe and Africa among patients with recent 253 
travel to the Arabian Peninsula and their close hospital and household contacts (18, 67-74). The 254 
fear of person-to-person transmission was further heightened by the occurrence of a large-scale 255 
outbreak involving over 20 patients in four interrelated hospitals in Al-Hasa, the Kingdom of 256 
Saudi Arabia (KSA), from April to May 2013 (75). 257 
 In view of the significant epidemiological link of all the reported cases to the region, the 258 
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ICTV formally named the novel virus MERS-CoV on 15 May 2013 (17). However, the epidemic 259 
was not contained within the Middle East as its name implied, and the number of patients and 260 
countries involved continued to escalate over the following years (76-81). In particular, there was 261 
a sudden surge of over 400 cases in KSA and the United Arab Emirates (UAE) within just two 262 
months from mid-March to May 2014 as a result of both an increased number of primary cases 263 
possibly related to the weaning season of dromedary camels, a probable zoonotic source of 264 
MERS-CoV, and an amplification of the number of secondary cases by several healthcare-265 
associated outbreaks in the region during the same period (82, 266 
http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_Update_09_May_2014.pdf)267 
. As of 17 December 2014, the WHO has reported a total of 938 laboratory-confirmed cases of 268 
MERS including 343 deaths. The affected countries with primary cases include KSA, Qatar, 269 
Jordan, UAE, Oman, Kuwait, Egypt, Yemen, Lebanon, and Iran in the Middle East. The 270 
countries with imported cases include the United Kingdom, Germany, France, Italy, Greece, the 271 
Netherlands, Austria, and Turkey in Europe, Tunisia and Algeria in Africa, Malaysia and the 272 
Philippines in Asia, and the United States in North America. 273 
 274 
EPIDEMIOLOGY 275 
Among the first 699 laboratory-confirmed cases of MERS, 63.5% were male and the median age 276 
was 47 years, with a range of 9 months to 94 years 277 
(http://www.who.int/csr/disease/coronavirus_infections/MERS-278 
CoV_summary_update_20140611.pdf). The persistence of the epidemic is postulated to be 279 
related to repeated animal-to-human transmissions from at least one type of animal reservoir that 280 
is in frequent contact with residents in the region, which are amplified by non-sustained person-281 
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to-person transmission in multiple large-scale healthcare-associated outbreaks and limited 282 
household clusters (67, 68, 70, 71, 73-75, 83, 84, 283 
http://www.who.int/csr/disease/coronavirus_infections/MERS-284 
CoV_summary_update_20140611.pdf). Human infection has been linked to the contacts with 285 
dromedary camels (Camelus dromedarius) or other humans infected with MERS-CoV, but 286 
alternative sources of infection are possible as many patients did not have epidemiological link to 287 
infected camels or humans. All primary MERS cases were epidemiologically linked to the 288 
Middle East and all secondary cases in other countries were linked to primary cases imported 289 
from the Middle East. The incubation period is estimated to be 5.2 days, with a range of 1.9 to 290 
14.7 days, and 95% of infected patients have symptom onset by day 12.4 (63, 75). The serial 291 
interval, representing the time between the case’s symptom onset and the contact’s symptom 292 
onset, is estimated to be 7.6 days with a range of 2.5 to 23.1 days, and is less than 19.4 days in 293 
95% of the cases (63, 75). The rate of secondary transmission among household contacts of 294 
MERS patients is estimated to be about 4% (85). 295 
 296 
Risk Factors for Severe Disease 297 
Among the first 536 laboratory-confirmed cases reported by the WHO, 62% were severe cases 298 
that required hospitalization (77). Severe cases requiring hospitalization were more commonly 299 
seen among primary cases which mainly consist of older patients with comorbidities. The 300 
secondary cases were mostly younger patients and healthcare workers without comorbidities, but 301 
severe nosocomial infection among patients sharing contaminated equipment with improper 302 




CoV_summary_update_20140611.pdf) (Table 4). In a clinical cohort from KSA with 47 severe 305 
cases requiring hospitalization, the patients’ median age was 56 years. There was a male 306 
predominance with a male to female ratio of 3.3 to 1 (63). About 96% of the patients had 307 
comorbidities, with the most common being diabetes mellitus (68%), chronic renal disease 308 
(49%), hypertension (34%), chronic cardiac disease (28%), and chronic pulmonary disease 309 
(26%). Smoking and obesity were also reported in 23% and 17% of the patients respectively. The 310 
predominance of older males with comorbidities among severe cases was also reported in other 311 
case series at variable rates, depending on the size and setting of the studies (63, 66, 75, 80, 86-312 
89). Furthermore, age of over 50 years, male sex, and the presence of multiple comorbidities 313 
were associated with a higher fatality rate (63, 87, 90). Some of these conditions are highly 314 
prevalent among residents in the Middle East, for example, diabetes mellitus in nearly 63% of 315 
persons at or older than 50 years in KSA (91). Their relative risk of developing severe MERS 316 
requires further evaluation in large-scale case-control studies. Patients who develop 317 
complications such as acute respiratory distress syndrome requiring hospitalization and/or 318 
intensive care are also at risk of fatal outcome (87). 319 
 320 
Seroepidemiology 321 
The interim WHO case definition used early in the epidemic was criticized for being focused on 322 
identifying severe cases which might have over-estimated the clinical severity and significance 323 
of MERS (92). This was supported by the increasing number of asymptomatic and mild cases 324 
identified in subsequent enhanced surveillance among contacts of MERS patients in various 325 
clusters. It was thus suggested that the genuine epidemiology of MERS-CoV might be more 326 
similar to that of HCoV-HKU1 rather than SARS-CoV in that the infection is prevalent in the 327 
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general population, but only manifests severely in the elderly and immunocompromised (93-96). 328 
However, seroepidemiological studies conducted so far have refuted this hypothesis as there is 329 
little evidence of past infection among the general population in the Middle East. Serum anti-330 
MERS-CoV antibodies were not detected in archived serum samples of 2400 control in- or out-331 
patients without MERS in KSA, suggesting that MERS-CoV was unlikely to be circulating in the 332 
general population during the preceding two years (9, 90). Similarly, serum neutralizing anti-333 
MERS-CoV antibodies were not detected among 158 children hospitalized for lower respiratory 334 
tract infections and 110 adult male blood donors in KSA between May 2010 and December 2012 335 
(97). Even among 226 slaughterhouse workers who had contact with various livestock species 336 
that might serve as zoonotic sources of MERS-CoV, neutralizing anti-MERS-CoV antibodies 337 
were not detected in serum samples collected in October 2012 (98). Additional region-wide 338 
seroepidemiological studies that include large collections of archived samples from earlier 339 
timepoints may determine the true prevalence and clinical severity of MERS among residents in 340 
the affected areas. 341 
 342 
Animal Surveillance 343 
Given the sudden emergence of MERS-CoV without definite serological evidence of past 344 
exposure in the general population, a novel episode of interspecies transmission of the virus was 345 
postulated. An intense hunt for animal reservoirs of MERS-CoV was sparked by the early 346 
recognition of the close phylogenetic relationship between MERS-CoV and the prototype lineage 347 
C βCoVs, Ty-BatCoV-HKU4 and Pi-BatCoV-HKU5, which suggested the possibility of MERS-348 
CoV being a zoonotic agent (9, 13, 14, 21, 99). Subsequent functional studies showed that Ty-349 
BatCoV-HKU4 also utilizes DPP4 as a functional receptor for cell entry in pseudotyped virus 350 
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assay (100, 101). These findings concur with the existing notion that bats are the likely gene 351 
sources of most αCoVs and βCoVs including SARS-CoV (1, 15, 102-107). Recent reports also 352 
show a high nonsynonymous (dN) to synonymous (dS) nucleotide substitutions per site ratio in 353 
the bat DPP4-encoding genes (108). This adaptive evolution on the bat DPP4 is suggestive of 354 
long-term interactions between bats and MERS-CoV-related viruses (108). In addition to Ty-355 
BatCoV-HKU4 and Pi-BatCoVHKU5 which are found in bats in Hong Kong and Southern 356 
China, other lineage C βCoVs closely related to MERS-CoV were also identified in different bat 357 
species in the Middle East, Africa, Europe, and Central America after the MERS epidemic 358 
started (Table 5). The virus that is most closely related to MERS-CoV phylogenetically was a 359 
βCoV detected in the fecal pellet of a Taphozous perforatus bat caught in Bisha, KSA, near the 360 
home of a patient with laboratory-confirmed MERS, which shared 100% nucleotide identity with 361 
MERS-CoV by partial RdRp gene sequencing (109). However, this study was limited by the 362 
short length of the gene fragment analyzed (182 nucleotides) and its detection in only one of 29 363 
(3.4%) T. perforatus bats caught at the same location. Furthermore, no live virus was isolated 364 
from any of these bats. Subsequent studies identified a closely related virus, NeoCoV, in the 365 
feces of a Neoromicia capensis bat in South Africa which had a complete genome sequence 366 
sharing 85.6% nucleotide identity with those of MERS-CoV from infected humans and 367 
dromedary camels (110, 111). Based on the estimated evolutionary rate of MERS-CoV, the most 368 
recent common ancestor between NeoCoV and human MERS-CoV strains was proposed to exist 369 
in bats more than 44 years ago (112). As the same lineage of CoVs are usually found and 370 
originate from closely related bat species, the likelihood of MERS-CoV originating from both T. 371 
perforatus (superfamily Emballonuroidea) and vespertilionid bats (Neoromicia capensis, 372 
Pipistrellus sp., and Tylonycteris pachypus in the superfamily Vespertilionoidea), which belong 373 
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to two distantly related superfamilies of insectivorous bats, is low (20, 110, 111). Interestingly, 374 
European hedgehogs (Erinaceus europaeus) belonging to the order Eulipotyphla, which is 375 
closely related to bats phylogenetically, also carry high concentrations of a MERS-CoV-related 376 
lineage C βCoV, Erinaceus CoV, in their feces and intestines (113). Further surveillance and full 377 
virus genome sequencing involving a larger population of different bat and bat-related species is 378 
required to confirm these preliminary findings. 379 
 Besides the possibility of direct interspecies transmission of SARS-CoV from bats to 380 
humans, it is postulated that intermediate amplifying animal hosts such as civets and raccoon 381 
dogs might also have been important in the transmission of SARS. Therefore, specific 382 
intermediate animal hosts of MERS-CoV with frequent contact with infected humans were 383 
sought since the early phase of the MERS epidemic (3, 114, 115). In in vitro studies, MERS-CoV 384 
can replicate efficiently not only in a variety of bat cell lines, but also in cell lines originating 385 
from other animal species including camelid, goat, pig, rabbit, and civet (116-118) (Table 6). The 386 
host range is mainly determined by the binding of the MERS-CoV S protein to the host receptor 387 
DPP4, which is relatively conserved among mammalian species (30, 48, 49, 119, 120). The first 388 
in vivo evidence to support the presence of an intermediate animal reservoir of MERS-CoV 389 
emerged when high-titer of serum neutralizing IgG against the MERS-CoV S1 RBD were 390 
detected in dromedary camels (121). All 50 Omani dromedary camels were seropositive as 391 
compared to less than 10% of the Spanish dromedary camels and none of the other common 392 
livestock species in the study. This suggested that widespread circulation of MERS-CoV or a 393 
closely related virus was present among dromedary camels in this Middle Eastern country. 394 
Numerous seroepidemiological studies also demonstrated serological evidence of MERS-CoV 395 
infection in dromedary camels in other Middle Eastern countries including KSA, Qatar, UAE, 396 
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and Jordan, and also in African countries including Egypt, Kenya, Nigeria, Ethiopia, Tunisia, 397 
Somalia, and Sudan where most of the camels found in the Middle East have originated from 398 
(Table 5). Serological evidence of infection among camels was detected in archived specimens 399 
collected in as early as 1992 and 1983 in KSA and eastern Africa respectively, and was 400 
especially prevalent in areas of high dromedary population density (122-133). These findings 401 
suggested that unrecognized primary human cases of MERS might also be present outside the 402 
Middle East. On the other hand, studies in Qatar and several other countries showed that anti-403 
MERS-CoV antibodies were not detected in the sera of other livestock species tested including 404 
goats, sheep, cows, water buffaloes, swine, and wild birds 405 
(http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_RA_20140613.pdf). 406 
Furthermore, it was also shown that the percent seropositivity of neutralizing anti-MERS-CoV 407 
antibodies was much lower in juvenile than adult dromedary camels, suggesting that acutely 408 
infected juvenile dromedary camels without neutralizing antibodies might be a more important 409 
source for transmission to humans than adult dromedary camels (123, 127).  410 
The significance of camels as the major source of animal-to-human transmission required 411 
further virological studies on the pattern of viral shedding in camels and their relationship to 412 
laboratory-confirmed human cases (Fig. 4). An investigation of a disease outbreak in dromedary 413 
camels in Qatar demonstrated MERS-CoV in nasal swabs, but not rectal swabs or fecal samples, 414 
of three of 14 (21.4%) camels by RT-PCR sequencing (133). The nucleotide sequences of a 940-415 
nucleotide ORF1a fragment and a 4.2 kb concatenated gene fragment of these camel strains were 416 
very similar to those of two epidemiologically-linked human strains. This study, however, was 417 
not able to conclusively establish the direction of transmission or exclude the presence of a third 418 
source of infection. Subsequently, the detection of MERS-CoV in dromedary camels was 419 
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reported in a number of studies conducted in different areas in the Middle East, which provided 420 
further insights into the viral shedding kinetics in camels (123, 128, 129, 131, 134). In agreement 421 
with the lower frequency of neutralizing anti-MERS-CoV antibodies in juvenile camels, the rate 422 
of detection of MERS-CoV RNA in the nasal and/or rectal swabs of juvenile camels was higher 423 
than those of adult camels (123). These findings may partially explain the absence of serum 424 
neutralizing anti-MERS-CoV antibodies among camel abattoir workers who have predominantly 425 
contacted adult camels (135, 136). These serological surveys should be confirmed by virus 426 
neutralization assays. Nevertheless, infected adult camels might still be a source of human 427 
infection. Similar to HCoVs and other respiratory viruses that can cause repeated infections in 428 
humans over a lifetime, MERS-CoV shedding could be observed in camels with pre-existing 429 
serum antibodies, suggesting that prior infection and passively acquired maternal antibodies 430 
might not provide complete protection from MERS-CoV infection and/or re-infection in camels 431 
(129). The fact that the majority of amino acid residues critical for receptor binding are identical 432 
between most human and camel strains further supports the potential of the dromedary MERS-433 
CoVs to infect humans despite differences in clinical manifestations of infected humans and 434 
camels (129, 131). The higher positivity rate of MERS-CoV RNA in nasal swabs than in rectal 435 
swabs or fecal samples, and the isolation of MERS-CoV from cultures of nasal swabs but not 436 
rectal swabs of camels in Vero E6 cells correlated with the predominantly upper respiratory tract 437 
symptoms in acutely infected symptomatic camels (129, 137). Together with the genetic stability 438 
of MERS-CoV in camels, these serological and virological data from animal surveillance support 439 
the hypothesis that MERS-CoV has likely originated from bats in Africa and then crossed species 440 
barriers to infect camels in the greater Horn of Africa many years ago. Infected camels were then 441 
transported to the Middle East where they transmitted the virus to non-immune humans to cause 442 
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the epidemic (111). 443 
The strongest evidence of direct cross-species transmission of MERS-CoV from camels 444 
to humans was provided in a study reporting the isolation of the virus from a dromedary camel 445 
which had a complete genome sequence identical to that of a human strain from a patient who 446 
developed MERS after close contact with sick camels that had rhinorrhea (138). Serological tests 447 
showed seropositivity in the camels but not in the patient before the human infection occurred 448 
(138). The air sample collected from the camel barn on the same day when a sick camel tested 449 
positive for MERS-CoV, but not on the subsequent two days, was also positive for MERS-CoV 450 
RNA by RT-PCR (139). This suggests that the virus may persist in the air surrounding infected 451 
animals or humans for less than 24 hours, although viral infectivity is uncertain because the virus 452 
was not culturable from the air sample. Another similar study also reported a human case of 453 
MERS that developed after the patient had contact with sick camels with respiratory symptoms 454 
(128). Comparison of eight RT-PCR fragments, constituting 15% of the virus genomes derived 455 
from the infected camel and from an epidemiologically-linked patient, showed nearly 100% 456 
nucleotide identity (128). The genomes of both the camel and human strains of MERS-CoV 457 
contained unique nucleotide polymorphism signatures not found in any other known MERS-CoV 458 
sequences and therefore supported direct cross-species transmission (128). Preliminary results 459 
from an ongoing investigation in Qatar showed that people working closely with camels, 460 
including farm workers, slaughterhouse workers, and veterinarians, may be at higher risk of 461 
developing MERS than those who do not have regular contact with camels 462 
(http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_RA_20140613.pdf). 463 
Notably, while these studies support camel-to-human transmission, a bidirectional mode of 464 
transmission cannot be completely excluded at this stage. 465 
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In spite of these examples that support the hypothesis of direct camel-to-human cross-466 
species transmission of MERS-CoV, a number of important questions remain unresolved at this 467 
stage. Firstly, it is uncertain whether camels are intermediate amplification hosts or the natural 468 
reservoirs of MERS-CoV. Although bats are postulated to be the natural host of most βCoVs 469 
including MERS-CoV, the detection of anti-MERS-CoV antibodies in archived sera of camels 470 
dating back to more than 28 years ago in eastern Africa and more than 20 years ago in KSA, the 471 
high genetic stability of MERS-CoV in camels, and the high sequence nucleotide identities 472 
between camel and human strains of MERS-CoV suggest that the virus was well adapated and 473 
circulating in camels for a long time (123, 129). The reason why human infection has not been 474 
reported until 2012 remains elusive. Notably, a different novel lineage A βCoV, named 475 
dromedary camel CoV UAE-HKU23, has also been discovered in the fecal samples of 476 
dromedary camels in Dubai, UAE recently (140). Further surveillance studies may provide novel 477 
insights into the role of this unique camelid species, which also have heavy-chain antibodies as 478 
humoral defense, in the emergence of novel CoVs (141). Another unresolved question is whether 479 
an alternative source may be present but undetected at this stage. It is noteworthy that a 480 
significant proportion of laboratory-confirmed human cases did not have a clear history of 481 
contact with camels (83, 142). Evaluation of other animal species endemic in the region using 482 
validated serological and virological assays should be conducted. Finally, the route of 483 
transmission of MERS-CoV from camels to humans remains unknown at this stage. Droplet 484 
transmission appears likely as evidenced by the high viral loads in the nasal and conjunctival 485 
swabs of camels and the surrounding air samples. However, viral shedding in nasal secretions is 486 
usually short-lasting during acute infection, which may limit viral transmission by this route 487 
(129). Direct contact with other infected bodily fluids including blood and feces is also possible, 488 
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but viral shedding in these samples is also transient in acute infection (129). Food-borne 489 
transmission through ingestion of infected unpasteurized camel milk, in which MERS-CoV can 490 




C, has also been suggested. But it has yet to be 491 
definitively proven that camels actively shed MERS-CoV in their milk as contamination by 492 
feces, nasal secretions, or calf saliva containing the virus cannot be completely excluded (143). 493 
The presence of neutralizing antibody in milk may also limit the virus’ infectivity in vivo (144). 494 
In human MERS cases without direct exposure to camels, contact with environments 495 
contaminated with infected camel secretions and aerosol transmission are other possibilities that 496 
warrant further investigations (139, 145).  497 
 498 
Molecular Epidemiology 499 
Detailed analysis of the molecular evolution and spatiotemporal distribution of genomes 500 
of human and animal strains of MERS-CoV provides useful information for detecting viral 501 
adaptation to animal-to-human and person-to-person transmissions, identifying zoonotic and 502 
other sources of human infections, and assessing the pandemic potential of the virus. 503 
Comparative analysis of 65 complete or near-complete genomes of human MERS-CoV strains 504 
identified early in the epidemic from June 2012 to September 2013 estimated the evolutionary 505 
rate of the coding regions of the viral genome to be 1.12  10-3 (95% confidence interval, 8.76  506 
10
-4
 to 1.37  10-3) substitutions per site per year (146). The time to the most recent common 507 
ancestor (TMRCA) of MERS-CoV was estimated to be March 2012 (95% confidence interval, 508 
December 2011 to June 2012) (112, 146). Compared with the genome of one of the earliest 509 
human MERS-CoV strains, the genomes of the MERS-CoV strains obtained from patients 510 
diagnosed between October 2012 and June 2013 showed various nucleotide changes in the last 511 
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third of the genomes, which represent potential amino acid changes in the accessory proteins and 512 
the S protein encoded at nucleotide positions 21,000-25,500 (112). Specifically, codon 1020 at 513 
the HR1 domain of the S gene was identified to be under strong episodic selection among 514 
different geographical lineages with either a histidine or arginine at this position (112, 146). 515 
Although the amino acid variations are not predicted to change the alpha helical structure of this 516 
region, the histidine and arginine provide an endosomal protonated residue and a potential 517 
endosomal protease cleavage site respectively that may affect the S protein membrane fusion 518 
activity (146). Codon 158 at the N-terminal domain and codon 509 at the RBD of the S gene are 519 
also noted to be under weaker positive selection (146). As mutations in the RBD of the S protein 520 
of CoVs may be associated with changes in the transmissibility across and within species, the 521 
phenotypic changes associated with these genomic variations should be ascertained (3, 29, 147-522 
149). 523 
In addition to the results of animal surveillance studies and investigations of human 524 
MERS outbreaks, genomic analysis also supports the hypothesis that MERS-CoV is transmitted 525 
from both animal-to-human and person-to-person. Among genomes of sporadic human MERS 526 
cases, numerous distinct phylogenetic clades and genotypes exist, which likely represent separate 527 
instances of incursions from animals to human (112). Indeed, at least four clades of MERS-CoV 528 
were identified in KSA, with three of them apparently no longer widely circulating during May 529 
to September 2013 (146). In a large healthcare-associated outbreak in Al-Hasa, person-to-person 530 
transmissions were supported by genomic analysis in at least 8 of 13 patients (75, 112). Two 531 
phylogenetically distinct MERS-CoV strains were detected in a family cluster in Riyadh, KSA, 532 
in October 2012, suggesting that at least two distinct lineages of MERS-CoV were circulating in 533 
Riyadh during this time period and that human clusters might involve multiple sources with more 534 
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than one virus lineage (112). The genomic diversity of MERS-CoV detected in patients from the 535 
same locality and the geographical dispersion of MERS-CoV lineages in the Middle East suggest 536 
the presence of multiple mobile infection sources such as animal reservoirs, infected animal 537 
products, and/or infected patients in the epidemic regions (146). This hypothesis fits well with 538 
the evidence of MERS-CoV infection in dromedary camels, which are an important vehicle for 539 
transportation of goods and travelers, as well as food source in the Middle East. Notably, 540 
quasispecies of MERS-CoV within single samples have been detected in samples from 541 
dromedary camels but not humans or Vero cell isolates from the same animal (137). Further 542 
studies using next-generation high throughput sequencing are required to confirm the presence of 543 
quasispecies and clonal virus populations within individual human cases, which may help 544 
identify specific genotypes that can pass the bottleneck selection to cause cross-species 545 
transmission from camels to humans, and help to explain the relative rarity of human cases 546 
despite the widespread circulation of MERS-CoV in dromedary camels for prolonged periods in 547 
the Middle East and North Africa (137). 548 
 549 
Mathematical Modeling 550 
Mathematical modeling has been widely used to predict the spread and pandemic potential of 551 
emerging viruses. Although the interval for data accumulation may diminish the predictive value 552 
of mathematical modeling and its impact on epidemiological control or policy setting, these 553 
studies provide a preliminary estimate of the pandemic potential of emerging viruses if enough 554 
data are included in the calculations. Three real-time predictions of the spread of MERS-CoV 555 
have been conducted for the current epidemic and have estimated the basic reproduction number 556 
(R0), the number of secondary cases per index case in a fully susceptible population, to be 0.30-557 
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0.77 (150), 0.60-0.69 (90), or 0.8-1.3 (151), as compared to about 0.8 for pre-epidemic SARS-558 
CoV. These estimates imply the occurrence of a subcritical epidemic in the Middle East, which is 559 
unlikely to sustain person-to-person transmission of MERS-CoV, especially when infection 560 
control measures are implemented (150). The estimated daily rate of MERS-CoV introductions 561 
into the human population in the Middle East is 0.12-0.85 and the expected yearly incidence of 562 
MERS introduction was estimated to be between 160 and 320 cases per year (90, 150). Clearly, 563 
these estimations are at most only modestly accurate for a number of reasons. Firstly, these 564 
studies were conducted early in the epidemic when the total number of laboratory-confirmed 565 
cases was only less than one-eighth of that reported by the WHO as of 17 December 2014 (90, 566 
150, 151). This low number limited the accuracy of the predictions as sufficient caseload is 567 
required to calculate the basic parameters for estimation of the worst- and best-case scenarios to 568 
gauge the magnitude of the epidemic. The omission of large clusters may underestimate the R0 569 
(90). Secondly, most of the cases reported in the early period of the epidemic were biased 570 
towards including more severe cases. The increasingly recognized number of asymptomatic or 571 
mildly symptomatic cases identified through enhanced surveillance programmes may further 572 
underestimate the R0 (90). Finally, the R0 may also be affected by community demographics, 573 
contact structure, large gatherings such as the Hajj, and exportation of patients from the 574 
relatively less populated Middle East to densely populated areas such as Southeast Asia (78, 90). 575 
Updated mathematical modeling using the latest available epidemiological and virological data 576 
may increase the accuracy of these estimates. 577 
 578 
CLINICAL MANIFESTATIONS 579 
The early reports of MERS have focused on severe cases which typically presented as acute 580 
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pneumonia with rapid respiratory deterioration and extrapulmonary manifestations (Table 7). 581 
Few clinical and radiological features can reliably differentiate MERS from acute pneumonia 582 
caused by other microbial agents (80). The common presenting symptoms of MERS are non-583 
specific, and include feverishness, chills, rigors, sore throat, non-productive cough, and dyspnea. 584 
Other symptoms of respiratory tract infections including rhinorrhea, sputum production, 585 
wheezing, chest pain, myalgia, headache, and malaise may also be present. Rapid clinical 586 
deterioration with development of respiratory failure usually occurs within a few days after these 587 
initial symptoms (80). Physical signs at the time of deterioration may include high fever, 588 
tachypnea, tachycardia, and hypotension. Diffuse crepitations may be present on chest 589 
auscultation, but they may be disproportionately mild compared with radiological findings (68). 590 
 Chest radiograph abnormalities are found in nearly all severe cases and often progress 591 
from a mild unilateral focal lesion to extensive multifocal or bilateral involvement especially of 592 
the lower lobes as the patient deteriorates (63). The radiological changes are non-specific and 593 
indistinguishable from other viral pneumonias associated with acute respiratory distress 594 
syndrome (ARDS), and include air-space opacities, segmental, lobar or patchy consolidations, 595 
interstitial ground glass infiltrates, reticulonodular shadows, bronchial wall thickening, increased 596 
bronchovascular markings, and/or pleural and pericardial effusions (Table 7). Rarely, pneumonia 597 
may be an incidental finding in chest radiograph and precede the sudden deterioration in 598 
respiratory function in patients who are harboring a “walking pneumonia” with minimal 599 
respiratory tract symptoms (63, 68). The most common thoracic computerized tomography (CT) 600 
scan features are bilateral, predominantly basilar and subpleural airspace involvement, with 601 
extensive ground-glass opacities, and occasional septal thickening and pleural effusions (152). 602 
Tree-in-bud pattern, cavitation, and lymph node enlargement have not been reported. Fibrotic 603 
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changes including reticulation, traction bronchiectasis, subpleural bands, and architectural 604 
distortion may be found in thoracic CT scans performed three weeks after symptom onset. These 605 
different changes in thoracic CT scan throughout the course of disease are suggestive of 606 
organizing pneumonia and may mimic those seen in other viral pneumonias such as influenza (4, 607 
8, 153-156).  608 
 Various extrapulmonary manifestations involving multiple body systems have been 609 
reported in MERS (Table 7). Acute renal impairment was the most striking feature in the early 610 
reports (9, 18). This finding was confirmed in subsequent sporadic reports and at least three case 611 
series that provided specific details on renal function, in which more than half of the patients 612 
developed acute renal impairment at a median time of around 11 days after symptom onset, with 613 
most requiring renal replacement therapy (88, 152, 157). This is unique among CoV infections of 614 
human. For SARS, only around 6.7% of patients developed acute renal impairment mainly due 615 
to hypoxic injury at a median duration of 20 days after symptom onset and 5% required renal 616 
replacement therapy (158, 159). The exceptionally high incidence of this distinctive 617 
manifestation of MERS is likely multi-factorial. These include the high prevalence of 618 
background chronic renal impairment among severe cases and the renal tropism of MERS-CoV 619 
(63, 116, 157). The presence of MERS-CoV RNA in urine also supports the possibility of direct 620 
renal involvement, but the exact incidence and prognostic significance of this finding is unknown 621 
at present (72). 622 
 As in humans infected with SARS-CoV and animals infected with other CoVs, patients 623 
infected with MERS-CoV may have enteric symptoms in addition to respiratory tract 624 
involvement (3, 160, 161). Gastrointestinal symptoms are found in more than a quarter of 625 
hospitalized cases in a large cohort in KSA (63). Diarrhea is the most common symptom and 626 
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occurs in 6.7% to 25.5% of severe cases. Nausea, vomiting, and abdominal pain may also occur. 627 
The detection of viral RNA in fecal samples has been reported, but longitudinal studies on the 628 
pattern of viral shedding are lacking (72). It remains to be determined whether cases of acute 629 
abdomen presenting as ischemic bowel or negative findings on laparotomy result from hypoxic 630 
damage or direct viral invasion of the gastrointestinal tract (88). 631 
 Other extrapulmonary features of MERS include hepatic dysfunction, pericarditis, 632 
arrhythmias, and hypotension (66). Hematological abnormalities include leukopenia or 633 
leukocytosis, usually accompanied by lymphopenia with normal neutrophil count, and 634 
thrombocytopenia. Compared to other patients with pneumonia, patients with MERS are more 635 
likely to have a normal leukocyte count on admission (80). Anemia, coagulopathy, and 636 
disseminated intravascular coagulation have also been reported (64, 72, 162). Elevated levels of 637 
serum transaminases, lactate dehydrogenase, potassium, creatine kinase, troponin, C-reactive 638 
protein, and procalcitonin, and reduced levels of serum sodium and albumin are seen 639 
occasionally. 640 
 Complications of MERS include bacterial, viral, and/or fungal co-infections, ventilator-641 
associated pneumonia, septic shock, delirium, and possibly stillbirth (9, 69, 71, 73) (Table 7). 642 
Respiratory failure with ARDS and multiorgan dysfunction syndrome is not uncommon, and the 643 
majority of such patients require admission to the intensive care unit at a median of 2 to 5 days 644 
from symptom onset. The median time from symptom onset to invasive ventilation and/or 645 
extracorporeal membrane oxygenation (ECMO) in these patients is 4.5 to 7 days, which is at 646 
least 6 days earlier than that of SARS (63, 75, 88, 162, 163). The duration of stay in the intensive 647 
care unit is often prolonged with a median of 30 days (range: 7 to 104 days). The case-fatality 648 
rate is up to 25.0% to 76.5% in various cohorts (Table 7). 649 
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 With enhanced surveillance of healthcare-associated and family contacts of MERS 650 
patients, an increasing number of asymptomatic and mild cases have been identified. Most of 651 
these patients are young, healthy female healthcare workers or children who do not have any 652 
comorbidities (65, 164). Among 402 patients identified in the recent clusters that occurred in 653 
KSA between 11 April 2014 and 9 June 2014, 109 (27.1%) were healthcare workers. Of note, 654 
though many were either asymptomatic or mildly symptomatic, more than one-third developed 655 
moderate to severe disease requiring hospitalization and nearly 4% died 656 
(http://www.who.int/csr/disease/coronavirus_infections/MERS-657 
CoV_summary_update_20140611.pdf). Severe and even fatal cases have also been reported 658 
among infected children, especially in those who have underlying diseases such as cystic fibrosis 659 
and Down’s syndrome with congenital heart disease and hypothyroidism (164). Therefore, even 660 
healthcare workers and children with MERS should be monitored closely for clinical 661 
deterioration. 662 
 663 
HISTOPATHOLOGY AND PATHOGENESIS 664 
The pathogenesis of MERS is under-studied and poorly understood. Serial sampling for 665 
characterization of the innate and adaptive immune responses is lacking in human cases of 666 
MERS. Due to religious and cultural reasons, post-mortem examination was seldom performed 667 
in Islamic patients who died of MERS and no post-mortem findings have been reported so far. 668 
Thus, the current understanding on the histopathology and pathogenesis of MERS is limited to 669 
findings in in vitro, ex vivo, and animal experiments. 670 
 671 
Histological Changes 672 
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In rhesus macaques infected with MERS-CoV, macroscopic changes of acute pneumonia 673 
including multifocal to coalescent bright red palpable nodules with congestion occurred 674 
throughout the lower respiratory tract in necropsy lung tissues collected on day 3 post-infection 675 
(165-167). On day 6 post-infection, these inflamed areas progressed into dark reddish purple 676 
lesions. Microscopically, the changes resembled those seen in mild to severe acute interstitial 677 
pneumonia, characterized by alveolar infiltration by small to moderate numbers of macrophages 678 
and fewer neutrophils with occasional multinucleate syncytia, and thickening of alveolar septae 679 
by edema fluid and fibrin on day 3 post-infection. Lesions similar to those described in early 680 
bronchiolitis obliterans with organizing pneumonia consisting of aggregations of fibrin, 681 
macrophages, and sloughed pulmonary epithelium that occluded small airways, and multifocal 682 
perivascular infiltrates of inflammatory cells within and adjacent to the affected areas of lungs 683 
were also reported. On day 6 post-infection, moderate to marked microscopic changes including 684 
type II pneumocyte hyperplasia, alveolar edema, and hyaline membranes of fibrin were observed 685 
(166). In situ hybridization and immunohistochemistry demonstrated viral RNA and antigen 686 
respectively in type I and II pneumocytes, alveolar macrophages, and occasionally round 687 
mononuclear cells and stellate cells within the cortex of the mediastinal lymph nodes, but not in 688 
pulmonary endothelial cells, on both days 3 and 6 post-infection (166, 167). Infected cells were 689 
not observed in the kidney, brain, heart, liver, spleen, and large intestine of the infected rhesus 690 
macaques (167). Common marmosets infected with MERS-CoV showed similar but more severe 691 
histological findings. In necropsied lungs of common marmosets euthanized on days 3 to 4 post-692 
infection, extensive transcriptional evidence of pulmonary fibrosis was present (168). In 693 
immunosuppressed rhesus macaques using cyclophosphamide and dexamethasone with depleted 694 
T and B cells and disrupted splenic and mesenteric lymph node architectures, MERS-CoV 695 
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replicated more efficiently and affected more tissues as compared to non-immunosuppressed 696 
controls. Interestingly, the immunosuppressed animals had fewer histological changes associated 697 
with infection despite having higher virus replication in the lungs, suggesting that 698 
immunopathology might also play a key role in MERS (169). 699 
 700 
Innate Immune Response 701 
Immune evasion is an important strategy utilized by CoVs to overcome the innate immune 702 
response for efficient replication in the host. MERS-CoV is capable of inhibiting recognition, 703 
delaying interferon induction, and dampening interferon-stimulated genes (ISGs) expression in 704 
polarized human bronchial epithelia (Calu-3) cells until peak viral titers have been reached (170). 705 
While MERS-CoV triggers an activation of pattern recognition receptors that is similar to SARS-706 
CoV, their subsequent levels of interferon induction in Calu-3 cells are markedly different (171). 707 
This may be related to the different structural and accessory proteins of the two viruses that act 708 
as interferon antagonists. Instead of the papain-like protease, accessory proteins 3b and 6, nsp1, 709 
M, and N proteins which are the major putative interferon antagonists of SARS-CoV, the papain-710 
like protease encoded by nsp3 of ORF1a/b, M protein encoded by ORF7, and accessory proteins 711 
4a and 4b encoded by ORF4a and -4b respectively of MERS-CoV antagonize interferons in vitro 712 
(3, 24, 25, 27, 28, 172). Among them, the MERS-CoV accesory protein 4a, a double-stranded 713 
RNA-binding protein, exhibits potent antagonistic activity at multiple levels of the interferon 714 
response including the prevention of interferon-β synthesis through the inhibition of interferon 715 
promoter activation and interferon regulatory factor 3 (IRF3) function, and inhibition of the 716 
interferon-stimulated response element (ISRE) promoter signaling pathway in human (HEK-717 
293T) and/or primate kidney (Vero) cells (24). Specifically, it inhibits PACT-induced activation 718 
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of retinoic acid-inducible gene 1 (RIG-I) and melanoma differentiation-associated protein 5 719 
(MDA5), which are key cytosolic recognition receptors of virus-derived RNAs (25). 720 
Furthermore, preliminary data show that MERS-CoV, but not SARS-CoV, may employ an 721 
additional mechanism to antagonize ISG via altered histone modification which affects a diverse 722 
spectrum of biological processes including gene regulation (170). With the attenuated interferon 723 
response at the cellular level, the virus may then employ the deISGylating and deubiquitinating 724 
activities of its papain-like protease to take over the host metabolic apparatus (28, 172, 173). 725 
Efficient viral replication may follow and result in cell damage through direct virus-induced 726 
cytolysis or immunopathology via dysregulated pro-inflammatory cytokine induction. 727 
 In addition to these in vitro data, the roles of the different branches of the innate immune 728 
response have been assessed in a limited number of animal models and patients. MERS-CoV 729 
infection is more severe in knockout C57BL/6 and BALB/c mice with impaired type I interferon 730 
or Toll-like receptor signaling than those with impaired RIG-I-like receptor signaling, suggesting 731 
that the former signaling pathways are more important for controlling the infection (174). The 732 
depletion of natural killer cells, a major cellular component of the innate immune response, does 733 
not significantly affect the clinical disease severity or viral clearance kinetics (174). In rhesus 734 
macaques, the innate immune response occurs and resolves very rapidly after MERS-CoV 735 
inoculation. A type I interferon response is observed on days 1 and 2 and disappears on day 3 736 
after infection (166, 175). Robust but transient up-regulation of the expression levels and 737 
elevated serum levels of proinflammatory cytokines and chemokines including interleukin-6 (IL-738 
6), chemokine (C-X-C motif) ligand 1 (CXCL1), and matrix metalloproteinase 9 (MMP9) are 739 
associated with chemotaxis and activation of neutrophils as evidenced by increased numbers of 740 
neutrophils in the blood and lungs of the infected animals (166). In humans who develop severe 741 
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MERS, significant differences are noted between the innate immune responses of fatal and non-742 
fatal cases. Compared to a patient who survived, a patient who died from MERS induced lower 743 
expression levels of RIG-I and MDA-5, which led to decreased expression levels of IRF3 and 744 
IRF7 (176). This was associated with a major decrease in the amount of mRNA and protein of 745 
interferon-α in serum and bronchoalvelolar lavage. Additionally, the antigen presentation 746 
pathway was broadly down-regulated and affected types I and II major histocompatibility 747 
(MHC) genes which were associated with significantly lower expression levels of the key 748 
cytokines involved in the activation of lymphocytes into CD4+ Th1 cells, including IL-12 and 749 
interferon-γ (176, 177). Increased levels of IL-17A and IL-23 in the serum and bronchoalveolar 750 
lavage within the first week after symptom onset, and persistent uncontrolled secretion of the 751 
type-1 interferon-triggered CXCL10 and IL-10 beyond the first week after symptom onset, were 752 
noted in fatal MERS cases and might be associated with poor outcome as in SARS and other 753 
respiratory viral infections (176, 178-181). A poorly coordinated innate immune response with 754 
ineffective activation of the adaptive immune response that failed to clear MERS-CoV viremia 755 
appeared to be associated with fatal outcome (176, 182). 756 
 757 
Adaptive Immune Response 758 
Systematic study on the adaptive immune response to MERS in large cohorts of human cases is 759 
lacking. T-cell or combined T- and B-cell deficiencies, but not B-cell deficiency, were found to 760 
be associated with persistent infections and lack of virus clearance in C57BL/6 and BALB/c 761 
mice transduced with adenoviral vectors expressing human DPP4, highlighting the important 762 
role of T cells in acute clearance of MERS-CoV (174). In terms of antibody-mediated immunity 763 
which is essential for protection against subsequent challenge by the virus, the CD8 T-cell 764 
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response to the immunodominant epitopes located in the MERS-CoV S protein is shown to peak 765 
at days 7 to 10 post-infection and exhibits only low level of cross-reactivity with the T-cell 766 
response to SARS-CoV infection (174). In rhesus macaques infected with MERS-CoV, serum 767 
neutralizing antibodies are detected on as early as day 7 post-infection, reaching a peak titer on 768 
day 14 post-infection, and decreasing slightly in titer on day 28 post-infection. In patients with 769 
MERS, high titers of serum neutralizing antibodies can be detected on day 12 and persist for at 770 
least 13 months after symptom onset (66, 72, 81, 183). Both IgM and IgG against S and N 771 
proteins are detectable in the sera of infected patients on day 16 after symptom onset, with the 772 
titer of IgG being at least 10 times higher than that of IgM, suggesting that the initial IgM 773 
antibody response is likely mounted before this time period (72). IgG titers peaked at three 774 
weeks after symptom onset, while IgM titers remained elevated between two to five weeks after 775 
symptom onset in a patient (184). Notably, serum anti-MERS-CoV antibodies were undetectable 776 
in a patient who died on days 26 and 32 after symptom onset, suggesting that inadequate 777 
antibody response may be associated with poor clinical outcome (66). The exact onset and 778 
changes in titer of serum neutralizing anti-MERS-CoV antibodies should be further evaluated in 779 
subsequent clinical cohorts consisting of patients with different severities and outcomes. 780 
Moreover, given the in vitro observation that the viral fitness and evolution may be restricted by 781 
the immunodominance of the anti-MERS-CoV-RBD neutralizing antibody response that blocks 782 
binding to human DPP4, B cell-associated antibodyome studies from MERS patients should be 783 
performed to further assess the role that immunoglobulin polymorphisms play in determining the 784 
protective antibody repertoire and clinical outcomes (40). 785 
 786 
Organ-Specific Pathology and Systemic Virus Dissemination 787 
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Although in vitro cell line studies and even ex vivo organ cultures may not completely represent 788 
in vivo scenarios, they have provided insightful clues to explain the pathogenesis involved in the 789 
pulmonary and extrapulmonary manifestations of MERS, before findings from animal models 790 
and post-mortem examination are available (Table 6). The in vitro observation that MERS-CoV 791 
replicates more efficiently in a variety of lower respiratory tract cell lines than in upper 792 
respiratory tract cell lines, and the inability of the human bronchial epithelium to mount a timely 793 
and adequate innate immune response against MERS-CoV infection in the absence of 794 
professional cytokine-producing cells including dendritic cells and macrophages may partially 795 
explain the high incidence of severe cases in MERS (116, 157, 171, 185-188). The finding in ex 796 
vivo culture systems that MERS-CoV is capable of infecting most cell types of the human 797 
alveolar compartment including non-ciliated and possibly ciliated epithelial cells, types I and II 798 
pneumocytes, and endothelial cells of pulmonary vessels further supports the notion that all the 799 
host cell factors necessary for viral replication are available in the human lung (187, 189-191). 800 
Additionally, MERS-CoV can also infect pulmonary vascular endothelial cells and lung 801 
macrophages, which corroborates with the clinical observation of systemic dissemination of the 802 
virus with viremia in severe cases (191). 803 
 Besides lower respiratory tract cells, MERS-CoV also exhibits a peculiar tropism for 804 
renal cells that is not seen in any other CoVs associated with human infections and not 805 
explainable by the expression of their respective host cell receptors. Avian nephropathogenic 806 
infectious bronchitis virus may cause lymphoplasmacytic interstitial nephritis, but rarely 807 
pneumonia, in broiler chickens (192). MERS-CoV replicates efficiently to about 5 logs above the 808 
baseline titer with abundant N protein expression and prominent cytopathic effects (CPE) within 809 
72 hours after infection in human embryonic kidney cells (116). In primary kidney epithelial 810 
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cells and primary bronchial epithelial cells infected with either MERS-CoV or SARS-CoV, 811 
pronounced CPE with rounding, detachment, and death of the majority of cells occur only in 812 
primary kidney epithelial cells infected with MERS-CoV, although viral replication was 813 
detectable with both viruses (157). The concentration of infectious MERS-CoV progeny in 814 
primary kidney epithelial cells was almost 1000-fold higher than that in primary bronchial 815 
epithelial cells (157). Together with the clinical observation that MERS-CoV RNA may be 816 
detectable in the urine without viremia after almost 2 weeks of symptom onset, these in vitro 817 
findings suggest that the kidney may be a potential site of autonomous virus replication (72, 818 
157). Comparable findings are also observed in many bat and primate kidney cell lines, although 819 
clinical disease in these animals is much milder than in humans and viral RNA is not detectable 820 
in the kidneys of infected rhesus macaques (116, 117). As in the case of ex vivo lung cultures, it 821 
would be important to elucidate the specific pathways involved in virus-host cell interactions 822 
affecting different cell types such as podocytes in the renal cortex and others in the medulla 823 
which are often involved in renal disease pathogenesis. 824 
 In view of the pronounced systemic inflammatory response with multi-organ involvement 825 
and hematological abnormalities seen in patients with MERS, the specific roles of immune cells 826 
in the pathogenesis of the disease have been investigated. Among the immune cells, human 827 
histiocytes efficiently support viral replication with N protein expression in vitro on as early as 828 
day 1 post-infection, while increased viral RNA levels without N protein expression are 829 
detectable in human monocyte and T lymphocyte cell lines (116). Correspondingly, ex vivo 830 
culture systems of human monocyte-derived dendritic cells and macrophages confirm that 831 
MERS-CoV can productively infect both of these important professional antigen-presenting cell 832 
types with high-level and persistent induction of immune cell-recruiting cytokines (191, 193). 833 
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This leads to recruitment and infiltration of a large number of immune cells into the infected lung 834 
tissues as is seen clinically. Moreover, the sequestration of lymphocytes at infected tissues 835 
resulting from the induction of CXCL10 and monocyte chemotactic protein 1 (MCP-1) may also 836 
explain marked peripheral lymphopenia that is commonly seen in MERS (191). Together with 837 
the wide distribution of DPP4 in different human cell types, the ability of MERS-CoV to hijack 838 
these professional antigen-presenting cells as vehicles for systemic dissemination to and 839 
induction of immunopathology at various organs may help to explain the unusually severe multi-840 
organ involvement in MERS.  841 
 842 
LABORATORY DIAGNOSIS 843 
There are no pathognomonic clinical, biochemical, or radiological features that reliably 844 
differentiate MERS from other causes of acute community- or hospital-acquired pneumonia. Due 845 
to the lack of Biosafety Level 3 (BSL-3) containment, nucleic acid amplification assays are the 846 
most widely used method to provide laboratory confirmation of MERS with a short turn-around 847 
time using a unified testing protocol that was established early on in the epidemic. The WHO 848 
criteria for a laboratory-confirmed case include either a positive RT-PCR result for at least two 849 
different specific targets on the MERS-CoV genome, or one positive RT-PCR result for a specific 850 
target on the MERS-CoV genome and an additional different RT-PCR product sequenced, 851 
confirming identity to known sequences of MERS-CoV (Table 8) 852 
(http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?u853 
a=1). Isolation of infectious MERS-CoV from respiratory tract specimens, and possibly also 854 
blood, urine, and fecal samples, also provides laboratory confirmation, but virus isolation has a 855 
longer turn-around time than nucleic acid amplification assays, requires experienced staff for 856 
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interpretation of CPE and confirmation of infection by RT-PCR or immunostaining. Serological 857 
assays for detection of specific neutralizing anti-MERS-CoV antibodies in paired sera, taken at 858 
the acute and convalescent phases 14 to 21 days apart, also provides evidence of infection, but 859 
none of the serological assays developed so far has been thoroughly validated or compared 860 
against each other. Furthermore, viral culture and neutralizing antibody detection assays using 861 
whole virus require BSL-3 containment, which is not widely available in standard clinical 862 
microbiology laboratories. 863 
 864 
Specimen Collection 865 
The ideal clinical specimen for laboratory diagnosis is one which can be readily obtained by non-866 
invasive means and contains a large number of infected cells with high viral load. Although 867 
lower respiratory tract specimens including tracheal aspirate and bronchoalveolar lavage contain 868 
higher viral loads and genome yields than upper respiratory tract specimens and sputum, they 869 
require invasive procedures for collection and may not be easily obtainable in the early phase of 870 
illness (71, 72, 194). Therefore, upper respiratory tract specimens including nasopharyngeal 871 
aspirate or swabs, and oropharyngeal swabs are the most commonly collected specimens in 872 
suspected cases of MERS. Clinical specimens from extrapulmonary sites, especially urine, feces, 873 
blood, and/or tissues, may occasionally be positive and should also be collected if available, 874 
especially for their possible impact on infection control implementation (71, 72, 81, 176, 182). 875 
Notably, the diagnosis of MERS in a Tunisian patient was established by RT-PCR targeting the 876 
upE and N genes followed by nucleotide sequencing of RNA from a serum sample collected 10 877 
days after symptom onset, whereas his mini-bronchoalveolar lavage tested negative (74). As for 878 
the optimal timing of specimen collection, there is a lack of data on the viral shedding kinetics of 879 
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MERS-CoV in infected humans over time. Analysis of a limited number of laboratory-confirmed 880 
MERS cases suggests that the pattern may be more similar to that of SARS than that of other 881 
HCoV infections (195). Thus, the viral load of MERS-CoV in nasopharyngeal specimens may 882 
also peak in the second week of illness rather than at symptom onset (163, 182, 196, 197). 883 
Repeated testing of upper and preferably lower respiratory tract specimens at different time 884 
points should be performed in suspected cases of MERS even when the first samples have tested 885 
negative (77, 886 
http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?ua887 
=1). Virus shedding in the upper respiratory tract may be found in up to 30% of case contacts 888 
with minimal symptoms (198). Severe cases appear to have more prolonged virus shedding than 889 
mild cases (198). In critically ill patients who may have detectable MERS-CoV RNA in 890 
respiratory tract specimens and/or blood for more than three weeks, continued compliance with 891 
infection control measures is required during patient-care procedures as a precautionary measure 892 
despite the presence of serum neutralizing antibody (88, 176, 182, 184). Aerosol-generating 893 
procedures for specimen collection should be performed under strict compliance with droplet 894 
precautions along with additional measures including the wearing of a N95 respirator, eye shield, 895 
long-sleeved gown and gloves in an adequately ventilated room 896 
(http://www.who.int/csr/disease/coronavirus_infections/IPCnCoVguidance_06May13.pdf?ua=1). 897 
The specimens should be sent to the laboratory in viral transport medium as soon as possible 898 
after collection, or be stored at -80
o






Nucleic Acid Amplification Assays 903 
With the successful isolation and propagation of MERS-CoV and sequencing of its complete 904 
genome early in the epidemic, specific primers and a standardized laboratory protocol were 905 
rapidly developed and evaluated (199). Several gene targets can be used for RT-PCR as 906 
screening and/or confirmatory testing for MERS-CoV (Table 8). The most widely adopted 907 
approach uses the upE assay as a screening test, followed by the ORF1a or the ORF1b assays as 908 
confirmation. If the ORF1a assay or the ORF1b assay is negative or equivocal despite a positive 909 
upE assay, further testing of other specific gene targets, including the N, RdRp, and/or S genes, 910 
followed by amplicon sequencing, should be performed. If further testing is not available, but the 911 
patient had a compatible epidemiological and clinical history, then the case is considered to be a 912 
probable case of MERS 913 
(http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?u914 
a=1). Notably, assays targeting the abundant N gene may be more sensitive than those targeting 915 
the other genes, although direct comparison with the upE assay in human clinical specimens has 916 
not been performed (133). However, a 6-nt deletion was found in N gene of the strain from the 917 
second laboratory-confirmed patient when compared to the one obtained from the first patient, 918 
and therefore potential false-negative results due to mutations in this region may occur (62). For 919 
all positive cases, a second sample should preferably be tested to exclude false-positive results 920 
due to amplicon carryover. Other novel diagnostic approaches for MERS which have short 921 
turnaround times, high sensitivities and specificities include reverse transcription loop-mediated 922 
isothermal amplification and reverse transcription isothermal recombinase polymerase 923 
amplification assays which may be useful in areas without easy access to laboratories equipped 924 
with RT-PCR and/or sequencing technologies (200, 201). Further validation using more clinical 925 
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specimens is required to assess their field performance. 926 
 927 
Antibody Detection Assays 928 
A number of assays for detection of non-neutralizing and neutralizing antibodies to MERS-CoV 929 
proteins have been developed but require further validation because some antibodies against 930 
βCoVs are generally known to cross-react within the genus (Table 9). Indeed, cross-reacting 931 
antibodies have been found not only in immunofluorescence assays, but also in virus 932 
neutralization tests, which are considered to be the most specific method of antibody detection 933 
(202, 203). Therefore, the European Centre for Disease Prevention and Control recommends 934 
against testing for immunofluorescent antibodies unless convalescent plasma is available to look 935 
for 4-fold increase in antibody titer because false positive results may arise in single tests. Cases 936 
with positive serology in the absence of PCR testing or sequencing should be considered 937 
probable only if they meet the other criteria of the case definition 938 
(http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?u939 
a=1). Nevertheless, antibody detection assays are important for retrospective diagnosis in 940 
clinically and epidemiologically suspicious cases with negative molecular test results, 941 
particularly in those with only upper respiratory tract specimens being tested. It can also be used 942 
for monitoring the evolution of epidemics in human and animal seroepidemiological studies, and 943 
contact tracing in outbreak investigations (126). The development of high throughput, non-whole 944 
virus-based assays such as enzyme-linked immunosorbent and pseudoparticle neutralization 945 
assays that do not required BSL-3 containment facilities may increase their utility especially in 946 




Antigen Detection Assays 949 
The development of antigen detection assays for MERS-CoV has only been reported in 950 
histopathological confirmation in infected tissues of animals and in cell cultures with positive 951 
CPE (166, 167, 174). Possible approaches include antigen detection with monoclonal antibodies 952 
or monospecific polyclonal antibodies against the abundantly expressed N protein using either 953 
enzyme immunoassay or immunofluroescence assay. These methods were found to be highly 954 
sensitive and specific for the laboratory diagnosis of SARS from sera and nasopharyngeal 955 
samples, and have the potential advantages of being non-labor-intensive and relatively high 956 
throughput without requiring a BSL-3 containment facility (3). More information on the timing 957 
of serum neutralizing antibody kinetics and viral shedding patterns in different clinical 958 
specimens is required to optimize these antigen detection assays.  959 
 960 
Viral Culture 961 
In contrast to other CoVs causing human infections, which are difficult to culture in in vitro 962 
systems, MERS-CoV grows rapidly in a wide range of human and non-human cell lines (Table 963 
6) (116-118). Indeed, the first identification of MERS-CoV was achieved by inoculation of the 964 
patient’s sputum sample in monkey kidney cell lines, including LLC-MK2 and Vero cell lines, 965 
for detection of CPE, before specific nucleic acid amplification assays were developed (9). 966 
MERS-CoV produces focal CPE with rounded refractile cells in various susceptible cell lines on 967 
day 5 after inoculation during primary isolation, and on as early as day 1 on subsequent passage 968 
(116). These changes then spread throughout the cell monolayers, leading to rounding and 969 
detachment of cells within 24 to 48 hours. Additionally, syncytium formation caused by fusion 970 
activity of the viral spike protein at neutral pH may be observed in LLC-MK2, Calu-3, Caco-2, 971 
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and Huh-7 cell lines, and Vero cells expressing TMPRSS2 (9, 52, 58, 116). Transmission 972 
electron microscopy of MERS-CoV-infected cells shows CoV-induced membrane structures that 973 
support RNA synthesis, including convoluted membranes surrounded by double-membrane 974 
vesicles measuring 150 to 320 nm with dense inner cores, in the perinuclear region, which is 975 
typical of cellular changes of CoV infection (58). Although the clinical use of viral culture for 976 
MERS-CoV is limited by the lack of BSL-3 facilities in most satellite hospitals, the ease of 977 
growing the virus in cell culture systems has greatly facilitated study on its pathogenesis and 978 
development of antiviral agents in reference research laboratories. 979 
 980 
CLINICAL MANAGEMENT AND ANTIVIRALS 981 
As in the case of other human CoV infections including SARS, specific antiviral agents with 982 
proven efficacy in randomized controlled trials are lacking for MERS (204, 205). Supportive 983 
care remains the mainstay of treatment for severe MERS cases with respiratory failure and 984 
extrapulmonary complications. ECMO has been increasingly used in severe viral pneumonia 985 
including some cases of MERS (18, 71, 153, 154, 156, 206). However, procedure-related factors 986 
such as the requirements of technical expertise and specific equipment, and patient factors 987 
including the presence of multiple comorbidities and coagulopathy may limit its use especially 988 
among patients in rural parts of the Middle East and Africa. Other forms of assisted ventilation 989 
and pulmonary rescue therapy, including mechanical ventilation using a lung protective strategy 990 
with a small tidal volume, non-invasive positive pressure ventilation, and inhaled nitric oxide 991 
have been tried for SARS and influenza with ARDS (3, 153). However, data on their efficacies in 992 
MERS are lacking (88, 207). Due to the apparently high incidence of acute and acute-on-chronic 993 
renal failure in patients with severe MERS, renal replacement therapy has been frequently used, 994 
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and was essential for tiding the patient over the oliguric phase (64, 88, 207). Circulatory failure 995 
is supported by the use of inotropes and volume expansion (207). Broad-spectrum antibacterials 996 
and neuraminidase inhibitors against influenza are used empirically before the diagnosis of 997 
MERS is established (207). Antimicrobials guided by interval surveillance or sepsis work-up 998 
should be used to treat secondary nosocomial infections in those with prolonged hospitalization 999 
and invasive ventilation, and opportunistic infections in patients who are immunocompromised, 1000 
especially those who receive corticosteroid for immunomodulation. As in SARS, 1001 
immunosuppressive dose of corticosteroid therapy should not be given because of its potential 1002 
side effects and immunosuppression. Only stress dose of corticosteroid should be considered in 1003 
patients with refractory shock and relative adrenal insufficiency 1004 
(http://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_1005 
NovelCoronavirus_11Feb13u.pdf?ua=1). 1006 
 The improvement in outcome of MERS with a case-fatality rate of over 30% depends on 1007 
the development of effective antiviral treatment for suppression of viral load. Candidate antiviral 1008 
agents are identified using three general approaches (Table 10). The first and fastest approach is 1009 
to test drugs with broad-spectrum antiviral activities including those with reported activities 1010 
against other CoVs associated with human infection, particularly SARS-CoV. This approach has 1011 
identified numerous agents with known antiviral mechanisms. Examples include interferons, 1012 
ribavirin, and cyclophilin inhibitors (58, 208, 209). Type I interferons, which are important in the 1013 
innate immunity against CoV infection, exhibit anti-MERS-CoV activity in various cell lines and 1014 
also rhesus macaques. MERS-CoV is 50 to 100 times more sensitive to pegylated interferon-α 1015 
than SARS-CoV in cell culture (58). Moreover, the combination of interferon-α2b and ribavirin, 1016 
a purine nucleoside analogue that inhibits guanosine triphosphate synthesis and viral RNA 1017 
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polymerase activity that has been widely used to treat SARS, has exhibited synergistic effects 1018 
against MERS-CoV in cell cultures (209, 210). In rhesus macaques infected with MERS-CoV, 1019 
this combination reduces virus replication, moderates host inflammatory response, and improves 1020 
clinical outcome (175). However, the regimen’s efficacy in humans remains uncertain. In a small 1021 
cohort of MERS cases in KSA, all five patients who received a combination of interferon-α2b, 1022 
ribavirin, and corticosteroid died. The delayed commencement of the antiviral regimen of at least 1023 
two weeks after symptom onset in these patients might have reduced treatment benefit, as 1024 
another patient who received treatment early on the day of admission survived, though MERS-1025 
CoV RNA remained detectable in his sputum samples until day 12 of treatment (211). A more 1026 
recent retrospective cohort study showed that 20 severe adult MERS patients who received oral 1027 
ribavirin and pegylated interferon-α2a (Pegasys; Roche Pharmaceuticals, Basel, Switzerland) for 1028 
8 to 10 days (initiatied on a median of 3 days after diagnosis) had significantly better survival 1029 
rates at 14 days but not at 28 days after diagnosis as compared to 28 historical controls who 1030 
received supportive care only (207). Possible reasons for the lack of long-term survival benefit in 1031 
the treatment group include the small number of patients in the study and the fact that both 1032 
ribavirin and pegylated interferon have high EC50 against MERS-CoV relative to their peak 1033 
serum concentrations achievable at clinically relevant dosages. Cyclophilin inhibitors, such as 1034 
cyclosporine A, are known to have antiviral activity against numerous human and animal 1035 
coroanviruses including SARS-CoV. However, the clinical relevance of cyclosporin A for 1036 
treating MERS is likely limited as the drug’s peak serum level achievable with clinically relevant 1037 
dosages is below its EC50 for MERS-CoV (58).  1038 
 The second approach to identify candidate antivirals for MERS involves screening of 1039 
chemical libraries that comprise large numbers of existing drugs or databases that contain 1040 
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information on transcriptional signatures in different cell lines. The advantages of this approach 1041 
include the commercial availability, known pharmacokinetics, and well-reported safety profiles 1042 
of the identified drugs. The first agent with potent in vitro anti-MERS-CoV activity identified by 1043 
this method was mycophenolic acid, an anti-rejection drug used in organ transplantation with 1044 
broad-spectrum antiviral activities that acts by inhibiting inosine-5’-monophosphate 1045 
dehydrogenase and depleting the lymphocyte guanosine and deoxyguanosine nucleotide pools 1046 
(210). The combination of mycophenolic acid and interferon-β1b shows synergistic activity 1047 
against MERS-CoV in Vero cells. The desirable pharmacokinetics of mycophenolic acid 1048 
compared to ribavirin warrants further evaluation, although the potential inhibitory effect on the 1049 
immune system and therefore neutralizing antibody production should be fully assessed in 1050 
animal models before use in humans. The very low EC50 when compared with the peak serum 1051 
level achieved at routine clinical dosages suggests that even a very low dose may be effective 1052 
without inducing significant immunosuppression. A fatal case of MERS was reported in a renal 1053 
transplant recipient who was receiving anti-rejection therapy consisting of prednisone, 1054 
mycophenolate mofetil, and cyclosporine, but the dosage, serum drug level of mycophenolate 1055 
mofetil, and the resulting lymphocyte count were not reported (68, 176). Following the 1056 
identification of mycophenolic acid as an inhibitor of MERS-CoV replication in vitro, many 1057 
other drugs have been found to exhibit in vitro anti-MERS-CoV activity in Vero and/or Huh-7 1058 
cells using a similar drug discovery approach. These drugs belong to a number of major 1059 
pharmacological categories including peptidic or small-molecule HIV entry inhibitors, 1060 
antiparasitics, antibacterials, and inhibitors of clathrin-mediated endocytosis, neurotransmitters, 1061 
estrogen receptor, kinase signaling, lipid or sterol metabolism, protein processing, and DNA 1062 
synthesis or repair (41, 177, 212-215). However, none of them has been tested in animal models 1063 
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for MERS, and many of them have doubtful clinical relevance in human infection because of 1064 
unachievable peak serum levels in relation to their EC50 against MERS-CoV. Two notable 1065 
exceptions which warrant further evaluation in clinical trials are lopinavir and chloroquine. 1066 
Lopinavir, which is routinely available as a lopinavir/ritonavir combination, shows inhibitory 1067 
effects on MERS-CoV infection in vitro in Huh-7 cells at concentrations observed in blood 1068 
during clinical use and has a well established toxicity profile (212, 213, 1069 
http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139281416). Moreover, 1070 
lopinavir/ritonavir has been used successfully in the treatment of SARS in a case-control study 1071 
(216). Viremia resolved after two days of combinational lopinavir/ritonavir, pegylated interferon, 1072 
and ribavirin therapy in a MERS patient (184). However, virus shedding in the airway was 1073 
persistent despite treatment (184). Chloroquine is an anti-malarial drug that inhibits MERS-CoV 1074 
in vitro in Huh-7 and Vero E6 cells at a concentration achievable by standard clinical oral dosage 1075 
through multiple possible mechanisms including inhibition of the pH-sensitive cathepsin L cell 1076 
entry pathway through elevation of endosomal pH (212, 213, 217, 1077 
http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139281416). However, previously 1078 
chloroquine has not been shown to work in BALB/c mice infected by SARS-CoV, possibly due 1079 
to the lack of inhibition of other cell entry pathways utilized by the virus (218). 1080 
 The third approach to identify treatment for MERS requires the development of 1081 
specific antiviral agents based on novel insights into the viral genome and structural biology of 1082 
MERS-CoV (219, 220). Understandably, the development of such candidate drugs is more time-1083 
consuming than that of the first two approaches. However, these tailor-made antiviral agents 1084 
represent the most specific and possibly most effective therapeutic options against MERS-CoV. 1085 
Of particular interests are agents that target the MERS-CoV S protein, which has essential roles 1086 
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in virus-host cell receptor interaction and immunogenicity. A number of potent monoclonal 1087 
antibodies targeting different epitopes on the RBD in the S1 subunit of the MERS-CoV S protein 1088 
have been identified by biopanning of ultra-large non-immune human antibody libraries 1089 
displayed in yeast or phage baited by the RBD (37-40). These monoclonal antibodies bind to the 1090 
RBD with 10- to 450-fold higher affinity than does the RBD to the human DPP4, conferring 1091 
broader and higher neutralizing activity. The production of these monoclonal antibodies in high 1092 
titers may help to overcome the potential cultural hurdle in collecting large amounts of 1093 
convalescent plasma from patients in the Middle East and the possibility of adverse outcomes 1094 
associated with immune enhancement with low antibody titer previously observed in in vitro and 1095 
animal experiments on SARS (221, 222). Moreover, possible selection of virus mutants capable 1096 
of escaping from antibody-mediated neutralization may be mitigated by using divergent 1097 
combinations of two or more synergistically acting neutralizing monoclonal antibodies that target 1098 
non-cross-resistant epitopes on the RBD (40). In vitro inhibition of S protein-mediated cell-cell 1099 
fusion and virus entry into host cell can also be achieved by specially designed antiviral peptides 1100 
that span the sequence of the HR2 domain of the S2 subunit of the MERS-CoV S protein. 1101 
Analogus to the HIV fusion inhibitor Enfuvirtide which binds to glycoprotein 41 of HIV to block 1102 
membrane fusion and virus entry, the MERS-CoV antiviral peptides block the fusion process of 1103 
MERS-CoV by preventing the interaction between the HR1 and HR2 domains required for the 1104 
formation of the heterologus six-helix bundle in viral fusion core formation (44, 45). Other drug 1105 
candidates that target specific enzymes of MERS-CoV include inhibitors of viral proteases and 1106 
helicase. The rapid determination of crystal structure for these enzymes have facilitated the 1107 
development of candidate drugs to be further tested in animal studies to evaluate their 1108 
pharmacokinetics and in vivo inhibitory effects, especially in view of the reported mutations in 1109 
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the papain-like protease of recently circulating MERS-CoV strains (146, 223-226). Inhibition of 1110 
MERS-CoV infection can also be achieved by agents that target the functional host cell receptor 1111 
DPP4. Because of the abundance of DPP4 in epithelial and endothelial cells, high titers of 1112 
monoclonal antibodies against specific binding regions of DPP4, but not the commercially 1113 
available reversible, competitive DPP4 antagonists such as sitagliptin, vildagliptin, and 1114 
saxagliptin, efficiently inhibit virus-cell receptor interaction (46, 50). Agents that manipulate the 1115 
levels of adenosine deaminase, a natural DPP4 antagonist, may also be considered (49). The 1116 
clinical efficacy of anti-DPP4 monoclonal antibodies and adenosine deaminase analogues 1117 
remains uncertain because expression of catalytically inactive DPP4 still allows for MERS-CoV 1118 
infection in vitro (227). Furthermore, the risk of physiological disturbances, immunopathology, 1119 
and T cell suppression should be assessed in animal studies given the wide distribution of DPP4 1120 
in different human cell types and its multiple essential metabolic and immunological functions 1121 
(228, 229). Alternatively, inhibitors of host cellular proteases including TMPRSS2 and 1122 
cathepsins, which affect virus entry into host cells, may be considered. However, the recent 1123 
finding that cathepsin activity is essential for Ebola virus infection in cell lines but not for viral 1124 
spread and pathogenesis in mice highlights the necessity to confirm the roles of cellular protease 1125 
inhibitors in in vivo spread of MERS-CoV (230, 231). Alternative host proteases that cleave the 1126 
MERS-CoV S protein should also be searched to broaden the range of existing antiviral options 1127 
(51). 1128 
 1129 
INFECTION CONTROL AND LABORATORY SAFETY 1130 
Similar to epidemics caused by other novel emerging respiratory viruses with no herd immunity 1131 
in the general population and limited effective treatment and immunization options, infection 1132 
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control measures to interrupt the chain of transmission remains the cornerstone to control the 1133 
MERS epidemic (3, 4, 153, 232-234). Based on the available epidemiological data, the scenario 1134 
is most compatible with a combination of animal-to-human and person-to-person transmission. 1135 
In endemic regions, multi-source sporadic animal-to-human transmissions occur in the 1136 
community, which may be amplified under special circumstances such as the breeding seasons of 1137 
dromedary camels. These primary infections may be followed by limited non-sustained person-1138 
to-person transmission among unprotected household contacts (67, 70, 73). When the patients are 1139 
hospitalized, the infection is introduced into the healthcare setting where lapses in infection 1140 
control measures culminate in large healthcare-associated outbreaks (66, 68, 71, 75, 235). The 1141 
infection can then be disseminated beyond the Middle East by air travel of infected patients 1142 
seeking medical care in other non-endemic countries (150, 236, 237). 1143 
 In the community setting, the primary goals of infection control are to identify and 1144 
segregate all zoonotic reservoirs and infected humans from immunologically naive persons. 1145 
Besides dromedary camels, bats, and hedgehogs, other livestock species prevalent in the Middle 1146 
East should be further surveyed by validated serological and virological tests to exclude 1147 
unrecognized MERS-CoV infection. Before these data are available, residents in and travelers to 1148 
the endemic regions should generally avoid contacting sick animals and especially camels. 1149 
Contact with environments contaminated with animal bodily fluids, tissues, or feces should be 1150 
avoided as MERS-CoV may be transmitted via direct contact or fomite due to prolonged 1151 
environmental survival lasting for at least 48 hours at 20
o
C in 40% relative humidity, and 24 1152 
hours at 30
o
C in 30% relative humidity (145, 238). Consumption of unpasteurized camel milk 1153 
should be cautioned against, as MERS-CoV may possibly be shed and survive in the milk of 1154 
camels with active nasal or fecal virus shedding (143, 144). Early recognition of human cases 1155 
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can be achieved by public education and dissemination of diagnostic tests to healthcare facilities. 1156 
Testing should be performed even among asymptomatic or mildly symptomatic persons with 1157 
known exposures to potential animal reservoirs or laboratory-confirmed human cases. They 1158 
should also undergo medical surveillance and quarantine in healthcare facilities or at home until 1159 
the incubation period is over 1160 
(http://www.who.int/csr/disease/coronavirus_infections/IPCnCoVguidance_06May13.pdf?ua=1). 1161 
Air travel should be restricted for laboratory-confirmed cases unless it is necessary to transfer the 1162 
patient to other countries for medical care. In such cases, compliance with infection control 1163 
measures including hand hygiene, wearing of personal protective equipment, and standard and 1164 
transmission-based precautions should be applied by the aircraft staff and accompanying medical 1165 
personnel. Though there is no documented in-flight transmission of MERS-CoV so far, the risk is 1166 
estimated to be one new infection in a five-hour flight in first class, and 15 infections from a 1167 
“super-spreader” in a 13-hour flight in economy class (236). Temperature checks at borders and 1168 
health declarations for travelers are used in some regions, but their value in controlling 1169 
international spread is unproven. The Hajj, which attracts millions of pilgrims from over 180 1170 
countries to gather in Mecca every year, poses a theoretical risk of causing massive outbreaks of 1171 
MERS as in the super-spreading events of SARS. Though MERS has not been reported among 1172 
pilgrims attending the annual Hajj in 2012 and 2013, the small number of subjects tested and the 1173 
lack of samples collected during the pilgrimage are major limitations of the few surveillance 1174 
studies conducted so far (239-241). Thus, persons at risk of developing severe infection should 1175 
consider postponing the Hajj until the epidemic is under control (242, 243). 1176 
 In the hospital setting, triage, early diagnosis, compliance with appropriate infection 1177 
control measures, prompt isolation of suspected cases, and timely contact tracing of case contacts 1178 
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are the key strategies to prevent nosocomial transmission. Indeed, the disappearance of the three 1179 
clades of MERS-CoV found earlier in the epidemic suggests the possible effects of enhanced 1180 
surveillance and early isolation of human cases in successfully interrupting person-to-person 1181 
transmission (146). In addition to standard, contact, and droplet precautions, airborne precautions 1182 
should be applied for aerosol-generating procedures such as intubation, non-invasive ventilation, 1183 
manual ventilation before intubation, bronchoscopy, tracheostomy, and suctioning of the airway 1184 
(244, 1185 
http://www.who.int/csr/disease/coronavirus_infections/IPCnCoVguidance_06May13.pdf?ua=1). 1186 
Designated healthcare workers and disposable equipments for managing laboratory-confirmed 1187 
cases in adequately ventilated single rooms or airborne infection isolation rooms should be 1188 
considered to limit the number of exposed contacts. All healthcare workers caring for patients 1189 
with suspected or confirmed MERS should undergo medical surveillance with daily temperature 1190 
checks and monitoring of the development of acute respiratory symptoms. Quarantine after 1191 
unprotected exposure is necessary to prevent unrecognized asymptomatic infection that may 1192 
serve as the source of nosocomial and community outbreaks (70). The duration of observation 1193 
should last for at least two incubation periods as applied in the medical surveillance of other 1194 
respiratory tract infections such as pandemic influenza A/H1N1/2009 (245). Although it has been 1195 
suggested that transmission-based precautions for MERS patients may be stopped 24 hours after 1196 
the resolution of symptoms, laboratory testing to exclude persistent virus shedding should be 1197 
conducted as viral RNA can be detected in the respiratory tract specimens and/or blood of 1198 
critically ill patients for over three weeks after symptom onset (88, 176, 182, 184, 211). Rarely, 1199 
asymptomatic cases may also have prolonged virus shedding for more than five weeks after case 1200 
contact (246). The infectivity of such prolonged viral shedding should be further evaluated to 1201 
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optimize infection control strategies. Patients who have no evidence of pneumonia or who have 1202 
recovered from pneumonia but remain positive for MERS-CoV RNA by RT-PCR may be 1203 
discharged from the hospital and isolated at home under appropriate supervision (247). 1204 
Collection of potentially infectious specimens should be performed by trained staff wearing 1205 
appropriate personal protective equipment. The specimens should be transported in leak-proof 1206 
double containers by hand instead of pneumatic-tube systems 1207 
(http://www.who.int/csr/disease/coronavirus_infections/IPCnCoVguidance_06May13.pdf?ua=1). 1208 
To prevent laboratory-related outbreaks as reported in SARS, all laboratories handling live 1209 
MERS-CoV should strictly comply with WHO standards for BSL-3 laboratories. 1210 
  1211 
VACCINATION 1212 
Active Immunization 1213 
Active immunization to protect at-risk humans and camels is a research priority in the control of 1214 
MERS because of the lack of herd immunity and effective antivirals for humans. Based on 1215 
previous experience gained from vaccine design for SARS, which shows the S protein to be one 1216 
of the major immunogenic components of CoVs, a number of vaccines that target the S protein 1217 
of MERS-CoV are being developed and evaluated in cell culture or animal experiments (Table 1218 
11). A viral vector-based vaccine using recombinant modified vaccinia virus Ankara expressing 1219 
full-length MERS-CoV S protein induced high levels of neutralizing antibodies in BALB/c mice 1220 
after intramuscular immunization (248). The possibility of induction of immunopathology as in 1221 
the case of a similar viral vector-based vaccine for SARS that led to enhanced hepatitis in ferrets 1222 
needs to be carefully assessed in subsequent investigations (222). Alternatively, several candidate 1223 
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recombinant vaccines containing either full-length MERS-CoV S protein or the RBD of the S1 1224 
subunit have been studied for their theoretical advantages of safety and ease of consistent 1225 
production based on constant conditions and well-defined immunogenic fragments. A 1226 
baculovirus-based expression system and a Venezuelan Equine Encephalitis Replicon Particles 1227 
approach have been successfully applied for the development of full-length MERS-CoV S 1228 
protein-based recombinant vaccines (174, 249). Identification and exclusion of non-neutralizing 1229 
epitopes in the immunopredominant domain of the MERS-CoV S protein may help to reduce the 1230 
risk of antibody-mediated disease enhancement during future optimization of these vaccines 1231 
(250). RBD-based subunit vaccines have elicited neutralizing activity against MERS-CoV in cell 1232 
culture-based assays, BALB/c mice, and rabbits (31, 34, 36, 42, 251). Among five different 1233 
available RBD constructs, a truncated 212-aa fragment at residues 377 to 588 of RBD fused with 1234 
human IgG Fc fragment (S377-588-Fc) showed the highest DPP4-binding affinity and induced 1235 
the highest titers of IgG and neutralizing antibodies in BALB/c mice and rabbits respectively 1236 
(36). Intranasal vaccination of this S377-588-Fc showed stronger systemic cellular and local 1237 
mucosal responses as compared to subcutaneous vaccination (43). Future research directions for 1238 
these promising subunit vaccine candidates include the optimization of adjuvant substances 1239 
which are required to increase the immunogenicity of subunit vaccines (252), and the inclusion 1240 
of chimeric S proteins containing multiple neutralizing epitopes from divergent subgroups, as 1241 
there are considerable variations in the receptor-binding subdomain region of S1 within 1242 
subgroups of MERS-CoV and across different CoV groups (202). 1243 
 1244 
Passive Immunization 1245 
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Passive immunization using convalescent plasma or hyperimmune globulin with high titers of 1246 
neutralizing antibody has been used for emerging respiratory viral infections including SARS 1247 
and pandemic influenza A/H1N1/2009 with relatively few side effects (253-256). The clinical 1248 
use of such therapy for MERS has not yet been evaluated in randomized controlled trials. 1249 
MERS-CoV-S-driven transduction in Caco-2 cells is inhibited by convalescent patient serum in a 1250 
concentration-dependent manner (51). In BALB/c mice transduced by adenoviral vectors 1251 
expressing human DPP4, adoptive transfer of sera containing anti-MERS-CoV-S antibodies 1252 
blocked virus attachment and accelerated virus clearance (174). The increasing number of 1253 
patients recovering from MERS and enhanced international collaboration for the preparation of 1254 
convalescent plasma samples will accelerate the availability of passive immunization before 1255 
neutralizing monoclonal antibodies become commercially available. 1256 
  1257 
ANIMAL MODELS AND ANIMALS SUSCEPTIBLE TO MERS-CoV 1258 
Contrary to SARS-CoV which can cause infection in a diverse range of susceptible mammalian 1259 
species, studies on MERS-CoV have been limited by the lack of animal models which are 1260 
representative of MERS in humans (Table 12). The Koch’s postulates for MERS-CoV as a 1261 
causative agent of MERS were fulfilled with a primate model using rhesus macaques, which 1262 
demonstrated mild to moderate clinical and histopathological features as compared to the 1263 
infection in humans (165). However, clinical signs varied between animals, and were usually 1264 
transient, lasting for only 3 days or less in most animals, which corroborated with the robust but 1265 
self-limiting inflammatory response and leukocyte activation in blood and lungs of tested 1266 
animals (166). Recently, common marmosets were also found to be susceptible to MERS-CoV 1267 
infection and resembled moderate to severe MERS in humans with viremia and disseminated 1268 
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infection as evidenced by the presence of viral RNA in blood and multiple organs (168). 1269 
Nevertheless, extrapulmonary manifestations that are commonly seen in human cases of MERS, 1270 
such as acute renal failure and diarrhea, were absent in both the rhesus macaque and common 1271 
marmoset models. Jamaican fruit bats infected with MERS-CoV do not develop clinical signs of 1272 
infection despite having respiratory and intestinal tract virus shedding up to day 9 post-infection 1273 
(257). Large animals including camels and goats were also found to be susceptible to MERS-1274 
CoV infection, but they developed predominantly upper respiratory tract symptoms without 1275 
pneumonia (257-259). Unlike human infection in which feces and urine might be positive for 1276 
viral RNA, the extrapulmonary specimens of infected camels and goats were negative. Most 1277 
small animal models that worked for SARS-CoV, including BALB/c mouse, Syrian hamster, and 1278 
ferret, were not susceptible to MERS-CoV infection. Infected animals had minimal clinical signs, 1279 
no detectable virus in respiratory tract and extrapulmonary specimens, and did not have 1280 
seroconversion. These findings suggest that MERS-CoV fails to enter these host cells because of 1281 
variable DPP4 binding affinities for MERS-CoV S RBD among different species (48). A mouse 1282 
model using C57BL/6 and BALB/c mice with prior transduction of respiratory epithelial cells 1283 
with adenoviral vectors expressing human DPP4 inoculated with MERS-CoV intranasally 1284 
showed virological, immunological, and histopathological features compatible with interstitial 1285 
pneumonia, but the clinical signs were mild and evidence of infection was confined to the lungs 1286 
without extrapulmonary involvement (174). Furthermore, it requires infection of the mice with 1287 
the adenoviral vectors prior to every experiment, and it is unknown whether the differences in 1288 
the targeted cells between the murine and human lungs may affect the immunological response 1289 
and clinical progress after infection. Nonetheless, this inhaled-adenoviral vector method allows 1290 
the quick use of a wide variety of pre-existing genetically modulated mice with 1291 
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immunodeficiencies to dissect the elements of host responses to MERS-CoV, and can be used to 1292 
test candidate drugs and vaccines in vivo. It also provides a rapid model for any novel emerging 1293 
respiratory viruses before appropriate receptor-transgenic mouse models become available. 1294 
Further refinement of small animal models that are more representative of MERS in humans is 1295 
urgently needed for evaluation of the efficacy of therapeutic and immunization options with in 1296 
vitro activity. 1297 
 1298 
CONCLUSIONS 1299 
In contrast to the public health chaos in the early phase of the SARS outbreak, the global health 1300 
community has demonstrated efficient and collaborative efforts to handle the MERS epidemic. 1301 
The clinical experience gained in SARS and the genomic data accumulated for other human and 1302 
animal CoVs discovered after SARS have facilitated the rapid development of diagnostic assays, 1303 
design of candidate antiviral agents and vaccines, rationalization of infection control measures, 1304 
and identification of zoonotic reservoirs for MERS (93, 104-107, 260-271). The MERS epidemic 1305 
has greatly enhanced our understanding of coronavirology and provided lessons that will be 1306 
useful for tackling future CoV outbreaks. Camels are now recognized as an important animal 1307 
reservoir for lineage A and C βCoVs and other viruses (140, 272, 273). Continued surveillance of 1308 
novel CoVs among different animal species, especially bats and mammals with frequent close 1309 
contact with humans, will strengthen our preparedness to face other emerging CoVs resulting 1310 
from interspecies transmissions in the future. The identification of DPP4 as a functional receptor 1311 
of MERS-CoV has expanded the list of membrane ectopeptidases known to be targeted by CoVs 1312 
and has increased our understanding on the pathogenesis of CoV infections. Finally, the newly 1313 
identified antiviral agents in drug-repurposing programs for MERS represent additional drug 1314 
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candidates that can be evaluated for novel CoVs that lack specific treatment options. Looking 1315 
ahead, the successful control of the expanding MERS epidemic will depend on the development 1316 
of an effective camel vaccine to stop ongoing camel-to-human transmissions, compliance with 1317 
infection control measures, and timely contacting tracing to prevent secondary healthcare-1318 
associated outbreaks. The key research priorities to optimize the clinical outcomes of MERS 1319 
include more in-depth understanding on the pathogenesis from post-mortem studies and serial 1320 
patient samples, testing of antiviral and vaccine candidates in more representative small animal 1321 
models, and evaluation of the efficacy of currently available therapeutic options in randomized 1322 
controlled trials in humans. Monitoring of the molecular evolution of MERS-CoV will facilitate 1323 
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Table 1 Comparison between MERS and SARS 1335 
Characteristics Middle East respiratory syndrome (MERS) Severe acute respiratory syndrome (SARS) References 
Epidemiology    
   Year of first identification 2012 2003 (2, 9) 
   Geographical origin Middle East with imported cases in Europe, Africa, 
Asia, & North America 
South China with imported cases causing large 
outbreaks in Canada & Asia 
(a, 3) 
   Natural reservoirb ?Bats (Neoromicia sp. in Africa) Chinese horse-shoe bats (Rhinolophus sinicus & 




   Amplification or intermediate hostb Dromedary camels (Middle East & Africa) Game food mammals (civets & raccoon dogs in 
southern China) 
(3, 12, 114, 
121, 133) 
   Epidemic centers of outbreaks or 
premises of acquisition 
1. ?Camel farms 
2. Hospital or household with MERS patients 
1. Wild life markets & restaurants 
2. Hospitals & laboratories 
3. Housing estate with faulty sewage system & hotels 
4. Planes 
(3, 12, 75, 
138, 139, 
276-278) 
   Seasonality May be related to camel breeding season Winter (c, d, 3) 




(3, 73, 138) 
   In-flight transmission Not yet documented Numerous episodes, related to physical proximity to 
the index patient 
(3, 278) 
   Modes of transmission ?Droplet, contact, airborne Contact, droplet, airborne (3, 75, 234) 
   Infection control measures Standard, contact, & droplet precautions; airborne 
precautions for aerosol-generating procedures 
Standard, contact, & droplet precautions; airborne 
precautions for aerosol-generating procedures 
(3, 75, 234) 
   Incubation period (days) 2-15 2-14, occasionally up to 21 days (3, 63, 75, 
234) 
   Basic reproduction number (R0) 0.3-1.3 0.3-4.1 (3, 90, 150, 
151, 279-
281) 
Virus-host interaction    
   Causative virus MERS-CoV SARS-CoV (2, 9, 165, 
282) 
   Viral phylogeny Lineage C βCoV Lineage B βCoV (2, 9) 
   Host receptor DPP4 (CD26) ACE2 (46, 283) 
   Major host proteases that activate 
spike protein 
1. TMPRSS2 
2. Cathepsin L 
3. Furin 
1. Cathepsin L 
2. TMPRSS2 
3. HAT 
(44, 51, 52, 
54, 284-
287) 
   Dominant cell entry pathway Cell membrane fusion Endosomal fusion (44, 51, 
284, 288) 








   Viral proteins with interferon 
antagonist activity 
PLpro, accessory proteins 4a, 4b, & 5, & membrane 
protein 
nsp1 protein, PLpro, accessory proteins 3b & 6, & 
nucleocapsid & membrane proteins 
(3, 24, 25, 
27, 28, 172, 
289-292) 
   Rapid evolution of virus in human Not yet detected Overall Ka/Ks ratio of >1 suggests rapid evolution 
with strong positive selection in human strains with 




Clinical features    
   Presenting clinical syndrome 1. Acute community- or hospital-acquired 
pneumonia in elderly & patients with multiple 
comorbidities 
2. Upper respiratory tract infection, influenza-like 
illness or asymptomatic infection in children & 
immunocompetent hosts 
Acute community- or hospital-acquired pneumonia 
in immunocompetent & immunocompromised hosts 
(2, 63, 294) 
   Common extrapulmonary 
manifestation 
1. Acute renal failure 
2. Diarrhea 
Diarrhea (63, 160, 
196) 
   Radiological changes  Focal to diffuse interstitial ground glass opacities 
and/or consolidations 
Focal to diffuse ground glass opacities and/or 
consolidations with pneumomediastinum 
(3, 63, 152) 
   Common changes in blood tests Leukopenia, lymphopenia, thrombocytopenia, 
impaired liver function at presentation; renal 
function impairment, leukocytosis & neutrophilia 
with progressive illness 
leukopenia, lymphopenia, thrombocytopenia, 
↑ alanine & aspartate 
aminotransferase levels 
(3, 63) 
   Severe complications ARDS, acute renal failure ARDS (3, 63) 
   Case-fatality rate  >35% ~10% (g, 3, 63) 
   Peak viral load in respiratory 
secretion  
Unclear  ~Day 10 after symptom onset (3, 160, 
196) 
   Onset of neutralizing antibody ≤12 days after symptom onset ~Day 5-10 after symptom onset  (3, 66, 72, 
81, 183, 
295) 
   Specimens for diagnosis with 
positive viral RNA (reverse 
transcription-polymerase chain 
reaction) or culture (cell culture) 
1. Lower respiratory tract: sputum, endotracheal 
aspirate, and/or bronchoalveolar lavage 
2. Upper respiratory tract: nasopharyngeal aspirate or 
swab, nasal and/or throat swab 
3. Extra-pulmonary: urine, feces, and/or blood 
4. Tissue: biopsied and/or autopsied specimens 
(findings not yet reported) 
1. Lower respiratory tract: sputum, endotracheal 
aspirate, and/or bronchoalveolar lavage 
2. Upper respiratory tract: nasopharyngeal aspirate or 
swab, nasal and/or throat swab 
3. Extra-pulmonary: urine, feces, blood, and/or 
cerebrospinal fluid 
4. Tissue: biopsied and/or autopsied specimens 
(3, 195, 
296) 
   Criteria for positive RT-PCR test Follow WHO criteria Follow WHO criteria (h, 3) 
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   Criteria for positive antibody 
testing 
No international standard 4-fold rise in serum (taken at least 14 days apart) 
neutralizing anti-SARS-CoV antibody titer (often 
just 4-fold rise in immunofluorescence antibody 
against fixed whole SARS-CoV if BSL-3 facility 
was not available) 
(h, 3) 
   Key treatment measures Ventilatory support & intensive care (ECMO & 
hemodialysis) 
Ventilatory support & intensive care (3, 88, 204, 
234) 
   Antivirals used in humans in non-
randomized trials 
Ribavirin & interferon-α2b Interferons (infacon1, interferon-b, leukocytic 
interferons) 
Combinations of protease inhibitor with ribavirin 
(3, 207, 
216) 
   Active immunization Vaccines containing RBD of S1 (mice) Recombinant S protein fragment (mice) (3, 36, 252, 
297) 
   Passive immunization Adoptive transfer of sera containing anti-MERS-
CoV-S antibodies blocked virus attachment in mice 
Convalescent plasma therapy used in humans (3, 174, 
298) 
   Animal models for testing antivirals 
& vaccinesi 
Common marmoset; no representative small animal 
model of severe human disease yet 
Representative models using various mammalian 
species including small animal models 
(3, 168) 
Abbreviations: ACE2, angiotensin-converting enzyme 2; ARDS, acute respiratory distress syndrome; BSL, Biosafety Level; CoV, 1336 
coronavirus; DPP4, dipeptidyl peptidase-4; ECMO, extracorporeal membrane oxygenation; HAT, human airway trypsin-like protease; 1337 
MERS, Middle East respiratory syndrome; ORF, open reading frame; PLpro, papain-like protease; RBD, receptor-binding domain; S, 1338 
spike; SARS, severe acute respiratory syndrome; TMPRSS2, transmembrane protease serine protease-2. 1339 
a
 http://www.who.int/csr/disease/coronavirus_infections/MERS-CoV_summary_update_20140611.pdf?ua=1 1340 
b
 Please refer to Table 5 for details on animal reservoirs of MERS-CoV 1341 
c
 http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_Update_09_May_2014.pdf 1342 
d
 http://www.who.int/csr/disease/coronavirus_infections/MERS-CoV_summary_update_20140611.pdf?ua=1 1343 
e
 Both animal (especially dromedary camels)-to-human and person-to-person transmission in nosocomial outbreaks are considered to 1344 
be important factors for the persistent MERS outbreak. Person-to-person transmission of SARS-CoV in “super-spreading events” and 1345 
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major nosocomial outbreaks is considered to be the major transmission type in the large-scale epidemic of SARS. 1346 
f
 Please refer to Table 6 for details on tissue and host tropism of MERS-CoV 1347 
g
 http://www.who.int/csr/don/17-december-2014-mers/en/ 1348 
h http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?ua=1 1349 
i
 Please refer to Table 12 for details on other animal modes of MERS
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(no. of amino acid 
residues in product) 
Gene product and/or 
putative functional 
domain(s) 
Characteristics and/or effect on cellular response of host References 
ORF1a/b    
   nsp1 (193) Unknown May induce template-dependent endonucleolytic cleavage of host mRNA but not viral RNA; 




   nsp2 (660) Unknown May interact with prohibitin 1 & 2, & disrupts intracellular signaling. (16, 20-22, 
252, 301) 
   nsp3 (1887) Papain-like protease  Structurally similar to the papain-like protease of SARS-CoV albeit only 30% sequence 
identity, consisting of a right-hand-like architecture with palm, thumb, & fingers domains. 
Specific conserved structural features include the ubiquitin-like domain, a catalytic triad 
consisting of C1594-H1761-D1776, & the ubiquitin-binding domain at the zinc finger. 
 
Functions: 
1. Proteolytic processing of the viral replicase polyprotein at 3 sites (nsp1-2, 2-3, & 3-4) to 
generate nsps that contribute to subgenomic RNA synthesis.  
2. DeISGylating (ISG15-linked ISGylation) & deubiquitinating (K48- & K63-linked 
ubiqutination) activities 
3. Interferon antagonist: reduces induction of NF-κB, blocks phosphorylation & nuclear 
translocation of IRF3, & blocks upregulation of cytokines CCL5, interferon-β, & CXCL10 











 Transmembrane domain 1 Uncertain function, but may be similar to other CoVs including SARS-CoV in anchoring the 
viral replication complex through recruitment of intracellular membranes to form a 
reticulovesicular network of CMs & DMVs interconnected via the outer membrane with the 
rough endoplasmic reticulum. 
(16, 20-22, 
252, 306) 
   nsp4 (507) Transmembrane domain 2 Similar to nsp3 & may help to form part of the viral replication complex. (16, 20-22, 
252, 306) 
   nsp5 (306) Main, chymotrypsin-like, 
or 3C-like protease 
Proteolytic processing of the replicative polyprotein at specific sites & forming key 
functional enzymes such as replicase & helicase.  
(16, 20, 22, 
252) 
   nsp6 (292) Transmembrane domain 3 Membrane-spanning integral component of the viral replication complex involved in DMV 
formation; substitutions lead to resistance to the viral RNA synthesis inhibitor K22.  
(16, 20-22, 
252, 306) 
   nsp7 (83) Unknown In SARS-CoV, nsp7 & -8 are part of a unique multimeric RNA polymerase complex. (16, 20-22,  
252, 307) 




   nsp9 (110) Unknown In SARS-CoV, nsp9 is an essential protein dimer with RNA/DNA binding activity. (16, 20-22, 
253, 308) 
   nsp10 (140) Unknown In SARS-CoV, nsp10 is required for nsp16 to bind both m7GpppA-RNA substrate & S-
adenosyl-L-methionine cofactor; nsp16 possesses the canonical scaffold of MTase & 
associates with nsp10 at 1:1 ratio. 
(16, 20-22, 
253, 309) 
   nsp11 (14) Unknown Unknown (16, 20-22, 
252) 
   nsp12 (933) RNA-dependent RNA 
polymerase 




   nsp13 (598) Superfamily 1 helicase Putative dNTPase & RNA 5’-triphosphatase activities. (16, 20-22, 
252) 
 Zinc-binding domain  (16, 20-22, 
252) 
   nsp14 (524) 3’-to’5’ exonuclease Putative endoribonuclease activity in the replication of the giant RNA genome. (16, 20-22, 
252) 
 N7-methyltransferase  (16, 20-22, 
252) 
   nsp15 (343) Nidoviral 
endoribonuclease specific 
for U 
Putative RNA endonuclease that is essential in the CoV replication cycle. (16, 20-22, 
252) 
   nsp16 (303) S-adenosylmethionine-
dependent ribose 2’-O-
methyltransferase 




ORF2 (1353) Spike (S) protein A type I transmembrane glycoprotein displayed on viral membrane surface critical for 
receptor binding & membrane fusion. 
(16, 20-22, 
252) 
ORF3 (103) Accessory protein 3 
(single transmembrane 
domain) 
Deletion of ORF3, -4, & -5 accessory cluster showed ~1.5 logs reduction in viral titer 
compared with recombinant MERS-CoV, & resulted in enhanced expression of subgenomic 
gRNA2 encoding the S protein associated with an increased fusion phenotype; not essential 




ORF4a (109) Accessory protein 4a 
(dsRNA-binding motif) 
A dsRNA-binding protein of with the dsRNA-binding domain (residues 3 to 83) that 
potently antagonizes host interferon response via inhibition of interferon production 
(interferon-β promoter activity, IRF-3/7 & NF-κB activation), ISRE promoter element 
signaling pathways, and/or suppression of PACT-induced activation of RIG-I & MDA5 in an 
RNA-dependent manner; not essential for virus replication in Vero A66 & Huh-7 cells. 
(16, 20-22, 
24, 25, 252, 
311) 
ORF4b (246) Accessory protein 4b 
(single transmembrane 
domain) 





ORF5 (224) Accessory protein 5 (three 
transmembrane domains) 
Interferon antagonist with no effect on interferon-β promoter activation; not essential for 






ORF6 (82) Envelope (E) protein Putative ion channel activity & is involved in viral budding & release; essential for efficient 
virus propagation in Vero A66 & Huh-7 cells. 
(16, 20-22, 
252, 311) 
ORF7 (219) Membrane (M) protein Surface protein that incorporates viral components into virions & interacts with N protein in 
infected cells; interferon antagonist. 
(16, 20-22, 
24, 252) 
ORF8a (413) Nucleocapsid (N) protein Interacts with C-terminal domain of M protein for binding & packaging of viral RNA in 
assembly of the virion. 
(16, 20-22, 
252) 
ORF8b (112) Unknown Unknown (16, 20-22, 
252) 
Abbreviations: CCL5, chemokine ligand 5; CM, convoluted membrane; CoV, coronavirus; CXCL10, chemokine (C-X-C motif) ligand 1352 
10; DMV, double membrane vesicle; ds, double-stranded; IRF3, interferon regulatory factor 3; ISG, Interferon-Stimulated Gene; nsp, 1353 
non-structural protein. 1354 
a
 The putative functions of the accessory gene products of MERS-CoV and SARS-CoV may not directly correlate as the accessory 1355 
genes of these two viruses are not homologous.   1356 
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TABLE 3 Sequence of events with epidemiological importance related to MERS 1357 
Date
a Place or Institution Important event References 
19 April 2012 Zarqa, Jordan 1st healthcare-associated cluster: an outbreak of severe respiratory disease among 13 patients & 
healthcare workers in an ICU. The index patient & a close contact (ICU nurse) were subsequently 
confirmed to be infected with MERS-CoV in November 2012. 
(66) 
6 to 24 June 2012 Jeddah, KSA 1st laboratory-confirmed case: a 60-year-old man was admitted to a regional hospital for severe 
acute community-acquired pneumonia complicated with acute renal failure & later died. A novel 
CoV was isolated in cell culture of a sputum sample obtained on admission. The virus was initially 
named human coronavirus-Erasmus Medical Center (HCoV-EMC). 
(9) 
3 September 2012 London, UK 1st imported case in UK: a 49-year-old man in Qatar with travel history to KSA was transferred 
from Doha, Qatar to an ICU in London, UK on 11 September 2012 for severe acute community-
acquired pneumonia. A novel CoV was detected in combined nose & throat swab, sputum, & 
tracheal aspirate samples. The replicase gene fragment of this strain shared 99.5% identity with the 
1st HCoV-EMC strain. 
(18, 84) 
23 September 2012 WHO WHO Disease Outbreak News: report of the first 2 laboratory-confirmed cases. c 
25 September 2012 WHO 1st interim case definition for HCoV-EMC infection was issued. d 




 complete genome of HCoV-EMC was available in GenBank (accession number: JX869059). (16) 
27 September 2012 ECDC Protocols for real-time RT-PCR (upE & ORF1b) assays published in Eurosurveillance. (312) 
5 October to 14 
November 2012 
KSA 1st household cluster: three household family members of a 70-year-old man with laboratory-
confirmed HCoV-EMC infection were hospitalized for severe respiratory disease. 
(67) 
9 October 2012 Riyadh, KSA 1st survived case: a 45-year-old man who was admitted for severe respiratory disease & renal failure 
recovered from HCoV-EMC infection. 
(64) 
13 October 2012 Essen, Germany 1st imported case in Germany (69) 
21 December 2012 WHO 1st interim recommendations for laboratory testing for HCoV-EMC were issued. e 
24 January to 16 
February 2013 
UK 1st cluster outside of the Middle East: a 60-year old man with recent travel history to KSA was 
admitted to an ICU for laboratory-confirmed HCoV-EMC. Two of his relatives who were close 
contacts also developed laboratory-confirmed MERS. 
(73) 
5 February 2013 UK 1st mild case: the 30-year-old female relative in the cluster only had mild, influenza-like illness 
symptoms & spontaneously recovered. 
(73) 
8 March 2013 UAE 1st case in UAE (72) 
8 April to May 
2013 
Al-Hasa, KSA 1st large-scale cluster: >20 laboratory-confirmed cases of HCoV-EMC were reported in household 
& hospital contacts in the eastern province of KSA. 
(75) 




 imported case in France (68, 71) 
6 May 2013 Tunisia 1st imported cases in Tunisia (74) 
15 May 2013 Coronavirus Study 
Group, ICTV 
Formal naming of the novel CoV as Middle East respiratory syndrome coronavirus. (17) 
25 May 2013 Italy 1st imported case in Italy f 
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2 June 2013b Italy 1st pediatric case: a 2-year-old girl who was a close contact of the 1st imported case in Italy 
(subsequently reclassified as a probable case). 
(313) 
9 August 2013 Oman 1st report on the detection of anti-MERS-CoV antibodies in dromedaries in the Middle East. (121) 
23 August 2013 CDC 1st report on the detection of a short (182-nt) fragment of the viral RdRp gene from a fecal pellet of a 
Taphozous perforatus bat in KSA which showed 100% identity to that of MERS-CoV (strain 
HCoV-EMC/2012). 
(109) 
16 September 2013 CDC 1st report on the detection of a MERS-CoV-like virus (Neoromicia coronavirus) with 85.6% nt 
identity (complete genome) in the fecal sample of a Neoromicia capensis bat in South Africa. 
(110, 111) 
26 October 2013 Oman 1st case in Oman g 
17 December 2013 Qatar 1st report on the detection of MERS-CoV RNA in nose swabs from dromedaries by RT-PCR. (133) 
13 February 2014 Kuwait 1st case in Kuwait h 
17 March 2014 Yemen 1st case in Yemen i 
9 April 2014 Malaysia 1st imported case in Malaysia (78) 
13 April 2014 The Philippines 1st imported case in the Philippines  j 
17 April 2014 Greece 1st imported case in Greece (76) 
18 April 2014 USA 1st imported case in USA (77, 81)  
22 April 2014 Egypt 1st imported case in Egypt k 
mid-March to May 
2014 
KSA & UAE Sudden surge of >400 cases associated with an increase in the number of primary cases amplified 
by several large healthcare-associated outbreaks in KSA & UAE. 
l, m 
22 April 2014 Lebanon 1st case in Lebanon n 
1 May 2014 The Netherlands 1st imported case in the Netherlands (79) 
11 May 2014 Iran 1st cases in Iran o 
23 May 2014 Algeria 1st imported cases in Algeria p 
4 June 2014 KSA 1st report on camel-to-human transmission of MERS-CoV.  
22 September 2014 Austria 1st imported case in Austria q 
25 September 2014 Turkey 1st imported case in Turkey r 
17 December 2014 WHO A total of 938 laboratory-confirmed cases of MERS including at least 343 deaths were reported. s 
Abbreviations: CoV, coronavirus; CDC, Centers for Disease Control and Prevention; ECDC, European Centre for Disease Prevention 1358 
and Control; ICTV, International Committee on Taxonomy of Viruses; ICU, intensive care unit; KSA, Kingdom of Saudi Arabia; 1359 
UAE, United Arab Emirates; UK, United Kingdom; USA, the United States of America; WHO, World Health Organization. 1360 
a
 The date of reported cases represents the date of symptom onset unless otherwise specified. 1361 
b
 The date of reporting by WHO. 1362 
c
 http://www.who.int/csr/don/2012_09_23/en/ 1363 
d
 http://www.who.int/csr/don/2012_09_25/en/ 1364 
e




 http://www.who.int/csr/don/2013_06_01_ncov/en/ 1366 
g
 http://www.who.int/csr/don/2013_10_31/en/ 1367 
h
 http://www.who.int/csr/don/2014_03_20_mers/en/ 1368 
i
 http://www.who.int/csr/don/2014_05_07_mers_yemen/en/ 1369 
j
 http://www.who.int/csr/don/2014_04_17_mers/en/ 1370 
k
 http://www.who.int/csr/don/2014_05_01_mers/en/ 1371 
l
 http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_Update_09_May_2014.pdf 1372 
m
 http://www.who.int/csr/disease/coronavirus_infections/MERS-CoV_summary_update_20140611.pdf?ua=1 1373 
n
 http://www.who.int/csr/don/2014_05_15_mers/en/ 1374 
o
 http://www.who.int/csr/don/2014_06_11_mers/en/ 1375 
p
 http://www.who.int/csr/don/2014_06_14_mers/en/ 1376 
q
 http://www.who.int/csr/don/02-october-2014-mers-austria/en/ 1377 
r
 http://www.who.int/csr/don/24-october-2014-mers/en/ 1378 
s
 http://www.who.int/csr/don/17-december-2014-mers/en/ 1379 
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 (87) (66) (63) (75) (80) (88) (314) Others (86, 
152) 
Time period April 2012 to 
22 October 
2013 
April 2012 1 September 
2012 to 15 
June 2013 
1 March 2013 
to 19 April 
2013 
1 April 2013 to 
3 June 2013 
May 2013 to 
August 2013 
1 October 
2012 to 31 
May 2014 
 










reported by the 
KSA Ministry 











care units in 
KSA 
70 cases at a 
single center in 
Riyadh, KSA 
Case reports or 
case series 





NA 45/47 (95.7%); 
28/45 (62.2%) 
fatal 







NA NA  12/47 
(25.6%); 10/12 
(83.3%) fatal 







20.8% of fatal 
cases; 2o 
(23.0%) > 1o 
(4.3%) cases 
NA 23/47 (48.9%); 
17/23 (73.9%) 
fatal 








at least 2 fatal; 
1o (7/47, 
14.9%) > 2o 
(2/61, 3.3%) 
cases 
1/8 (12.5%) 13/47 (27.7%); 
10/13 (76.9%) 
fatal 












8.3%), & PVD 




y (1/7; 14.3%) 
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Diabetes mellitus 12/120 
(10.0%); 3.8% 
of fatal cases; 
1o (11/47, 
23.4%) > 2o 
(1/61, 1.6%) 
cases 
NA 32/47 (68.1%); 
21/32 (65.6%) 
fatal 
17/23 (73.9%) 13/15 (86.7%) 8/12 (66.7%) NA 3/7 (42.9%) 
Hypertension NA 2/8 (25.0%) 16/47 (34.0%); 
13/16 (81.3%) 
fatal 
NA NA 6/12 (50.0%) NA 3/7 (42.9%) 
Obesity NA NA 8/47 (17.0%); 
5/8 (62.5%) 
fatal 








7/70 (10.0%) 1/7 (14.3%) 
Smoking NA 2/8 (25.0%) 11/47 (23.4%); 
7/11 (63.6%) 
fatal 
NA NA 4/12 (33.3%) 9/70 (12.9%) 2/7 (28.6%) 
Malignancy NA NA  1/47 (2.1%); 
fatal 
NA 1/15 (6.7%) 1/12 (8.3%) NA 2/7 (28.6%) 
Others NA Pregnancy Immunosuppre
ssive therapy 
(3/47, 6.4%; 
all 3 fatal)  







Abbreviations: BMI, body mass index; CHF, congestive heart failure; KSA, Kingdom of Saudi Arabia; MI, myocardial infarction; 1382 
NA, not available; PVD, peripheral vascular disease; vs, versus; WHO, World Health Organization.  1383 
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TABLE 5 Evidence of zoonotic sources of MERS-CoV and closely related CoVs 1384 
Animal species (virus) Country (area) / Specimen collection date Main findings References 
Bats    
Superfamily Vespertilionoidea    
   Family Vespertilionidae    
      Asia    
      Tylonycteris pachypus (Ty-
BatCoV HKU4) 
China (Hong Kong) / April 2005 to August 
2012 
Detected in 29/99 (29.3%) alimentary samples; shared 90.0% 
(RdRp), 67.4% (S), & 72.3% (N) aa identities with MERS-CoV 
(HCoV-EMC/2012) 
(13, 99) 
      Pipistrellus abramus (Pi-
BatCoV HKU5) 
China (Hong Kong) / April 2005 to August 
2012 
Detected in 55/216 (25.5%) alimentary samples; shared 92.3% 
(RdRp), 64.5% (S), & 70.5% (N) aa identities with MERS-CoV 
(HCoV-EMC/2012) 
(13, 99) 
      Vespertilio superans (Bat 
CoV-BetaCoV/SC2013) 
China (Southwestern part) / June 2013 Detected in 5/32 (15.6%) anal swabs; shared 75.7% (complete 
genome of 1 strain) nt identity; & 96.7% (816-nt RdRp fragment) 
& 69.0% (S) aa identities with MERS-CoV (HCoV-EMC/2012) 
(315) 
      Africa    
      Neoromicia capensis 
(NeoCoV) 
South Africa (KwaZulu-Natal & Western 
Cape Provinces) / 2011 
Detected in 1/62 (1.6%) fecal sample; shared 85.6% (complete 
genome) nt identity; & 64.6% (S), 89.0% (E), 94.5% (M), & 91.7% 
(N) aa identities with MERS-CoV from humans & camels; placing 
them in the same viral species based on taxonomic criteria. 
(110, 111) 
      Europe    
      Pipistrellus pipistrellus, 
Pipistrellus nathusii, & 
Pipistrellus pygmaeus 
(Pipistrellus bat βCoVs) 
Romania (Tulcea county) & Ukraine (Kiev 
region) / 2009-2011 
Detected in 40/272 (14.7%) fecal samples; shared 98.2% (816-nt 
RdRp fragment) aa identity with MERS-CoV (HCoV-EMC/2012) 
(316) 
      Pipistrellus kuhlii, Hypsugo 
savii, Nyctalus noctula, & an 
unknown Pipistrellus sp. 
(βCoVs) 
Italy (Lombardia & Emilia regions) / 2010-
2012 
10 βCoVs detected in fecal specimens of Pipistrellus kuhlii (7), 
Hypsugo savii (1), Nyctalus noctula (1), & an unknown Pipistrellus 
sp. (1) bats; shared 85.2% to 87% nt identity & 95.3% to 96.1% 
(329-nt RdRp fragment) aa identity with MERS-CoV (HCoV-
EMC/2012) 
(317) 
Superfamily Emballonuroidea    
   Family Emballonuridae    
      Taphozous perforatus KSA (Bisha) / October 2012 A βCoV detected in 1/29 (3.4%) fecal sample; shared 100% nt 





Superfamily Molossoidea    
   Family Molossidae    
      Nyctinomops laticaudatus 
(Mex_CoV-9) 
Mexico (Campeche) / 2012 Detected in 1/5 (20.0%) rectal swabs; shared 96.5% (329-nt RdRp 
fragment) aa identity with MERS-CoV (HCoV-EMC/2012) 
(318) 
Superfamily Noctilionoidea    
   Family Mormoopidae    
      Pteronotus davyi (BatCoV-
P.davyi49/Mexico/2012) 
Mexico (La Huerta) / 2007-2010 Detected in 1/4 (25.0%) intestinal sample; shared 71.0% (439-nt 
RdRp fragment) nt identity with MERS-CoV (HCoV-EMC/2012) 
(319) 
Superfamily Rhinolophoidea    
   Family Nycteridae    
      Nycteris gambiensis 
(Nycteris bat CoV) 
Ghana (Bouyem, Forikrom, & Kwamang) / 
2009-2011 
Detected in 46/185 (24.9%) fecal samples; shared 92.5% aa identity 
(816-nt RdRp fragment) with MERS-CoV (HCoV-EMC/2012) 
(316) 
Hedgehogs    
   Europe    
      Erinaceus europaeus 
(Erinaceous CoV) 
Northern Germany / unknown date Two clades detected in 146/248 (58.9%) fecal samples; shared 
89.4% (816-nt RdRp fragment), 58.2% (S), 72.0% (E), 79.4% (M), 
& 72.1% (N)  aa identities with MERS-CoV (HCoV-EMC/2012); 
RNA concentration was higher in the intestine & fecal samples than 
other solid organs, blood, or urine, suggestive of viral replication in 
the lower intestine & fecal-oral transmission; 13/27 (48.2%) sera 
contained non-neutralizing antibodies 
(113) 
Camelids    
   Middle East    
      Camelus dromedarius KSA (countrywide) / 1992 to 2010; & 
November to December 2013 
Serum Ab: 150/203 (73.9%) (2013) & 72%-100% (1992 to 2010); 
adults (95%) > juveniles (55%) 
 
Viral RNA: nasal > rectal swabs; juveniles (36/104; 34.6%) > 
adults (15/98; 15.3%) 
 




      Camelus dromedarius KSA (Riyadh & Al Ahsa) / 2012 to 2013 Serum nAb: 280/310 (90.3% with titer ≥1:20) adults (233/245; 
95.1%) > juveniles (47/65; 72.3%) 
(127) 
      Camelus dromedarius KSA (Jeddah) / 3 November 2013 Direct camel-to-human transmission: phylogenetical (identical full 
genome sequences of patient strain & an epidemiologically-linked 
camel strain) & serological (the virus was circulating in the 
epidemiologically-linked camels but not in the patient before the 
human infection occurred) evidence 
(138) 
      Camelus dromedarius KSA (Jeddah) / 14 November to 9 
December 2013 
Serum Ab: 4-fold rise in paired sera in 2/9 (22.2%) 
 
Viral RNA: detected in nasal swabs of both camels (upE & ORF1a) 
(128) 
      Camelus dromedarius KSA (Al-Hasa) / November 2013 to 
February 2014 (peak calving season) 
Serum nAb: 280/310 (90.3%)  
 
Viral RNA: nasal > fecal specimens 
 
Viral genome: highly stable with an estimated mutation rate of 0 nt 
substitutions per site per day 
 
Clinical: both calves & adults could be infected; symptoms 
included mild respiratory symptoms (cough, sneezing, respiratory 
discharge), ↑ body temperature, & ↓ appetite; acute infection was 
not associated with prolonged viremia or viral shedding 
(320) 
      Camelus dromedarius UAE (Dubai) / 2003 & 2013 Serum Ab: 151/151 (100%) (2003) & 481/500 (96.2%) (2013); 
high titers of nAb >1:640 in 509/651 (78.2%) 
(124) 
      Camelus dromedarius UAE (Dubai) / February to October 2005 Serum nAb: 9/11 (81.8%) (125) 
      Camelus dromedarius Oman / March 2013 & Spain (Canary 
Islands) / April 2012 to May 2013  
Serum Ab: 50/50 (100%) of Omani & 15/105 (14.3%) of Spanish 
camels; all 50/50 (100%) of Omani (titers 1/320 to 1/2560) & 9/105 
(9%) of Spanish camels had nAb (titers 1/20 to 1/320) 
(121) 
      Camelus dromedarius Oman (countrywide) / December 2013 Viral RNA: high concentrations in nasal & conjunvtival swabs of 
5/76 (6.6%) camels (≥2 gene targets) 
(321) 
      Camelus dromedarius Jordan (al Zarqa governorate) / June to 
September 2013 
Serum nAb: 11/11 (100%) (126) 
      Camelus dromedarius Qatar / 17 October 2013 Serum nAb: 14/14 (100%); titers 1/160 to 1/5120 
  
Viral RNA: 5/14 (35.7%) nasal swabs by 3 gene targets (upE, N, & 
ORF1a), 1/14 (7.1%) by 2 gene targets, & 5/14 (35.7%) by 1 gene 
target 
 
Viral genome: 3/5 samples shared 100% identity (357-nt S 
fragment) with sequences from 2 epidemiologically-linked patients; 




strain & 2 epidemiologically-linked patient strains: only 1 nt 
difference in ORF1a & 1 nt difference in ORF4b 
      Camelus dromedarius Qatar (Doha) / February 2014 Viral RNA: 1/53 (1.9%) nasal swab from an 8-month-old camel 
(1/53, 1.9%) (upE & N) 
 
Viral genome: complete genome (MERS-CoV 
camel/Qatar_2_2014) shared 99.5% to 99.9% nt identities with 
other camel & patient strains 
(131) 
      Camelus dromedarius Qatar (Al Shahaniya & Dukhan) / April 
2014 
Serum & milk Ab: all 33 camels had IgG in serum & milk 
 
Viral RNA: detected in the nose swabs and/or feces of 7/12 camels, 
& the milk of 5/7 of these camels in Al Shahaniya 
(144) 
      Camelus dromedarius KSA (Al Hasa, As Sulayyil, Hafar Al-Batin, 
Medina) / 1993, Egypt / 2014, & Australia 
(central Australia & Queensland) / 2014 
Serum nAb: 118/131 (90.1%) of KSA camels & 0/25 (0%) of 
Australian camels 
(322) 
   Africa    
      Camelus dromedarius Somalia / 1983 to 1984, Sudan / June & 
July 1983, Egypt / June & July 1997 
Serum nAb: Somalia (70/86, 81.4%), Sudan (49/60, 81.0%) & 
Egypt (34/43, 79.1%) by MNT 
(132) 
      Camelus dromedarius Kenya / 1992 to 2013 Serum Ab: 213/774 (27.5%); including 119/774 (15.4%) with nAb; 
seropositive camels were found in all sampling sites throughout the 
study period; ↑ seroprevalence was significantly correlated with ↑ 
camel population density 
(130) 
      Camelus dromedarius Nigeria / 2010 to 2011, Tunisia / 2009 & 
2013, & Ethiopia / 2011 to 2013 
Serum Ab: Nigeria (94.0% of adults) & Ethiopia (93.0% of 
juveniles & 97.0% of adults); lower rates in Tunisia (54.0% of 
adults & 30.0% of juveniles) 
(323) 
      Camelus dromedarius Egypt (Cairo & Qalyubia governorate) / 
June 2013 
Serum nAb: 103/110 (93.6% with titer ≥1:20) by MNT & 108/110 
(98% with titer ≥1:20) by spike ppNT 
(122) 
      Camelus dromedarius Egypt (Alexandra, Cairo, & Nile Delta 
region) / June to December 2013 
Serum nAb: 48/52 (92.3% with titers between 1:20 to ≥1:640); 
0/179 abattoir workers 
 
Viral RNA: 4/110 (3.6%) nasal swabs (upE & ORF1a)  
(134) 
Abbreviations: aa, amino acid; KSA, Kingdom of Saudi Arabia; N, nucleocapsid; nAb, neutralizing antibody; nt, nucleotide; ORF, 1385 
open reading frame; MNT, micro-neutralization test; RT-PCR, reverse transcription polymerase chain reaction; ppNT, pseudoparticle 1386 
neutralization test; RBD, receptor-binding domain; RdRp; RNA-dependent RNA polymerase; S, spike; UAE, United Arab Emirates.  1387 
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TABLE 6 Tissue and host tropism of MERS-CoV demonstrated in cell culture systems 1388 
Cell culture system Anatomic site or animal species Main findingsa References 
Cell lines    
   Human cell types    
      Lower respiratory tract    
         A549 Lung adenocarcinoma Replication with ↑ viral load (~1-2),  N protein expression & CPE (116) 
         Calu-3 Polarized bronchial epithelia Replication with ↑ viral load (~4-5), N protein expression & CPE (cell 
rounding, detachment, & prominent syncytia formation)  
(116) 
  Replication in Calu-3 cells  with ↑ viral load (~5-6) & CPE at 24 hpi; 
infection & release of virions through both the apical & basolateral 
routes 
(185) 
         HFL Embryonic lung fibroblasts Replication with ↑ viral load (~4-5), N protein expression & CPE (116) 
         Differentiated HTBE Human tracheobronchial epithelia Replication with ↑ viral load (~2.5-4.5) in differentiated HTBE cells; 
virions released exclusively from the apical but not the basolateral side 
(186) 
         Nondifferentiated HTBE Human tracheobronchial epithelia Replication with ↑ viral load (<1) in nondifferentiated  but much less 
than that observed in differentiated HTBE cells 
(186) 
         HAE  Pseudostratified human airway 
epithelia 
Productive infection in HAE cultures peaks at 48 hpi: host cell factors 
required for cell entry, RNA synthesis, & virus assembly & release are 
available in human 
(187) 
  Replication in HAE, lung fibroblasts, type II pneumocytes, & 
microvascular endothelial cells; most efficient in HAE & lung 
fibroblasts 
(188) 
         HBEpC Human primary bronchial epithelium Replication with ↑ viral load (~0.5-1) (~1000-fold lower 
concentrations of virus progeny than in HREpC) & without CPE 
(157) 
      Kidney    
         HEK 293 Human embryonic kidney Replication with ↑ viral load (~4-5), N protein expression & CPE (116) 
         769-P Renal cell adenocarcinoma Replication with ↑ viral load (~3-4) (117) 
         HREpC Human primary kidney epithelium Replication with ↑ viral load (~3-4) (~1000-fold higher concentrations 
of virus progeny than in HBEpC) & CPE (rounding & detachment of 
cells with cell death in the majority of cells after only 20 hpi) 
(157) 
      Colon    
         Caco-2 Colorectal adenocarcinoma Replication with ↑ viral load (~4-5), N protein expression & CPE (cell 
rounding, detachment, & prominent syncytia formation) 
(116) 
         LoVo Metastatic colonic adenocarcinoma Replication in LoVo cells with ↑ viral load (~5-6) & CPE at 4 dpi (185) 
      Liver    
         Huh-7 Hepatocellular carcinoma Replication with ↑ viral load (~4-5), N protein expression & CPE (cell 
aggregates with marked shrinkage) 
(116) 
      Neuromuscular cells    
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         NT2 Neuro-committed teratocarcinoma Replication with ↑ viral load (~2-3), but no N protein expression & 
CPE 
(116) 
      Immune cells    
         THP-1 Peripheral blood monocytes from 
AML 
Replication with ↑ viral load (<1), but no N protein expression & CPE (116) 
         U937 Monocytes from histiocytic lymphoma Replication with ↑ viral load (<0.5), but no N protein expression & 
CPE 
(116) 
         H9 T lymphocytes from T-cell leukemia Replication with ↑ viral load (<0.5), but no N protein expression & 
CPE. 
(116) 
         Jurkat_CD26DPP4+ Human T lymphocytes transfected 
with a human DPP4-encoded plasmid 
Conversion from non-susceptible state to susceptible state with 
productive viral infection after plasmid transfection  
(185) 
         His-1 Malignant histiocytoma Replication with ↑ viral load (~3-4), N protein expression & CPE (116) 
   Nonhuman cell types    
      Primates    
         LLC-MK2 Rhesus monkey kidney Replication with ↑ viral load (~4-5), N protein expression & CPE (116) 
         Vero African green monkey kidney Replication with ↑ viral load (~4-5), N protein expression & CPE (116) 
         Vero-TMPRSS2 African green monkey kidney cells 
expressing TMPRSS2 
Early appearance of large syncytia at18hpi & virus particle-induced 
cell-cell fusion at 3hpi 
(52) 
         Vero E6 African green monkey kidney Replication with ↑ viral load (~4-5) & N protein expression; slower & 
less obvious CPE than those in Vero cells 
(58, 116) 
         COS-7 with DPP4 African green monkey fibroblasts 
transfected with a human DPP4-
encoded plasmid 
Conversion from non-susceptible state to susceptible state with 
productive viral infection after plasmid transfection  
(46) 
      Bats    
         RoNi/7 Old World bat (Rousettus aegyptiacus) 
kidney 
Replication with ↑ viral load (~3-4) (117) 
         PipNi/1 Old World bat (Pipistrellus 
pipistrellus) kidney 
Replication with ↑ viral load (~1-2) (117) 
         PipNi/3 Old World bat (Pipistrellus 
pipistrellus) kidney 
Replication with ↑ viral load (~1-2) (117) 
         RhiLu Old World bat (Rhinolophus landeri) 
lung 
Replication with ↑ viral load (~2-3) (117) 
         MyDauNi/2 Old World bat (Myotis daubentonii) 
kidney 
Replication with ↑ viral load (~1-2) (117) 
         CarNi/1 New World bat (Carollia perspicillata) 
kidney 
Replication with ↑ viral load (<0.5) (117) 
         EFF New World bat (Eptesicus fuscus) 
embryo 
Susceptible to MERS-CoV pseudovirus infection (23) 
         EidNi/41.3 Old World bat (Eidolon helvum) adult 
kidney 
Replication with ↑ viral load (~106 PFU/ml) (324) 
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         EpoNi/22.1 Old World bat (Epomops buettikoferi) 
adult kidney 
Replication with ↑ viral load (~104 PFU/ml) (324) 
         HypLu/45.1 Old World bat (Hypsignathus 
monstrosus) fetal lung 
Replication with ↑ viral load (~105 PFU/ml) (324) 
         HypNi/1.1 Old World bat (Hypsignathus 
monstrosus) fetal kidney 
Replication with ↑ viral load (~105 PFU/ml) (324) 
         PESU-B5L New World bat (Pipistrellus subflavus) 
adult lung 
Did not support productive MERS-CoV infection unless transfected 
with a plasmid expressing human DPP4 
(324) 
         RO5T Old World bat (Rousettus aegyptiacus) 
embryo 
Did not support productive MERS-CoV infection unless transfected 
with a plasmid expressing human DPP4 
(324) 
         RO6E Old World bat (Rousettus aegyptiacus) 
embryo 
Did not support productive MERS-CoV infection unless transfected 
with a plasmid expressing human DPP4 
(324) 
         RoNi/7.1 Old World bat (Rousettus aegyptiacus) 
adult kidney 
Replication with ↑ viral load (~106 PFU/ml) (324) 
         RoNi/7.2 Old World bat (Rousettus aegyptiacus) 
adult kidney 
Replication with ↑ viral load (~106 PFU/ml) (324) 
         Tb1Lu New World bat (Tadarida brasiliensis) 
adult lung 
Did not support productive MERS-CoV infection unless transfected 
with a plasmid expressing human DPP4 
(324) 
      Camelids    
         TT-R.B Arabian camel (Camelus dromedarius) 
umbilical cord 
Replication with ↑ viral load (~1) but without production of infectious 
virus particles  
(118) 
         LGK-1-R Alpaca (Llama pacos) kidney Replication with ↑ viral load (~2-3) & production of infectious virus 
particles 
(118) 
      Other mammals    
         ZLu-R Goat (Capra hircus) lung Replication with ↑ viral load (~1-2) & production of infectious virus 
particles 
(118) 
         ZN-R Goat (Capra hircus) kidney Replication with ↑ viral load (~3-4) & production of infectious virus 
particles 
(118) 
         PK-15 Pig kidney Replication with ↑ viral load (~4-5), N protein expression & CPE (116) 
         PS Pig kidney Replication with ↑ viral load (<1) (117) 
         RK-13 Rabbit kidney Replication with ↑ viral load (~1-2), but no N protein expression & 
CPE 
(116) 
         CL-1 Civet lung fibroblasts Replication with ↑ viral load (~1-2), N protein expression & CPE (116) 
         MDCK with human DPP4 Dog kidney transfected with a human 
DPP4-encoded plasmid 
Conversion from non-susceptible state to susceptible state with 
productive viral infection after plasmid transfection 
(46) 
         LR7 with human DPP4 Mouse fibroblasts transfected with a 
human DPP4-encoded plasmid 
Conversion from non-susceptible state to susceptible state with 
productive viral infection after plasmid transfection 
(46) 
         CRFK with human DPP4 Cat kidney cortex epithelium 
transfected with a human DPP4-
encoded plasmid 
Conversion from non-susceptible state to susceptible state with 




         BHK with human DPP4 Baby hamster kidney cells expressing 
human DPP4 
Conversion from non-susceptible state to susceptible state after 
transfection with a human but not hamster or ferret DPP4-encoded 
expression vector 
(325) 
         Primary ferret kidney with 
human DPP4 
Primary ferret kidney cells expressing 
human DPP4 
Conversion from non-susceptible state to susceptible state with after 
transfection with a human but not hamster or ferret DPP4-encoded 
expression vector 
(325) 
Ex-vivo organ or cell cultures    
   Respiratory tract    
      Lower respiratory tract Human lung Infection & replication in most cell types of the human alveolar 
compartment (ciliated & non-ciliated cells in simple columnar & 
simple bronchial epithelium, types I & II pneumocytes, endothelial 
cells of large & small pulmonary vessels, but not alveolar 
macrophages) 
(189) 
 Human bronchus & lung Productive replication in both human bronchial & lung ex vivo organ 
cultures (non-ciliated bronchial epithelium, bronchiolar epithelial cells, 
alveolar epithelial cells, & endothelial cells); virions were found within 
the cytoplasm of bronchial epithelial cells & budding virions were 
found in alveolar epithelial cells (type II) 
(190) 
 Human lung Infection of airway epithelial cells (pneumocytes & epithelial cells of 
terminal bronchioles, endothelial cells, & lung macrophages) 
(191) 
   Immune cells    




Productively infection & replication in MDMs with ↑ viral load (~3-4) 
& aberrant induction of inflammatory cytokines & chemokines (higher 
expression levels of IL-12, IFN-γ, IP-10, MCP-1, MIP-1α, IL-8, CCL-
5, MHC class I & costimulatory molecules > SARS-CoV-infected 
MDMs) 
(191) 
 Human monocyte-derived dendritic 
cells (MoDCs) 
Productive infection of MoDCs with ↑ viral load (~2-3) & significantly 
higher expression levels inflammatory cytokines & chemokines (IL-
12, IFN-γ, IP-10, CCL-5, MHC class II & the costimulatory molecule 
CD86) than SARS-CoV-infected MoDCs 
(193) 
Abbreviations: AML, acute monocytic leukemia; CCL, chemokine C-C motif ligand; CPE, cytopathic effects; dpi, days post infection; 1389 
hpi, hours post infection; IFN, interferon; IL, interleukin; IP, interferon-γ-induced protein; MCP, monocyte chemotactic protein; MHC, 1390 
major histocompatibility complex; MIP, macrophage inflammatory protein; N, nucleocapsid; PFU, plaque-forming unit; TMPRSS2, 1391 




Values of viral loads are presented in log10 virus RNA genome copies equivalents per mL of cell culture supernatant unless otherwise 1393 
specified.  1394 
82 
 
TABLE 7 Clinical, laboratory, and radiological features of MERS 1395 
 
Clinical, laboratory, and 
radiological features 
  
Clinical cohorts (references) 
 
 (66) (63) (75) (80) (88) (314) Others (9, 18, 
64, 67, 69, 71-
73, 86, 152, 
157, 326) 
Time period April 2012 1 September 
2012 to 15 June 
2013 
1 March 2013 to 
19 April 2013 
1 April 2013 to 
3 June 2013 
May 2013 to 
August 2013 
1 October 2012 
to 31 May 2014 
 





reported by the 
KSA Ministry of 
Health to WHO 
Outbreak 
investigation in 





3 intensive care 
units in KSA 
70 cases at a 
single center in 
Riyadh, KSA 
Case reports or 
case series 
Clinical features        
   Systemic        
      Fever >38oC 8/9 (88.9%) 46/47 (97.9%) 20/23 (87.0%) 6/15 (40.0%) 8/12 (66.7%) 43/70 (61.4%) 6/7 (85.7%) 
      Chills and/or rigors 1/9 (11.1%) 41/47 (87.2%) NA 1/15 (6.7%) NA NA NA 
   Respiratory        
      Rhinorrhea 1/9 (11.1%) 2/47 (4.3%) NA NA 1/12 (8.3%) NA NA 
      Sore throat NA 10/47 (21.3%)  20/23 (87.0%) 1/15 (6.7%) 1/12 (8.3%) NA NA 
      Cough 8/9 (88.9%) 39/47 (83.0%) NA NA 10/12 (83.3%) 38/70 (54.3%) 7/7 (100%) 
      Sputum NA 17/47 (36.2%) NA NA 2/12 (16.7%) 23/70 (23.9%) 3/7 (42.9%) 
      Hemoptysis NA 8/47 (17.0%) NA 1/15 (6.7%) 1/12 (8.3%) NA NA 
      Wheezing NA NA NA 2/15 (13.3%) 2/12 (16.7%) 6/70 (8.6%) NA 
      Chest pain 4/9 (44.4%) 7/47 (14.9%) NA 1/15 (6.7%) NA NA NA 
      Dyspnea 5/9 (55.6%) 34/47 (72.3%) 11/23 (47.8%) 10/15 (66.7%)  11/12 (91.7%) 42/70 (60.0%) 4/7 (57.1%) 
   Renal        
      Acute renal failure NA NA NA NA 7/12 (58.3%) 30/70 (42.9%) 7/7 (100%) in 
one cohort; & 
9/12 (75.0%) in 
another with at 
least 6/9 
(75.0%) fatal; 
median time = 




   Gastrointestinal        
      Nausea NA 10/47 (21.3%) NA NA 1/12 (8.3%) NA NA 
      Vomiting NA 10/47 (21.3%) 4/23 (17.4%) 1/15 (6.7%) NA 21/70 (30.0%) NA 
      Diarrhea NA 12/47 (25.5%) 5/23 (21.7%) 1/15 (6.7%) 2/12 (16.7%) 21/70 (30.0%) NA 




colectomy (1) & 
negative 
laparotomies (2) 
17/70 (24.3%) 1/7 (14.3%) 
        
   Other symptoms        
      Myalgia NA 15/47 (31.9%) NA 1/15 (6.7%) NA  14/70 (20.0%) 1/7 (14.3%) 
      Headache NA  6/47 (12.8%) NA 1/15 (6.7%) 2/12 (16.7%) 9/70 (12.9%)  
      Malaise 3/9 (33.3%) NA NA NA 2/12 (16.7%) 29/70 (41.4%) 1/7 (14.3%) 
   Complications        
      Co-infections        




























albicans & C. 
glabrata) 
         Viral NA 0/47 (0%) NA NA Influenza B 
(1/12, 8.3%) 
0/70 (0%) Influenza 
A(H1N1)pdm09 
(1) & type 2 
parainfluenza 
(2) 
      ICU admissiona 4/8 (50.0%) 42/47 (89.4%) 18/23 (78.3%); 
time from 
symptom onset 
8/15 (53.3%) 12/12 (100%); 
time from 
symptom onset 
49/70 (70.0%) 60/133 (45.1%) 
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= 5 days (1 to 
10 days) 
to ICU 
admission = 2 
days; duration = 
30 days (7 to 
104 days) 
      Mechanical ventilationa 2/8 (25.0%) 34/47 (72.3%); 
time from 
presentation = 7 





= 7 days (3 to 11 
days)  




ventilation = 4.5 
days; duration = 
16 days (4 to 30 
days) 
49/70 (70.0%) NA 





(SVT & VT), & 
delirium 













stillbirth at 5 
months of 
gestation 
      Deatha 2/8 (25.0%); 
time from 
symptom onset 




14 days (5 to 36 
days); CFR ↑ 
with ↑ age 
At least 15/23 
(65.2%); time 
from symptom 
onset = 11 days 
(5 to 27 days)  
13/17 (76.5%)  7/12 (58.3%) at 
day 90 of 
symptom onset 
42/70 (60.0%) 291/837 
(34.8%) (April 
2012 to 23 July 
2014) (86) 
Laboratory features        
   Hematological 
abnormalities 
       
      Leukocytosis NA NA 3/23 (13.0%) 2/17 (11.8%) NA Yes NA 
      Leukopenia 2/7 (28.6%) 7/47 (14.9%) 2/23 (8.7%) 1/17 (5.9%) NA NA 3/7 (42.9%) 
      Normal neutrophil 
count 
NA 43/47 (91.5%) NA NA NA Yes NA 
      Lymphocytosis NA 5/47 (10.6%) NA NA NA NA NA 
      Lymphopenia 6/7 (85.7%) 16/47 (34.0%) NA 6/17 (35.3%) 9/12 (75.0%) on 
ICU admission 
& 11/12 









      Thrombocytosis NA NA 1/23 (4.3%) NA NA NA NA 
      Thrombocytopenia NA 17/47 (36.2%) 4/23 (17.4%) NA 2/12 (16.7%) on 
ICU admission 
& 7/12 (58.3%) 
during ICU stay 
NA 3/7 (42.9%) 








   Biochemical 
abnormalities 
       
      Elevated serum ALT NA 5 (10.6%) NA 3/17 (17.6%) 2/12 (16.7%) on 
ICU admission 
& 5/12 (41.7%) 
during ICU stay 
22/70 (31.4%) NA 
      Elevated serum AST NA 7/47 (14.9%) 3/13 (23.1%) 9/17 (52.9%) 2/12 (16.7%) on 
ICU admission 
& 8/12 (66.7%) 
during ICU stay 
22/70 (31.4%); 
median 59 IU/l 
NA 
      Elevated serum LDH NA 23/47 (48.9%) NA 8/17 (47.1%) NA NA NA 












Radiological findings 7/7 (100%) had 
CXR lesions in 
≤3 days of 
presentation 





lesions (mild to 






























Bi- (6/7; 85.7%) 
& unilateral 
(1/7; 14.3%) 
























































Abbreviations: ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; CFR, 1396 
case-fatality rate; CRAB, carbapenem-resistant Acinetobacter baumannii, CT, computerized tomography scan; CXR, chest 1397 
radiograph; DIC, disseminated intravascular coagulation; ICU, intensive care unit; INR, international normalized ratio; KSA, the 1398 
Kingdom of Saudi Arabia; LDH, lactate dehydrogenase; MRSA, methicillin-resistant Staphylococcus aureus, NA, not available; SVT, 1399 
supraventricular tachycardia; UK, the United Kingdom; VRE, vancomycin-resistant enterococci, VT, ventricular tachycardia; WHO, 1400 
World Health Organization. 1401 
a
 Values represent median time intervals  1402 
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TABLE 8 Characteristics of nucleic acid amplification tests for laboratory diagnosis of MERS 1403 
Diagnostic method and 
target gene 
Clinical specimen(s) Recommended use Technical LOD Remarks References 
Nucleic acid amplification       
   upE assay 
   (upstream of E gene) 
Respiratory swab, 
sputum, & endotracheal 
aspirate 
Screening  1.6 to 3.4 RNA 
copies/reaction 
Most widely used test globally (312) 
   ORF1a assay 
   (ORF1a gene) 





As sensitive as upE assay (62, 69) 
   RealStar® MERS-CoV RT-
PCR kit 1.0 
Aspiration tube flushed 
with PBS, BAL, mouth 
exudates, nose exudates, 
stool, urine, CVC flushed 
with PBS 
Screening upE assay: 5.3 
copies/reaction 
ORF1a assay: 9.3 
copies/reaction 
As sensitive as the in-house upE & 
1A assays; rapid & less labor-
intensive than the in-house assays 
(327) 
   ORF1b assay 
   (ORF1b gene) 
Respiratory swab, 







Less sensitive than upE & 1A 
assays; no overlap with those of 
known pan-CoV assays 
(312) 
   RdRpSeq assay 
   (RdRp gene & sequencing) 




0.3 to 3.0 PFU/ml May cross-react with other βCoVs 
as the gene target is highly 
conserved 
(62, 69) 
   NSeq assay 
   (N gene & sequencing) 




0.03 to 0.3 PFU/ml Highly sensitive & specific for 
MERS-CoV; may have deletion or 
mutation in the amplified fragment 
(62, 69) 
   N2 assay 
   (N gene) 




5 to 10 RNA 
copies/reaction 
As sensitive as upE assay (328) 
   N3 assay 
   (N gene) 
URT, LRT, serum, stool Confirmatory of 
upE- or N2-positive 
samples 
5 to 10 RNA 
copies/reaction 
As sensitive as upE assay (328) 
   RT-RPA assay 
(N gene) 






As sensitive as RT-PCR, faster 
TAT (≤30 minutes), & mobile 
(200) 
   RT-LAMP Medium containing 
pharyngeal swabs 
(healthy adults) mixed 
with MERS-CoV 
Field use 3.4 RNA 
copies/reaction 
As sensitive as upE & ORF1a 




Abbreviations: BAL, bronchoalveolar lavage; CoV, coronavirus; CVC, central venous catheter; Ig, immunoglobulin; LOD, lower limit 1404 
of detection; LRT, lower respiratory tract; PCR, polymerase chain reaction; N, nucleocapsid; NPA, nasopharyngeal aspirate; ORF, 1405 
open reading frame; RdRp, RNA-dependent RNA polyemerase; RT-LAMP, reverse transcription loop-mediated isothermal 1406 
amplification; RT-PCR, reverse transcription polymerase chain reaction; RT-PRA, reverse transcription isothermal Recombinase 1407 
Polymerase Amplification; TAT, turnaround time; URT, upper respiratory tract.  1408 
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TABLE 9 Characteristics of antibody detection assays for laboratory diagnosis of MERS and related seroepidemiological data in 1409 
human 1410 
Diagnostic method and 
detection target 
Antigen used Source of tested sera Cross-reactivity Main findings References 
IFA      
   Indirect IFA (anti-
MERS-CoV Ab)  
Whole virus 2 laboratory-confirmed 
cases & blood donors 
1/85 (1.2%) cross-reactive 
IgM in blood donors; 
detected in cells 
overexpressing 
recombinant S or N 
proteins 
Better cell morphology; used as 




  130 blood donors & 
226 slaughterhouse 
workers (Jeddah & 
Makkah, KSA) 
8/226 slaughterhouse 
workers had cross-reactive 
Ab in IFA 
No evidence of widespread 
circulation of MERS-CoV in 
Jeddah & Makkah, KSA 
(98) 
   Indirect IFA (anti-
MERS-CoV Ab) 
Whole virus Animal handlers, SARS 
patients, & healthy 
blood donors in 
southern China 
2/94 (2.1%) of animal 
handlers, 17/28 (60.7%) 
SARS patients, & 0/152 
(0%) of healthy blood 
donors had cross-reactive 
anti-MERS-CoV Ab 
An epitope around HR2 domain 
of S2 subunit may induce cross-
reactivity in IFA against βCoVs. 
(203) 
   IFA on Vero B4 cells 
(anti-MERS-CoV Ab) 
Recombinant S & N 
proteins 
2 serum samples from 1 
patient (weeks 3 & 8) 
None in samples from a 
few German blood donors; 
detected in cells 
overexpressing 
recombinant S or N 
proteins 
Does not require optimization of 
infection dose & duration, & 
BSL-3 containment 
(62, 69) 
  1laboratory-confirmed 
case & 85 contacts 
None Helps to confirm the positive 
tests in conventional IFA 
(183) 
ELISA      
   ELISA (anti-S & anti-N 
Ab) 
S & N proteins 
expressed in VRP 
Mouse sera Cross-reactive anti-N Ab 
against MERS-CoV & 
other lineage 2c βCoVs; 
little cross-reactive anti-S 
Ab; no cross-reactive anti-
N or anti-S Ab between 
MERS-CoV & SARS-
Strain specific anti-S responses 
with very low level of cross-
reactivity within or across CoV 
subgroups; cross-reactive anti-N 





CoV or αCoVs 
Western blot       
   Western blot (anti-S & 
anti-N Ab) 
Recombinant S & N 
proteins 
2 serum samples from 1 
patient (weeks 3 & 8) 
Not tested Confirms the presence of anti-S 
& anti-N Ab detected in IFA 
(62) 
   Western blot (anti-S & 
anti-N Ab) 
S & N proteins 
expressed in VRP 
Mouse sera Cross-reactive anti-N Ab 
against MERS-CoV & 
other lineage C βCoVs, 
little cross-reactive anti-S 
Ab; no cross-reactive anti-
N or anti-S Ab between 
MERS-CoV & SARS-
CoV or αCoVs 
Strain specific anti-S responses 
with very low level of cross-
reactivity within or across CoV 
subgroups; cross-reactive anti-N 
Ab within but not across CoV 
subgroups 
(202) 
Protein microarray Soluble S1 subunit of S 
protein 
Patients with MERS, 
SARS, and/or other 
human CoV infections; 
& sera from 
cynomolgus macaques 
& rabbit infected with 
MERS-CoV 
None Allows 1-stage, high-
throughput, testing with minimal 
sample requirement & can use 
dried blood spots for testing to 
facilitate sample transfer 
(329) 
Neutralization test     (195) 
   PRNT (anti-MERS-CoV 
Ab) 
Whole virus 1laboratory-confirmed 
case & 85 contacts 
None Used as a confirmatory test in a 
2-stage protocol 
(183) 
  130 blood donors & 
226 slaughterhouse 
workers (Jeddah & 
Makkah, KSA) 
8/226 slaughterhouse 
workers had cross-reactive 
Ab in IFA but not PRNT 
PRNT is more specific than IFA (98) 
   PRNT (anti-MERS-CoV 
Ab) 
Whole virus Patients with MERS, 
SARS, and/or other 
human CoV infections; 
& sera from camels 
&other animals 
None in human samples Used as a confirmatory test in a 
2-stage protocol 
(121) 
   PRNT (anti-S & anti-N 
Ab) 
S & N proteins 
expressed from VRP 
Mouse sera & 1patient 
with MERS 
Very low levels of cross-
neutralization of MERS-
CoV by mouse antisera to 
SARS-CoV using high 
concentrations of serum 
S but not N protein is the major 
determinant of neutralizing Ab 
response to MERS-CoV; N 
proteins of CoVs cross-react 
within but not between 
subgroups; S proteins of CoVs 
have little cross-neutralization or 
cross-reactivity within subgroup 




   Neutralization of MERS-
CoV-S-driven transduction 
(anti-S Ab 
S proteins expressed by 
lentiviral vectors 
Sear from hospitalized 
children & male blood 
donors in KSA 
None Estimated MERS-CoV 
seroprevalence in the study area 
was <2.3% in children during 
2010 to 2011, & <3.3% in male 
adults in 2012 
(51, 97) 
   Microneutralization 
assay (neutralizing anti-
MERS-CoV Ab) 
Whole virus Animal handlers, SARS 
patients, & healthy 
blood donors in 
southern China 
0/94 (0%), 7/28 (25.0%) of 
SARS patients, & 0/152 
(0%) of healthy blood 
donors had low-titer cross-
reactive neutralizing anti-
MERS-CoV Ab 
An epitope around HR2 domain 
of S2 subunit may induce cross-
reactive neutralizing Ab against 
βCoVs 
(203) 
   Microneutralization 
assay (neutralizing anti-
MERS-CoV Ab) 
Whole virus Human sera from 
general populations in 
Egypt & Hong Kong; 
MERS & SARS 
patients; & animal sera 
from Egypt 
None in human samples 10 times less sensitive than the 
ppNT assay 
(122) 
   ppNT assay (neutralizing 
anti-S Ab) 
S pseudoparticle  
expressed by a 
replication-incompetent 
HIV virus containing a 
luciferase reporter gene 
Human sera from 
general populations in 
Egypt & Hong Kong; 
MERS & SARS 
patients; & animal sera 
from Egypt 
None in human samples 10 times more sensitive than the 
conventional microneutralization 
assay, does not require BSL-3 
containment 
(122) 
Abbreviations: Ab, antibody; BAL, bronchoalveolar lavage; BSL, Biosafety Level; CPE, cytopathic effects; CVC, central venous 1411 
catheter; ELISA, enzyme-linked immunosorbent assay; HIV, human immunodeficiency virus; HR2, heptad repeat 2; Ig, 1412 
immunoglobulin; IFA, immunofluorescence assay; KSA, Kingdom of Saudi Arabia; LRT, lower respiratory tract; MNT, 1413 
microneutralization test; N, nucleocapsid protein; NPA, nasopharyngeal aspirate; PCR, polymerase chain reaction; ppNT, 1414 
pseudoparticle neutralization; PNRT, plaque reduction neutralization test; RT-PRA, reverse transcription isothermal Recombinase 1415 
Polymerase Amplification; S, Spike; TAT, turnaround time; TCID50, 50% tissue culture infective dose; URT, upper respiratory tract; 1416 
VRP, Venezuelan equine encephalitis virus replicons.  1417 
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TABLE 10 Antiviral agents and immunomodulators against MERS-CoV 1418 
Antiviral agents and/or 
immunomodulator(s) 
Drug target and/or proposed 
mechanism 
Study setting and methods 
(virus strain) 
Main findings References 
In vitro studies      
   Interferons     
      IFN-universal type 1 Exogenous IFN Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 113.8 U/ml (330) 
      Pegylated IFN-α Exogenous IFN Vero (HCoV-EMC/2012) ↓ CPE at ≥1ng/ml (58) 
      IFN-α2a Exogenous IFN Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 160.8 U/ml (330) 
      IFN-α2b Exogenous IFN Vero (HCoV-EMC/2012) IC50 = 58.08 µg/ml (209) 
  LLC-MK2 (HCoV-
EMC/2012) 
IC50 = 13.26 µg/ml (209) 
  Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 21.4 U/ml (330) 
      IFN-α2b (Intron A) Exogenous IFN Vero (HCoV-EMC/2012) IC50 = 6709.79 IU/ml (210) 
      IFN-β1a (Avonex) Exogenous IFN Vero (HCoV-EMC/2012) IC50 = 5073.33 IU/ml (210) 
      IFN-β1a (Rebif) Exogenous IFN Vero (HCoV-EMC/2012) IC50 = 480.54 IU/ml (210) 
      IFN-β1b (Betaferon) Exogenous IFN Vero (HCoV-EMC/2012) IC50 = 17.64 IU/ml (210) 
     Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 1.37 U/ml (330) 
      IFN-γ Exogenous IFN Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 56.5 U/ml (330) 
   Cyclophilin inhibitors     
      Cyclosporin A Inhibitor of cyclophilins & their 
interactions with Nsp1 
Vero (HCoV-EMC/2012) Complete inhibition of infection at 
9 µM of cyclosporin A 
(58) 
  Huh-7 (HCoV-EMC/2012) Partial & complete inhibition of 
infection at 7.5 µM & 15 µM of 
cyclosporin A respectively 
(58) 
   Viral protease inhibitors     




1/2012) tested were less sensitive; 
inhibition of a post-entry step 
(213) 
      N3 3C-like protease inhibitor Not available IC50 = 0.28 µmol/l (223) 
      CE-5 3C-like protease inhibitor HEK293T (HCoV-
EMC/2012) 
IC50 = 12.5 µM (224) 
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      GRL-001 3C-like protease inhibitor Vero (Hu/England-N1/2012) Completely blocked viral 
replication at early time points (<24 
hpi), ↓ viral replication by ~100-
fold at 24 hpi, & ↓virus-induced 
cytopathology in infected cells 
(225) 
   Helicase inhibitors     
      SSYA10-001 Helicase inhibitor Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 25 µM, SI ≥ 20 (226) 
   Cellular protease 
inhibitors 
    
      Camostat mesylate TMPRSS2 inhibitor Vero-TMPRSS2 (HCoV-
EMC/2012) 
↓ cell entry by ~15-fold (10 µM) & 
inhibited syncytia formation in a 
dose-dependent manner (1 to 100 
µM)  
(52) 
  Calu-3 (HCoV-EMC/2012) ↓ cell entry by ~10-fold (10 µM), 
inhibited the multistep growth of 
the virus by ~90-fold (10 µM) to 
~270-fold (100 µM), & delayed 
virus-induced cell death by 2 (10 
µM) to 5 days (100 µM) 
(52) 
      Leupeptin Protease inhibitor Calu-3 (HCoV-EMC/2012) ↓ virus entry into cells (10 & 100 
µM) 
(52) 
      E-64-D Broad-spectrum cathepsin inhibitor Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 1.275 µM (212) 
      EST Cathepsin inhibitor Vero-TMPRSS2 (HCoV-
EMC/2012) 
↓ virus entry into cells by ~3-fold 
(10 µM) 
(52) 
      Cathepsin L inhibitor III Cathepsin L-specific inhibitor Vero E6 & LLC-MK2 
(HCoV-EMC/2012) 
↓ entry of MERS-CoV pseudovirus 
by 97% 
(23) 
      MDL-28170 Cathepsins B & L inhibitor MRC5 (HCoV-EMC/2012) MERS-CoV-S mediated 
transduction was blocked 
(51) 
   Nucleic acid and/or protein 
synthesis inhibitors 
    
      Anisomycin Protein & DNA synthesis inhibitor by 




IC50 = 0.003 µM (212) 
      Cycloheximide Protein synthesis inhibitor Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 0.189 µM (212) 




IC50 = 5.468 µM (212) 
      Emetine dihydrochloride Protein synthesis inhibitor by binding Vero E6 (Hu/Jordan- IC50 = 0.014 µM (212) 
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hydrate to 40S ribosomal subunit N3/2012) 
      Gemcitabine 
hydrochloride 




IC50 = 1.216 µM (212) 
      Homoharringtonine 
(omacetaxine mepesuccinate) 
Protein synthesis inhibitor Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 0.0718 µM (212) 




IC50 =  17.689 µM (212) 
      K22 Specifically targets membrane-bound 
viral RNA synthesis 
HAE (HCoV-EMC/2012) ↓ viral replication by >4-log  & 
substantial reduction of dsRNA (50 
µM) 
(306) 
      Mycophenolic acid Inhibitor of IMPDH & depletion of 
guanosine & deoxyguanosine 
nucleotide pools  
Vero (HCoV-EMC/2012) IC50 = 0.17 µg/ml (210) 
  Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 2.87 µM (330) 
      Ribavirin Nucleoside polymerase inhibitor Vero (HCoV-EMC/2012) IC50 = 41.45 µg/ml (209) 
  Vero (HCoV-EMC/2012) IC50 = 9.99 µg/ml (210) 
  LLC-MK2 (EMC/2012) IC50 = 16.33 µg/ml (209) 
  Vero E6 (Hu/Jordan-
N3/2012) 
IC50 ≥250 µM (330) 
   mAb against Spike protein     
      Mersmab1 mAb against RBD of S1 subunit of S 
protein 
Huh-7 (HCoV-EMC/2012) Blocked entry of MERS-CoV-S-
mediated pseudovirus into cells 
with ND50 <0.16 µg/ml 
(37) 
  Vero E6 (HCoV-EMC/2012) Neutralizing inhibitory activity with 
ND50 <2 µg/ml 
(37) 
  Calu-3 (HCoV-EMC/2012) Neutralizing activity with CPE 
inhibition 
(37) 
      MERS-4 mAb mAb against RBD of S1 subunit of S 
protein 
Huh-7 (IC50) & COS7 
(syncytia formation) (HCoV-
EMC/2012) 
Inhibited syncytia formation & 
neutralizing inhibitory activity with 
IC50 = 0.37 nM (pseudovirus) & 
3.33nM (live) 
(39) 
      MERS-27 mAb mAb against RBD of S1 subunit of S 
protein 
Huh-7 (IC50) & COS7 
(syncytia formation) (HCoV-
EMC/2012) 
Neutralizing inhibitory activity with 
IC50 = 63.96 nM (pseudovirus) & 
13.33nM (live) 
(39) 
      m336 mAb mAb against RBD of S1 subunit of S 
protein 




Neutralizing inhibitory activity with 
IC50 <0.01 µg/ml (live) & 0.07 
µg/ml (pseudovirus); inhibited 





      m337 mAb mAb against RBD of S1 subunit of S 
protein 




Neutralizing inhibitory activity with 
IC50 <0.01 µg/ml (pseudovirus) & 
<10 µg/ml (live); inhibited RBD-
DPP4 binding (IC50 = 0.044 µg/ml) 
(38) 
      m337 mAb mAb against RBD of S1 subunit of S 
protein 




Neutralizing inhibitory activity with 
IC50 <0.1 µg/ml (pseudovirus) & <1 
µg/ml (live); inhibited RBD-DPP4 
binding (IC50 = 0.041 µg/ml) 
(38) 
      1E9 scFvFc Single-chain variable domain fragment 
against RBD of S1 subunit of S 
protein fused with hFc 




Neutralizing inhibitory activity 
(IC50 = 3.21 µg/ml) 
(40) 
      1F8 scFvFc Single-chain variable domain fragment 
against RBD of S1 subunit of Sprotein 
fused with hFc 




Neutralizing inhibitory activity 
(IC50 = 6.27 µg/ml) 
(40) 
      3A1 scFvFc Single-chain variable domain fragment 
against RBD of S1 subunit of S 
protein fused with hFc 




Neutralizing inhibitory activity 
(IC50 = 1.46 µg/ml) 
(40) 
      3B12 scFvFc Single-chain variable domain fragment 
against RBD of S1 subunit of S 
protein fused with hFc 




Neutralizing inhibitory activity 
(IC50 = 1.25 µg/ml) 
(40) 
      3C12 scFvFc Single-chain variable domain fragment 
against RBD of S1 subunit of S 
protein fused with hFc 




Neutralizing inhibitory activity 
(IC50 = 2.00 µg/ml) 
(40) 
      3B11 scFvFc Single-chain variable domain fragment 
against RBD of S1 subunit of S 
protein fused with hFc 




Neutralizing inhibitory activity 
(IC50 = 1.83 µg/ml) 
(40) 
      M14D3 scFvFc Single-chain variable domain fragment 
against RBD of S1 subunit of S 
protein fused with hFc 




Neutralizing inhibitory activity 
(IC50 = 4.30 µg/ml) 
(40) 
   mAb against DPP4     
      Clone 2F9 mAb mAb against DPP4 Huh-7 (?strain) Near complete inhibition of NSP4 
expression in infected cells 
(50) 
      Clone YS110 mAb mAb against DPP4 Huh-7 (?strain) Partial inhibition of NSP4 (50) 
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expression in infected cells 
   Inhibitors of clathrin-
mediated endocytosis 
    
      Astemizole Antihistamine & anticholinergic; 




IC50 = 4.884 µM (212, 214) 
      Clomipramine 
hydrochloride 




IC50 = 9.332 µM (212, 214)  
      Chlorpromazine Antipsychotic (phenothiazine); 
inhibitor of clathrin-mediated 
endocytosis 
Huh-7 (HCoV-EMC/2012) IC50 = 4.9 µM, SI = 4.3. Inhibition 
of an early step with or without 
another post-entry step in the 
replicative cycle. 
(213, 214)  
  Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 9.514 µM. (212, 214) 
      Fluphenazine 
hydrochloride 
Antipsychotic (piperazine); inhibitor 
of clarthrin-mediated endocytosis 
Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 5.868 µM (212, 214)  
      Promethazine 
hydrochloride 
Antihistamine & antipsychotic 




IC50 = 11.802 µM (212, 214) 
      Tamoxifen citrate Estrogen receptor inhibitor; inhibitor 
of clarthrin-mediated endocytosis 
Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 10.117 µM (212, 214)  
      Thiothixene Antipsychotic (thioxanthene); 




IC50 = 9.297 µM (212, 214)  
      Triflupromazine 
hydrochloride 
Antipsychotic (phenothiazine); 




IC50 = 5.758 µM (212, 214) 
  Other cell entry inhibitors     
      HR2P peptide HR2-based fusion inhibitor; inhibitor 
of clarthrin-mediated endocytosis 
Vero (HCoV-EMC/2012) IC50 = 0.6 µM (44, 214) 
  Calu-3 (HCoV-EMC/2012) IC50 = 0.6 µM (44) 
  HFL (HCoV-EMC/2012) IC50 = 13.9 µM (44) 
      P1 peptide HR2-based fusion inhibitor Huh-7 (HCoV-EMC/2012) Inhibited MERS-CoV pseudovirus 
with IC50 = 3.013µM. 
(45) 
      dec-RVKR-CMK Furin inhibitor Huh-7, MRC-5, WI-38, 
Vero, & NHBE cells (HCoV-
EMC/2012) 
Dose-dependent & significant ↓ 
virus infection in various cell types. 
(54) 
      S377-588-Fc protein Recombinant truncated RBD of S 
protein fused with human IgG Fc 
fragment 





      HP-HSA 3-hydroxyphthalic anhydride-modified 
human serum albumin targeting HIV-1 
gp120 and/or CD4 receptor 
Huh-7 & NBL-7 (MERS-
CoV pseudovirus expressing 
full-length S protein of 
HCoV-EMC/2012) 
Around 90% of pseudovirus entry 
inhibition (20 µM); minimal 
cytotoxicity in Huh-7 cells at up to 
100 µM 
(41) 
      ADS-J1 Small molecule entry inhibitor 
targeting HIV gp41 
Huh-7 & NBL-7 (MERS-
CoV pseudovirus expressing 
full-length S protein of 
HCoV-EMC/2012) 
CC50 = 26.9 µM, IC50 = 0.6 µM, 
& SI = 45 
(41) 
      C34 Peptidic HIV entry inhibitor Huh-7 & NBL-7 (MERS-
CoV pseudovirus expressing 
full-length S protein of 
HCoV-EMC/2012) 
Around 50% of pseudovirus 
inhibition at 20 µM in NBL cells 
but no activity in Huh-7 cells. 
(41) 
      T20 Peptidic HIV entry inhibitor Huh-7 & NBL-7 (MERS-
CoV pseudovirus expressing 
full-length S protein of 
HCoV-EMC/2012) 
Around 50% of pseudovirus 
inhibition at 20 µM in NBL cells 
but no activity in Huh-7 cells. 
(41) 
      Adenosine deaminase Natural DPP4 ligand Huh-7 (HCoV-EMC/2012) Dose-dependent inhibition of 
MERS-CoV infection 
(49) 
  Human DPP4 plasmid-
transfected MDCK  (HCoV-
EMC/2012) 
Blocks S1 binding & MERS-CoV 
infection despite expression of 
DPP4 
(49) 
   Miscellaneous     






IC50 = 6.212 µM (212) 
      Benztropine mesylate Anticholinergic Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 16.627 µM (212) 
      Chloroquine Anti-parasitic Huh-7 (HCoV-EMC/2012) IC50 = 3.0 µM, SI = 19.4. Inhibition 
of an early step in the replicative 
cycle. 
(213) 
  Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 6.275 µM. (212) 
      Chlorphenoxamine 
hydrochloride 
Antihistamine & anticholinergic Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 12.646 µM (212) 
      Dabrafenib Raf inhibitor Huh-7 (HCoV-EMC/2012) 45% inhibition (10 µM ) (215) 
      ESI-09 Epac-specific inhibitor Calu-3 (HCoV-EMC/2012) Dose-dependent CPE inhibition (1 
to 10 µM) & viral yield reduction 
(2.5 to 40 µM); treatment before 
infection unnecessary; extended 
therapeutic window (≥20 hours); 




CC50 >50 µM; changed DPP4 
expression pattern on the membrane 
of Calu-3 cells 
  Vero E6 (HCoV-EMC/2012) Dose-dependent CPE inhibition & 
viral yield reduction 
(331) 
      Everolimus mTOR inhibitor Huh-7 (HCoV-EMC/2012) 56% to 59% inhibition (10 µM ) (215) 




IC50 = 7.477 µM (212) 
      Hydroxychloroquine 
sulfate 
Anti-parasitic Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 8.279 µM. (212) 
      Loperamide µ-opioid receptor agonist  Huh-7 (HCoV-EMC/2012) IC50 = 4.8 µM; SI = 3.2; inhibition 
of an early step in the replication 
cycle 
(213) 




IC50 = 7.416 µM (212) 
      Miltefosine AKT inhibitor Huh-7 (HCoV-EMC/2012) 28% inhibition (10 µM ) (215) 
      SB203580 Kinase inhibitor Vero E6 (HCoV-EMC/2012) Pretreatment of infected cells with 
SB203580 decreased 15% & 7% of 
the log10 viral titer at 24 hpi & 48 
hpi respectively 
(177) 
      Selumetinib ERK/MAPK signaling inhibitor  Huh-7 (HCoV-EMC/2012) >95% inhibition (10 µM ) (215) 
      Sorafenib Raf inhibitor Huh-7 (HCoV-EMC/2012) 93% inhibition (10 µM ) (215) 
      Terconazole Sterol metabolism inhibitor Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 12.203 µM (212) 
      Thiethylperazine maleate Antiemetic (phenothiazine) Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 7.865 µM (212) 
      Toremifene citrate Estrogen receptor inhibitor Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 12.915 µM (212) 
      Trametinib ERK/MAPK signaling inhibitor Huh-7 (HCoV-EMC/2012) >95% inhibition (0.1 µM ) (215) 
      Triparanol Sterol metabolism inhibitor Vero E6 (Hu/Jordan-
N3/2012) 
IC50 = 5.283 µM (212) 
   Combinational treatment     
      Ribavirin / IFN-α2b (1:5) Nucleoside polymerase inhibitor / 
exogenous IFN 
Vero (HCoV-EMC/2012) Additional ↓ viral titer by 0.40 to 
2.16-logs with ribavirin 
(209) 
      Mycophenolic acid / IFN-
β1b  
IMPDH inhibitor / exogenous IFN Vero (HCoV-EMC/2012) IC50 of mycopheonlic acid = 1.7-2.8 
times lower with 6.25-12.5 IU/ml 
of IFN-β1b; IC50 of IFN-β1b 1.1-
1.8 times lower with 0.016-0.063 
µg/ml of mycophenolic acid 
(210) 
      MERS-4 & MERS-27 mAbs against RBD of S1 subunit of S Huh-7 (HCoV-EMC/2012) Synergistic neutralizing effect (39) 
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mAbs protein against pseudovirus 
Animal experiments     





Regimen: loading dose of 
30mg/kg of ribavirin i.v. & 5 
MIU/kg of IFN-α2b s.c.; 
followed by 10mg/kg q8h of 
ribavirin i.m. & 5MIU/kg of 
IFN-α2b s.c. q16h until 72 
hpi 
Compared to untreated, infected 
macaques, treated macaques had no 
breathing abnormalities, minimal 
radiological evidence of 
pneumonia, lower levels of serum 
& pulmonary proinflammatory 
markers, few viral genome copies, 
lower expression of inflammatory 
genes, & less severe 
histopathological changes in lungs 
(175) 
   Poly I:C TLR3 agonist Ad5-hDPP4-transduced mice 
(HCoV-EMC/2012) 
Accelerated virus clearance from 
lungs of infected mice 
(174) 
Human trials     
   Ribavirin / IFN-α2b / 
corticosteroid 
Nucleoside polymerase inhibitor / 
exogenous interferon / corticosteroid 
5 critically ill MERS patients 
 
Regimen: oral ribavirin, s.c. 




Mean age = 57.6 (24-81) years; 3 
males & 2 females; admitted 4 (2-
10) days after symptom onset; all 
had co-morbidities; time between 
admission & antiviral treatment = 
16.8 (11-21) days & corticosteroid  
15.8 (6-22) days; side effects = 
hemolytic anemia, 
thrombocytopenia, pancreatitis, ↑ 
lipase, & deranged liver & renal 
function tests; all died after a mean 
of 39.6 (32-52) days after 
admission 
(332) 
   Ribavirin / IFN-α2b  ± 
corticosteroid 
Nucleoside polymerase inhibitor / 




Regimen: oral ribavirin & 
s.c. IFN-α2b for 2 weeks (& 
i.v. methylprednisolone 
500mg q24h for 3 days for 
index case) 
Both the index case (treatment) & 
contact (prophylaxis) had clinical & 
radiological improvement after 
receiving ribavirin & IFN-α2b 
(211) 
   Ribavirin / IFN-α2a Nucleoside polymerase inhibitor / 
exogenous IFN ± corticosteroid 
20 severe MERS patients 
 
Regimen: oral ribavirin for 
8-10 days & pegylated IFN-
Compared to the comparator group 
(28 severe MERS patients who 
received supportive care only), the 




α2a 180 µg/week for 2 
weeks; 11/19 (58%) patients 
received corticosteroid 
improved survival at 14 days but 
not 28 days after the diagnosis of 
MERS; significantly greater 
reduction in hemoglobin level was 
noted in the treatment group 
      Ribavirin / lopinavir / IFN-
α2a  
Nucleoside polymerase inhibitor / 
protease inhibitor / exogenous IFN 
1 severe MERS patient  
 
Regimen: oral ribavirin 
1200mg q8h & 
lopinavir/ritonavir 
(400/100mg) q12h for 8 
days, & pegylated IFN-α2a 
180 µg/week for 2 weeks  
Viremia resolved 2 days after 
initiation of antiviral treatment 
(started on day 13 of illness); 
persistent virus shedding in 
respiratory tract secretions until 4th 
week of illness 
(184) 
Abbreviations: ABL1, Abelson murine leukemia viral oncogene homolog 1; Ad5-hDPP4, adenovirus expressiong human host-cell 1419 
receptor dipeptidyl peptidase 4; AKT, protein kinase B; CC50, 50% inhibition of cell survival; DPP4, dipeptidyl peptidase 4; Epac, 1420 
exchange proteins directly activated by cAMP; ERK/MAPK, extracellular signal-regulated kinases/mitogen-activated protein kinases; 1421 
HAE, primary human airway epithelia; hFc, constant region fragment of human IgG; hpi, hours post infection; HR, heptad repeat; 1422 
IC50, 50% maximal inhibitory concentration; IFN, interferon; IMPDH, inosine-5’-monophosphate dehydrogenase; i.v., intravenous; 1423 
mAb, monoclonal antibody; MIU, mega international units; mTOR, mammalian target of rapamycin; ND50, 50% neutralization dose; 1424 
Nsp1, non-structural protein 1; RBD, receptor-binding domain; S, spike; s.c., subcutaneous; SI, selectivity index; TLR3, Toll-like 1425 
receptor 3; TMPRSS2, type II transmembrane serine protease.  1426 
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TABLE 11 Active and passive immunization against MERS 1427 
Vaccine Components (virus strain) Animal model 
(administration) 
Main findings (animal model) References 
Active immunization     
   MVA-MERS-S Recombinant modified 
vaccinia virus Ankara 
expressing full-length 
MERS-CoV S protein 
(HCoV-EMC/2012) 
BALB/c mice (2 i.m. 
immunizations at days 0 
& 21) 
High levels of nAb were induced (248) 
   VRP-S Venezuelan Equine 
Encephalitis Replicon 




BALB/c mice (2 
immunizations in the 
footpads at days 0 & 28) 
Reduction of viral titers to nearly undetectable levels 
by 1 dpi 
(174) 
   Spike protein nanoparticles Purified S protein 
nanoparticles produced in Sf9 
cells infected with specific 
recombinant baculovirus 
cloned with MERS-CoV S 
protein gene sequence (Al-
Hasa_1_2013) 
BALB/c mice, 6 to 8 
weeks old (2 i.m. 
immunizations on days 0 
& 21) 
Inducted nAb in mice receiving MERS-CoV S 
inoculation with adjuvants Matrix M1 or Alum, but 
not in those receiving MERS-CoV S inoculation 
alone (Matrix M1 > Alum > no adjuvant); nAb levels 
were not significantly different between regimens 
consisting of 1 µg & 3 µg, & between sera obtained 
on days 21 &45 
(249) 
   S-RBD-Fc Recombinant protein 
containing RBD (residues 
377 to 662) of S1 (HCoV-
EMC/2012) 
Mice (2 s.c. 
immunizations on days 0 
& 14) 
Sera of vaccinated mice showed neutralizing activity 
(>96%) against MERS-CoV pseudo- (Huh-7 cells) & 
live (Vero E6 cells) virus infection 
(41) 
   358-to-588 S1-Fc RBD (residues 358 to 588) of 
S1 fused with human IgG Fc 
fragment (HCoV-EMC/2012) 
Vero cells (inoculation of 
sera containing 
polyclonal Ab raised in 
immunized rabbits) 
Polyclonal antibodies against 358-to-588 S1-Fc 
variant efficiently neutralized virus infectivity 
(34) 
   S377-588-Fc Truncated 212-aa fragment of 
RBD (residues 377 to 588) of 
S1 fused with human IgG Fc 
fragment (HCoV-EMC/2012) 
BALB/c mice, 6 to 8 
weeks old (3 s.c. 
immunizations) 
↑ neutralizing IgG1 (Th2) & IgG2a (Th1) Ab 
responses specific for the RBD in the S1 subunit 
were induced after each immunization with 
Montanide ISA 51 adjuvant 
(31, 42)  
     BALB/c mice, 4 to 6 
weeks old (5 s.c. or i.n. 
immunizations at days 0, 
21, 42, 3 months & 6 
months) 
i.n. vaccination with Poly(I:C) adjuvant induced 
similar degree of systemic humoral immune 
responses, including nAb, & more robust systemic 
cellular & local (lung) mucosal immune responses as 
comparable to those induced by s.c. vaccination with 




  BALB/c mice, 6 to 8 




Among 5 versions of RBD fragments, the S377-588-
Fc showed the highest DPP4-binding affinity, & 
induced the highest-titer IgG Ab in mice & 
neutralizing Ab in rabbits 
(36) 
   rRBD (combined with 
different adjuvants) 
Recombinant RBD protein 
containing a 240-aa fragment 
of RBD (residues 367-606) 
of S1(HCoV-EMC/2012) 
combined with different 
adjuvants [Alum alone, Alum 
plus CpG-ODNs, Alum plus 
Poly(I:C), or CpG-ODNs 
plus IFA] 
BALB/c mice, 6 to 8 
weeks old (3 i.m. or s.c. 
immunizations at days 0, 
21 & 42) 
The combination of rRBD and Alum plus CpG-
ODNs given by the i.m. route provided the most 
robust RBD-specific humoral and cellular immunity. 
(251) 
Passive immunization     




BALB/c mice (sera 
obtained 2-4 weeks after 
immunization with VRP-
S, & transferred into 
mice i.p. 1 day before 
infection) 
Adoptive transfer of sera containing anti-MERS-
CoV-S Ab blocked virus attachment & accelerated 
virus clearance to nearly undetectable levels by 5 dpi 
(174) 
Abbreviations: aa, amino acid; Ab, antibody; Ad5-hDPP4, adenoviral vectors expressing human dipeptidyl peptidase 4; Alum, 1428 
aluminium hydroxide; CpG-ODNs, cysteine-phosphate-guanine oligodeoxynucleotides; dpi, days post infection; IFA, incomplete 1429 
Freund’s adjuvant; i.m., intramuscular; i.n., intranasal; i.p., intraperitoneal; nAb, neutralizing antibody; Poly(I:C), polyriboinosinic 1430 














Clinical, virological, & immunological 
findings 
Histopathological & IHC results References 
Susceptible      





7 × 106 TCID50 
i.t., i.n., oral & 
ocular (HCoV-
EMC/2012) 
Up to 6 Clinical: mild to moderate symptoms 
including nasal swelling, piloerection, ↓ 
bowel opening, ↑ or ↓ respiratory rate, ↓ 
food intake, & hunched posture on 1-6 
dpi; leukocytosis with neutrophilia & 
lymphopenia on 1 dpi 
Virological: viral RNA detected in upper 
& lower respiratory tract specimens, 
conjunctiva, & lymphoid tissues 
(mediastinal & tonsils) from 1 dpi, & in 1 
macaque’s urogenital swab on 1 dpi 
Immunological: significant up-
regulation of genes associated with 
proinflammatory process (IL-6, CXCL1, 
MMP9); rapid resolution of controlled 
interferon-mediated innate immune 
response 
Macroscopic: multifocal to coalescent, 
mild to marked interstitial pneumonia 
Microscopic: thickening of alveolar 
septae by edema fluid & fibrin with 
predominantly macrophages; BOOP-like 
changes with multinucleate syncytia 
formed by alveolar macrophages, fibrin 
aggregates, & occluded small airways by 
sloughed pulmonary epithelium, & 
perivascular infiltrates of inflammatory 
cells; type II pneumocyte hyperplasia; 
hyaline membrane formation 
IHC: viral Ag detected in types I & II 
pneumocytes, & macrophages/monocytes 
or dendritic cells 
(165, 166) 









Up to 28 Clinical: fever & reduced water intake on 
1-2 dpi; CXR showed varying degrees of 
localized infiltration & interstitial 
markings on 3-5 dpi 
Virological: viral RNA detected in lungs 
on 3 dpi 
Immunological: neutralizing Ab detected 
at 7 dpi, & peaked at 14 dpi 
Macroscopic: congestion & palpable 
nodules scattered in distribution 
Microscopic: multifocal mild-to-moderate 
interstitial pneumonia & exudative 
changes in lungs 
IHC: viral Ag detected in types I & II 
pneumocytes, & alveolar macrophages 
(167) 





5.2 × 106 
TCID50 i.t., i.n., 
oral & ocular 
(HCoV-
EMC/2012) 
Up to 55 Clinical: moderate to severe symptoms 
including ↑respiratory rate, open mouth 
and/or labored breathing, frothy 
hemorrhagic discharge from mouth, ↓ 
food intake, & ↓ activity level since 1-3 
dpi & peaked o 4-6 dpi. Clinical scores 
retuned to baseline by 13 dpi; 2/9 animals 
Macroscopic: multifocal, extensive, 
severe lesions especially in lower lobes; 
lungs were firm, failed to collapse, & fluid 
filled 
Microscopic: multifocal to coalescing, 
moderate to marked acute 
bronchointerstitial pneumonia centered on 




were euthanized because of severe 
disease; CXR showed varying degrees of 
interstitial infiltration on 3-4 dpi 
Virological: viral RNA detected in upper 
(since 1 dpi) & lower respiratory tract 
specimens, blood, & multiple organs 
(conjunctiva, lymph nodes, tonsils, 
kidneys, heart, adrenal glands, liver, 
spleen, pancreas, colon, ileum, frontal 
lobe, cerebellum, brain stem, urinary 
bladder, & testes) since 3 dpi    
Immunological: tissue differentiation 
with development of pulmonary fibrosis 
as evidenced by activation of pathways 
associated with chemotaxis & ell 
migration, cell cycle progression, cell 
proliferation, fibrogenesis, inflammation, 
vascularization, endothelial activation, 
smooth muscle cell proliferation, & tissue 
repair; upregulation of innate & adaptive 
immune genes; induction of type I IFNs, 
IL-2, IL-4, & IL-6; inhibition of type II 
IFNs, IL-1 & TNFα 
neutrophils & macrophages; thickening of 
alveolar septa; edema, hemorrhage & 
fibrin filled the alveolar spaces (3-4 dpi); 
type II pneumocyte hyperplasia & 
formation of hyaline membrane (6 dpi) 
IHC: viral Ag detected in affected areas, 
especially in type I pneumocytes & 
alveolar macrophages 




weeks (young) & 
18-22 months 
(aged) 
1 × 105 PFU 
i.n. (HCoV-
EMC/2012) 
Up to 14 Clinical: young BALB/C mice failed to 
gain weight, aged C57BL/6 & BALC/c 
mice lost weight 
Virological: clearance of virus by 6-8 dpi 
in young mice & 10-14 in aged mice 
Immunological: requirement of type I 
IFN induction & signaling, CD8 T cells 
& Ab for virus clearance; low level of 
cross-reactivity between MERS-CoV & 
SARS-CoV 
Macroscopic: vascular congestion & 
inflammation 
Microscopic: perivascular & 
peribronchial lymphoid infiltration 
initially, with progression to an interstitial 
pneumonia 
IHC: viral Ag detected in lungs 
(175) 




107 TCID50 i.t., 
i.n. & ocular 
(HCoV-
EMC/2012) 
 Clinical: mild upper respiratory tract 
symptoms including rhinoorhea & mild 
↑ temperature 
Virological: infectious virus detected in 
nasal (up to 7 dpi & 108 PFU/ml) & oral 
(up to 5 dpi & 102 PFU/ml) swabs; viral 
RNA detected in nasal (up to 35 dpi & 
Macroscopic: lesions found in the upper 
respiratory tract, trachea, bronchi & 
bronchioles, but not in the alveoli (up to 
28 dpi) 
Microscopic: mild to moderate acute 
intraepithelial & submucosal inflammation 




106 TCID50 equivalent/ml) & oral (up to 
35 dpi & 104 TCID50 equivalent/ml) 
swabs  
Immunological: neutralizing Ab detected 
at 14 dpi, & peaked at 35 dpi 
pseudostratified epithelial cells & 
infiltration of small numbers of 
neutroprophils & macrophages (up to 28 
dpi) 
IHC: viral Ag detected in affected areas 
(up to 28 dpi) 
   Goats N/A N/A Clinical: asymptomatic to mildly 
symptomatic 
Immunological: seroconversion in all 14 
goats by 14 dpi 
N/A (258) 
   Jamaican fruit 
bats 
N/A N/A Clinical: no clinical signs or elevation in 
temperature 
Virological: virus shedding from 
respiratory & intestinal tract for up to 9 
dpi 
N/A (257) 
Non-susceptible      
   Syrian hamster 
(Mesocricetus 
auratus) 
4 × 102 TCID50 
aerosols,  103 
TCID50 i.t., or 
106 TCID50 i.t. 
(HCoV-
EMC/2012) 
Up to 21 Clinical: no significant weight loss or 
fever 
Virological: no viral RNA detected in 
nasal, oropharyngeal, urogenital & rectal 
swabs from 1-11 dpi; & lungs, spleen & 
mandibular lymph nodes on 2, 4, & 8 dpi 
Immunological: no seroconversion 
Macroscopic: no gross lesions 
Microscopic: no lesions in trachea, heart, 
lung, spleen, liver, kidney, ileum, colon, 
urinary bladder, nasal turbinates, & brain 
tissues 
(333) 
   BALB/c, 
129/SvEv, & 
129/SvEv STAT1 
knockout mice; 8 
weeks 




Up to 9 Clinical: no significant weight loss 
Virological: no detectable virus in lungs 
Microscopic: no sign of viral infection 
(apoptotic cells & syncytia formation); 
129S6/SvEv & 129/SvEv STAT1 
knockout mice had only minor signs of 
pathological lesions or inflammatory 
response, with a few lesions of focal 
interstitial pneumonitis composed of 
neutrophils & macrophages; BALB/c mice 
had perivascular cuffing with scattered 
neutrophils & foci of pneumonia around 
proximal airways 
(334) 
   Ferret (Mustela 
putorius furo) 
1 × 106 TCID50 
i.n. & i.t. 
(HCoV-
EMC/2012) 
Up to 14 Virological: no infectious virus was 
detected in nose & throat swabs 
Immunological: no seroconversion 
 
In vitro: ferret primary kidney cells did 
not bind recombinant S protein S1 & could 
not be infected with MERS-CoV, despite 
DPP4 surface expression 
(49) 
Abbreviations: Ab, antibody; Ad5-hDPP4, adenoviral vectors expressing human dipeptidyl peptidase 4; Ag, antigen; BOOP, 1434 
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bronchiolitis obliterans organizing pneumonia; CXCL1, chemokine C-X-C ligand 1; dpi, days post inoculation; IFN, interferon; IHC, 1435 
immunohistochemistry; IL, interleukin; i.n., intranasal; i.t., intratracheal; MMP9, matrix metalloproteinase 9; N/A, not available; PFU, 1436 
plaque-forming unit; S, spike; TCID50, 50% tissue culture infectious dose.  1437 
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FIGURE LEGENDS 1438 
 1439 
FIG. 1A. Taxonomy of Coronaviridae according to the International Committee on Taxonomy 1440 
of Viruses. 1441 
 1442 
FIG. 1B. Phylogenetic tree of 50 coronaviruses with partial nucleotide sequences of RNA-1443 
dependent RNA polymerase. The tree was constructed by the neighbor-joining method using 1444 
MEGA 5.0. The scale bar indicates the estimated number of substitutions per 20 nucleotides. 1445 
Abbreviations (accession number): AntelopeCoV, sable antelope coronavirus (EF424621); 1446 
BCoV, bovine coronavirus (NC_003045); BdCoV HKU22, bottlenose dolphin coronavirus 1447 
HKU22 (KF793826); BuCoV HKU11, bulbul coronavirus HKU11 (FJ376619); BWCoV-SW1, 1448 
beluga whale coronavirus SW1 (NC_010646); CMCoV HKU21, common moorhen coronavirus 1449 
HKU21 (NC_016996); DcCoV HKU23, dromedary camel coronavirus HKU23 (KF906251); 1450 
ECoV, equine coronavirus (NC_010327); ErinaceousCoV, Betacoronavirus 1451 
Erinaceus/VMC/DEU/2012 (NC_022643); FIPV, feline infectious peritonitis virus (AY994055); 1452 
HCoV-229E, human coronavirus 229E (NC_002645); HCoV-HKU1, human coronavirus HKU1 1453 
(NC_006577); HCoV-NL63, human coronavirus NL63 (NC_005831); HCoV-OC43, human 1454 
coronavirus OC43 (NC_005147); Hi-BatCoV HKU10, Hipposideros bat coronavirus HKU10 1455 
(JQ989269); IBV-partridge, partridge coronavirus (AY646283); IBV-peafowl, peafowl 1456 
coronavirus (AY641576); MERS-CoV, Middle East respiratory syndrome coronavirus 1457 
(NC_019843.3); MERS-CoV KSA-CAMEL-363, Middle East respiratory syndrome coronavirus 1458 
isolate KSA-CAMEL-363 (KJ713298);  MHV, murine hepatitis virus (NC_001846); Mi-BatCoV 1459 
1A, Miniopterus bat coronavirus 1A (NC_010437); Mi-BatCoV 1B, Miniopterus bat coronavirus 1460 
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1B (NC_010436); Mi-BatCoV HKU7, Miniopterus bat coronavirus HKU7 (DQ249226); Mi-1461 
BatCoV HKU8, Miniopterus bat coronavirus HKU8 (NC_010438); MRCoV HKU18, magpie 1462 
robin coronavirus HKU18(NC_016993); MunCoV HKU13, munia coronavirus HKU13 1463 
(FJ376622); My-BatCoV HKU6, Myotis bat coronavirus HKU6 (DQ249224); NeoCoV, 1464 
coronavirus Neoromicia/PML-PHE1/RSA/2011 (KC869678); NHCoV HKU19, night heron 1465 
coronavirus HKU19 (NC_016994); PEDV, porcine epidemic diarrhoea virus (NC_003436); 1466 
PHEV, porcine haemagglutinating encephalomyelitis virus (NC_007732); Pi-BatCoV-HKU5, 1467 
Pipistrellus bat coronavirus HKU5 (NC_009020); PorCoV HKU15, porcine coronavirus HKU15 1468 
(NC_016990); PRCV, porcine respiratory coronavirus (DQ811787); RbCoV HKU14, rabbit 1469 
coronavirus HKU14 (NC_017083); RCoV parker, rat coronavirus parker (NC_012936); Rh-1470 
BatCoV HKU2, Rhinolophus bat coronavirus HKU2 (EF203064); Ro-BatCoV-HKU9, Rousettus 1471 
bat coronavirusHKU9 (NC_009021); Ro-BatCoV HKU10, Rousettus bat coronavirus HKU10 1472 
(JQ989270); SARS-CoV, SARS coronavirus (NC_004718); SARSr-CiCoV, SARS-related palm 1473 
civet coronavirus (AY304488); SARSr-Rh-BatCoV HKU3, SARS-related Rhinolophus bat 1474 
coronavirus HKU3 (DQ022305); Sc-BatCoV 512, Scotophilus bat coronavirus 512 1475 
(NC_009657); SpCoV HKU17, sparrow coronavirus HKU17 (NC_016992); TCoV, turkey 1476 
coronavirus (NC_010800); TGEV, transmissible gastroenteritis virus (NC_002306); ThCoV 1477 
HKU12, thrush coronavirus HKU12 (FJ376621); Ty-BatCoV-HKU4, Tylonycteris bat 1478 
coronavirus HKU4 (NC_009019); WECoV HKU16, white-eye coronavirus HKU16 1479 
(NC_016991); WiCoV HKU20, wigeon coronavirus HKU20 (NC_016995). 1480 
 1481 
FIG. 2. Genome arrangement of MERS-CoV with emphasis on the clinical applications of the 1482 
key non-structural and structural genes. * denotes furin cleavage sites. Abbreviations: 3CLpro, 1483 
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3C-like protease; AP, accessory protein; CP, cytoplasmic domain; E, envelope; FP, fusion 1484 
peptide; Hel, helicase; HR, heptad repeat; IFN, interferon; M, membrane; mAb, monoclonal 1485 
antibody; N, nucleocapsid; nsp, non-structural protein; ORF, open reading frame; pp, 1486 
polyprotein; PLpro, papain-like protease; RBD, receptor binding domain; RdRp, polymerase; 1487 
RT-RPA; reverse transcription isothermal Recombinase Polymerase Amplification; S, spike; SP, 1488 
signal peptide; TM, transmembrane domain. 1489 
 1490 
FIG. 3. Candidate antiviral agents for MERS-CoV in relation to the viral replication cycle. (+) 1491 
and (-) denotes positive- and negative-strand RNA respectively. Abbreviations: AKT, protein 1492 
kinase B; Cyps, cyclophilins; DPP4, dipeptidyl peptidase-4; E, envelope; ER, endoplasmic 1493 
reticulum; ERGIC, endoplasmic reticulum Golgi intermediate compartment; ERK, extracellular 1494 
signal-regulated kinases; HR2P, heptad repeat 2 peptide; IFN, interferon; M, membrane; mAb, 1495 
monoclonal antibody; MAPK, mitogen-activated protein kinases; MPA, mycophenolic acid; 1496 
mRNA, messenger RNA; mTOR, mammalian target of rapamycin; N, nucleocpasid; NFAT, 1497 
nuclear factor of activated T-cells; nsp, non-structural protein; ORF, open reading frame; PI3K, 1498 
phosphatidylinositide 3-kinases; S, spike; TMPRSS2, transmembrane protease serine protease-2.  1499 
 1500 
FIG. 4. Phylogenetic tree of representative human and camel strains of MERS-CoV rooted by 1501 
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